


JC10 Rec'd PCT/PTO 12 DEC 2001

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				078883-0139	
INTERNATIONAL APPLICATION NO. PCT/GB00/02641		INTERNATIONAL FILING DATE 06/15/2000		U.S. APPLICATION NO. (If known, see 37 CFR 1.55) Unassigned <b>10/009570</b>	
PRIORITY DATE CLAIMED 06/17/1999					
TITLE OF INVENTION PROMOTER					
APPLICANT(S) FOR DO/EO/US Iain Alasdair DONALDSON et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. <input type="checkbox"/> Applicant claims small entity status under 37 CFR 1.27.					
Items 12. to 17. below concern other document(s) or information included:					
12. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> Other items or information: Statement to Support Filing and Submission of Sequence Listing; Paper Copy of Sequence Listing; Computer Readable Diskette of Sequence Listing and Copy of International Search Report					

U.S. APPLICATION NO. (if known, see 37 CFR 1.50) Unassigned <b>107 009570</b>		INTERNATIONAL APPLICATION NO PCT/GB00/02641		ATTORNEY'S DOCKET NUMBER 078883-0139	
18. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b> <span style="float:right">PTO USE ONLY</span>	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$890.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$710.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$740.00					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1,040.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))				\$130.00	
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	26	- 20	= 6	x \$18.00	\$108.00
Independent Claims	8	- 3	= 5	x \$84.00	\$420.00
Multiple dependent claim(s) (if applicable)				\$280.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1548.00</b>	
Reduction by 1/2 for filing by small entity, if applicable.				\$0.00	
<b>SUBTOTAL =</b>				<b>\$1548.00</b>	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f). +					
<b>TOTAL NATIONAL FEE =</b>				<b>\$1548.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1548.00</b>	
				Amount to be: refunded \$	
				charged \$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1548.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$1548.00 to the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u>. A duplicate copy of this sheet is enclosed.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
<p>SEND ALL CORRESPONDENCE TO:</p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>Foley &amp; Lardner Customer Number: 22428</p>  <p><b>22428</b></p> <p>PATENT TRADEMARK OFFICE</p> </div> <div style="width: 50%;"> <p>SIGNATURE <u>Michele M. Simkin</u></p> <p>NAME <u>MICHELE M. SIMKIN</u></p> <p>REGISTRATION NUMBER <u>34,717</u></p> </div> </div>					

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: DONALDSON et al.  
 Title: PROMOTER  
 Appl. No.: Unassigned  
 Filing Date: Concurrently Herewith  
 Examiner: Unassigned  
 Art Unit: Unassigned

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
 Washington, D.C. 20231

Sir:

Prior to examination, please amend this application as follows.

**IN THE SPECIFICATION:**

In accordance with 37 C.F.R. § 1.121, please replace the following paragraphs with the identified rewritten paragraphs of the application. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

Page 13, please delete Table 1 and insert therefor:

Functional elements in the RSus3 promoter region	Position	Position (-intron)	RSus3 Sequence <sup>1</sup>	Consensus Sequence	Reference (Consensus Sequence)
Translation start site	+1	+1	CAATGG	CAATGG	[Joshi 1987]
Intron (Acceptor splice site) 1	-27		TCCAG GC	TGCAG GT	[Simpson & Filipowicz 1996], consensus for monocots
Intron (Donor splice site) 1	-892		AG GTAGAG	AG GTAAGT	
TATA box	-986	-121	TATAAATA	TATATATA	[Joshi 1987]
CAAT box	-999	-134	GCACA7T7T	GGNCAATCT	
GCN4 box	-1032	-167	GTGAGGCAG	(G/A) TGA (G/C) TCA (T/G)	[Müller & Knudsen 1993], cis-

				(G/C) TCA (T/G)	Knudsen 1993], cis- element involved in endosperm specificity
Endosperm boxes	-1072	-207	AGTAAAG	TB (T/C/A) AAA (G/A)	[Marzábal et al. 1998], cis- element involved in endosperm specificity
	-1130	-265	TGCAAAC		
	-1349	-484	TGTCAAA		
Legumin boxes (RY repeats)	-1539	-674	CGTGCATG	CATGCATG	[Bäumlein et al. 1992] cis- element involved in seed specificity
	-1586	-721	CATGTATG' (piece of SEQ ID NO: 7)		
	-1624	-759	CATGCATA'		
	-1707	-842	CATGCATGC ATG		
	-2115	-1250	CATGCCTG		
	-2480	-1615	CAGGCATGC ATC (piece of SEQ ID NO: 7)		

1. Deviations from the consensus sequence are in cursive.--

Page 59, please replace paragraph 9 with the following:

--Figure 3 is a restriction map of the promoter of the present invention  
 (SEQ ID NO: 7).—

Page 67, please replace the first paragraph with the following:

--Primers and oligos (SEQ ID NOS 8-27, respectively, in order of appearance)  
 Listed in alphabetical order (Storage name, size)—

Page 68, please replace the fourth paragraph with the following:

--Lower sequencing primers (SEQ ID NOS 28-34, in order of appearance)  
 (Listed in numerical order):--



Page 69, please replace the first paragraph with the following:

--Upper sequencing primers (SEQ ID NOS 35-39, respectively, in order of appearance)  
(Listed in numerical order) —

Page 69, please replace the seventh paragraph with the following:

--M13 sequencing primers (SEQ ID NOS 40 and 41, respectively, in order of appearance):--

Page 72, please replace the fourth paragraph with the following:

--For isolation of the RSus3 promoter region, the following sequence-specific primer  
was designed:

5'-ACG ACG GAA TGG ATA ATA GCA GAT A-3' (SEQ ID NO: 43) —

Page 74, please replace the fourth full paragraph with the following:

--The resulting products were cloned in pCR2.1-TOPO and then subcloned into  
pGUSNOST as XhoI/NcoI fragments. Positive clones were identified by restriction  
mapping of miniprep DNA. Although the pGUSTNOST was linearised with both SalI  
and NcoI, the vector was treated with phosphate before ligation to prevent religation of  
plasmid that was cut with only one enzyme due to the close placement of the SalI and  
NcoI sites (G/TCGAC/CATGG) (SEQ ID NO: 43). —

Pages 76-77, please replace the paragraph bridging the pages with the  
following:

--The resulting products were cloned in pCR2.1-TOPO and then subcloned into  
pGUSNOST as XhoI/NcoI fragments. Positive clones were identified by restriction  
mapping of miniprep DNA. Although the pGUSTNOST was linearised with both SalI  
and NcoI, the vector was treated with phosphate before ligation to prevent religation of  
plasmid that was cut with only one enzyme due to the close placement of the SalI and  
NcoI sites (G/TCGAC/CATGG) (SEQ ID NO: 43). —

**IN THE CLAIMS:**

In accordance with 37 C.F.R. § 1.121, please substitute for claims 4, 5, 7, 8, 10, 12, 13, 15-18, 20, 22, and 26 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

5. (Amended) A promoter according to claim 1 wherein the promoter is obtainable from a plant of the genus *Oryza*.

7. (Amended) A promoter according to claim 1 wherein the promoter is operably linked to a NOI.

8. (Amended) A promoter according to claim 1 wherein the promoter is linked to the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or fragment thereof.

10. (Amended) A promoter according to claim 1 wherein the promoter comprises one or more of the identified sequences presented in Table 1 or a variant, homologue or fragment thereof.

12. (Amended) A promoter according to claim 10 wherein the promoter comprises all of the identified sequences presented in Table 1.

13. (Amended) A promoter according to claim 1 wherein the promoter is linked to the sequence presented as SEQ ID No. 5, or a variant, homologue, derivative or fragment thereof.

15. (Amended) A construct comprising the promoter according to claim 1 but wherein the promoter is operably linked to a NOI.

16. (Amended) An expression vector comprising the invention according to claim 1.

17. (Amended) A transformation vector comprising the invention according to claim 1.

18. (Amended) A transformed host or host cell comprising the invention according to claim 1.

20. (Amended) A method of preparing a POI, the method comprising expressing an NOI which encodes at least a part of the POI, wherein the NOI is operably linked to a promoter, optionally isolating the expression product of the NOI, forming the POI if the expression product of the NOI is not all of the POI, optionally isolating the POI; wherein the promoter is the promoter according to claim 1.

22. (Amended) A method for expressing an NOI in endosperm, the method comprising expressing the NOI when it is operably linked to the promoter according to claim 1.

26. (Amended) A promoter substantially as described herein and with reference to claim 1.

#### **REMARKS**

Formal examination of this application is respectfully requested.

The specification and claims 4, 5, 7, 8, 10, 12, 13, 15-18, 20, 22, and 26 were amended to recite sequence ID numbers for the listed sequences and to eliminate multiple dependencies of the claims.

As the foregoing amendments do not introduce new matter, entry thereof by the Examiner is respectfully requested.

Atty. Dkt. No. 078883/0139  
Appln. No. Unassigned

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Dec 12, 2001  
FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

By Michele M. Simkin

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717

**"Version of the Specification with Markings to Show Changes Made"**

Page 13, please delete Table 1 and insert therefor:

Functional elements in the RSus3 promoter region	Position	Position (-intron)	RSus3 Sequence <sup>1</sup>	Consensus Sequence	Reference (Consensus Sequence)
Translation start site	+ 1	+ 1	CAATGG	CAATGG	[Joshi 1987]
Intron (Acceptor splice site) 1	-27		TCCAG GC	TGCAG GT	[Simpson & Filipowicz 1996], consensus for monocots
Intron (Donor splice site) 1	-892		AG GTAGAG	AG GTAAGT	
TATA box	-986	-121	TATAAATA	TATATATA	[Joshi 1987]
CAAT box	-999	-134	GCACA TTT	GGNCAATCT	
GCN4 box	-1032	-167	GTGAGGCAG	(G/A) TGA (G/C) TCA (T/G)	[Müller & Knudsen 1993], cis-element involved in endosperm specificity
Endosperm boxes	-1072	-207	AGTAAAG	TB (T/C/A) AAA (G/A)	[Marzábal et al. 1998], cis-element involved in endosperm specificity
	-1130	-265	TGCAAAC		
	-1349	-484	TGTCAA		
Legumin boxes (RY repeats)	-1539	-674	CGTG CATG	CATG CATG	[Bäumlein et al. 1992] cis-element involved in seed specificity
	-1586	-721	CATG TATG' (piece of SEQ ID NO: 7)		
	-1624	-759	CATG CATA'		
	-1707	-842	CATG CATG C ATG		
	-2115	-1250	CATG CCTG		
	-2480	-1615	CAGG CATG C ATC (piece of SEQ ID NO: 7)		

1. Deviations from the consensus sequence are in cursive.

Page 59, please replace paragraph 9 with the following:

--Figure 3 is a restriction map of the promoter of the present invention  
(SEQ ID NO: 7). —

Page 67, please replace the first paragraph with the following:

--Primers and oligos (SEQ ID NOS 8-27, respectively, in order of appearance)  
Listed in alphabetical order (Storage name, size) —

Page 68, please replace the fourth paragraph with the following:

--Lower sequencing primers (SEQ ID NOS 28-34, in order of appearance)  
(Listed in numerical order):--

Page 69, please replace the first paragraph with the following:

--Upper sequencing primers (SEQ ID NOS 35-39, respectively, in order of appearance)  
(Listed in numerical order) —

Page 69, please replace the seventh paragraph with the following:

--M13 sequencing primers (SEQ ID NOS 40 and 41, respectively, in order of appearance):--

Page 72, please replace the fourth paragraph with the following:

--For isolation of the RSus3 promoter region, the following sequence-specific primer  
was designed:

5'-ACG ACG GAA TGG ATA ATA GCA GAT A-3' (SEQ ID NO: 43) —

Page 74, please replace the fourth full paragraph with the following:

--The resulting products were cloned in pCR2.1-TOPO and then subcloned into  
pGUSNOST as XhoI/NcoI fragments. Positive clones [was] were identified by  
restriction mapping of miniprep DNA. Although the pGUSTNOST was linearised with  
both Sall and NcoI, the vector was treated with phosphate before ligation to prevent

religation of plasmid that was cut with only one enzyme due to the close placement of the Sall and NcoI sites (*G/TCGAC/CATGG*) **(SEQ ID NO: 43)**. —

Pages 76-77, please replace the paragraph bridging the pages with the following:

--The resulting products were cloned in pCR2.1-TOPO and then subcloned into pGUSNOST as XhoI/NcoI fragments. Positive clones [was] were identified by restriction mapping of miniprep DNA. Although the pGUSTNOST was linearised with both Sall and NcoI, the vector was treated with phosphate before ligation to prevent religation of plasmid that was cut with only one enzyme due to the close placement of the Sall and NcoI sites (*G/TCGAC/CATGG*) **(SEQ ID NO: 43)**. —

**"Version of the Claims with Markings to Show Changes Made"**

5. (Amended) A promoter according to [any one of claims] claim 1 [to 4] wherein the promoter is obtainable from a plant of the genus *Oryza*.
7. (Amended) A promoter according to [any one of claims] claim 1 [to 6] wherein the promoter is operably linked to a NOI.
8. (Amended) A promoter according to claim 1 [any one of the preceding claims] wherein the promoter is linked to the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or fragment thereof.
10. (Amended) A promoter according to claim 1 [any one of the preceding claims] wherein the promoter comprises one or more of the identified sequences presented in Table 1 or a variant, homologue or fragment thereof.
12. (Amended) A promoter according to claim 10 [or claim 11] wherein the promoter comprises all of the identified sequences presented in Table 1.
13. (Amended) A promoter according to claim 1 [any one of the preceding claims] wherein the promoter is linked to the sequence presented as SEQ ID No. 5, or a variant, homologue, derivative or fragment thereof.
15. (Amended) A construct comprising the promoter according to claim 1 [any one of claims 1 to 14] but wherein the promoter is operably linked to a NOI.
16. (Amended) An expression vector comprising the invention according to claim 1 [any one of claims 1 to 15].



17. (Amended) A transformation vector comprising the invention according to claim 1 [any one of claims 1 to 16].
18. (Amended) A transformed host or host cell comprising the invention according to claim 1 [any one of claims 1 to 16].
20. (Amended) A method of preparing a POI, the method comprising expressing an NOI which encodes at least a part of the POI, wherein the NOI is operably linked to a promoter, optionally isolating the expression product of the NOI, forming the POI if the expression product of the NOI is not all of the POI, optionally isolating the POI; wherein the promoter is the promoter according to claim 1 [any one of claims 1 to 19].
22. (Amended) A method for expressing an NOI in endosperm, the method comprising expressing the NOI when it is operably linked to the promoter according to claim 1 [any one of claims 1 to 20].
26. (Amended) A promoter substantially as described herein and with reference to claim 1 [any one of the preceding claims].

## SEQUENCE LISTINGS

## 5 SEQ ID NO. 1

ACTTTAGATAATAAAGTAAGTCACAAGAAAAATAAATAATAATTCCAAATTTTTTTAATAAGA  
CGAGTGGTCAAACAGTACAAGTAAAAACTCAAAATTCCTTATATTATGGGACTTATATTATGG  
GACGGAGGAAGTAGAAGATTGTAGCCAAGAAAAAACAAAAACAAACACACCGCCACCTGGCA  
10 GGCATGCATCTTAGGTCGGCACATTGAGAGGTCGGCAGTAGACGAGTTACCTACACAACTGC  
TTCTTCAGTGAGCTAGCTGCATGTTCTGTTCTGCATTTACATTGCAGGCAGCAGCTAGCAACA  
GTTTGCAGGAACAATCGATAATCCATTGTGTGAGGAGGAACATGGAGAAAAACCGGGGCTGG  
AGACGAACGGGAGCAGCTGTACCGTACGTTTCTGAAGGCTGAACCCATCTGCGAAATCCGCAG  
ATTGGTTTGTTCATTTCCAACCTGCAGTCCTTCAGATTGGTTGCATGTTCAACCGTAGTACAT  
15 CTGAAAAATGAAGTGTTAAATACCTTGAGAAGACCTTCATGGAAGCATGCCTGCAGGCGATTA  
GCTAAGAAAAAATAAATGTACTTTTCGAACTTAATTTTGGAGTTAGATTTTAGGGTGT  
TTCCATCGTAGTGTATTTTCTACTATTGCAGTTTAAACCGCTAATAGTCAGATATAAAATTTT  
ATCTATAGATCATTTATAAATCATTTTTTAGTTGCTTCGTTTCTTACCCTTATCAACC  
ATAGCTCAACTGATCAATTGACAATAAAAGTTACTAAACGACATCGCTCATCACACACCCAAC  
20 GCTCACCGATGGGTGCCTCTCGACCACGAGTTTAGCACTTGTGCAACATATATGCGTGCATG  
AACATCTACTGATGCGCCATGCGAATTTTAGCGTTTCGTTTCATGACGCTTCCAACGGCAGAG  
GCTGAGCAGCAGCATGCATGCATGGCTCTTGTGAAAACAAAAAGGTTACTGGTAAATGACAT  
GCTGCTGTAGCTAGTTAGCAGAATGCAAGGCCATGCATATGCAATGCTATGCAACAAGTATA  
GTACCAGCATGTATGGTAGCCAGCTAACTAATCTATCAGCAGAGGCAGCAAGCTCGTGCATGG  
25 TGTGATGCACTTCTCTCCAGTAATCTAGTGTAATTTTACCCAAAGCGTTGCTCATATGGAC  
AGTAATTAGTAATATTACCAAGGTTTACAATCCCGTTACCTGACCAATACTACTCACGAATG  
GTATCTCTGGTTTTCTGTTAAAACCGTTGGTAAACCAGCAAAAATAGACAAAATTTGTCAAAT  
TTTAAATTTTAGTTTTTTTTTTAACTTAGCCGGGAAACCTTGAAGTTTGTGCTGTGAGCTGT  
CCTGGGAAGGACGGTTTTGGTTGGGATTGTGAACCTGGTTACTGCACTTCATTTTTGAACAG  
30 ATATTAGTGCAACAGACAAATGCCAACGCATTTTTTCTGTTTACCGGCAAGCTGAAGCTTTT  
ACGATCCCCATACCGCGTTGCTGCAACCTGCCAAGAAAGAGCAGCAGAAACAGGTGTCATT  
TTGTGGTGGAAGCCAAGTAAAGTAAACAGAAGATGGAAGATAGTGAGGACCAGGGAGTGAGG  
CAGGGGACACATGGCCCACGCCTCCCTGCACATTTTCGTGTATAAATACAGGTGGATGCATCG  
CTCTCCCAGCATCCATCGGTTCTCTGCTCTGTTTCATCCATAGAGTTTCTCTCTCTCTCTC  
35 AGTGCAAG

## SEQ ID NO. 2

GTAGAGAAGAGCATGTGTGTGTGTGTGTGAACTGTGAAGTGACAGAGTGCTTCTGTAGTTCT  
40 GTGTTATGTCCATAGTGATCTTGTTAGGATTGTTGCTATGGATGCATGATGTTATGGTTAATC  
TCTGAATTACAGTAGGGACTTCTCTGAGATCTCTGGATTAGTGGGGGGTGCTAAATTTTTTTC  
TGGTTGCATCAGCTTGGGTTTCTGGGATTGGTGTGGGTTCTTGCTCTGAATTTTGGTTAGAA  
TGTCGATTTGTTTTGTGTTTGCCCTCTGAAGTTGAGAGTAGCTATGATCCATCCAGCACAGAA  
CTGCAGGTCCCTGCCTGCCGGCAGCATATACAGGACATGCCATTTTGCAAGCTCTGGGCTTAT  
45 GGTTCCTCTTTTGGAGTTCTTCTTCTGATGATCTGTGTTCTCTAACAAGAAGCAAGATTT  
AGCAACTTTATTTCAGAGACAAGAAAAGGATCTGGCAACCTTTTGTCTGTCTTATCTTACTC  
GTAAAGATTGTTATTTAAGCAAAAATTTCCCAAAAGTTTAAATATAAATTTCCATGATGTGCC  
ACTCTCATGTCCTTGAACCTGGCAGCTCATTATGGGCTCCTCAGAAGTGCTGTAGCTAATGTCA  
CTAATCTTTTGTATCTTTGTTTCGTAGTCTTGTATTTTATGATGCTTATCCCTTTGTGCTTTCC  
50 ATGTTTGTATGTCCAAATGTCATGGCAATGTTTTTGAATTTCTAGTAGGGGTTTTAGTACCTTTT  
TGTTAGATAAGTACATCCAAATCTGTTTATTTATTCAAAAATCATTCTGTTTATTCACTGAA  
AACATTTGTCCATTCAATGGAATCGTAAACTGTCTGTGTTTTTCAG

## SEQ ID NO. 3

ACTTTAGATAATAAAGTAAGTCACAAGAAAAATAAATAAATTCCAAATTTTTTTAATAAGA  
CGAGTGGTCAAACAGTACAAGTAAAACTCAAATTCCTTATATTATGGGACTTATATTATGG  
5 GACGGAGGAAGTAGAAGATTGTAGCCAAGAAAAAACAAAAACAAACACACCGCCACCTGGCA  
GGCATGCATCTTAGGTCGGCACATTGAGAGGTCGGCAGTAGACGAGTTACCCTACACAACCTGC  
TTCTTCAGTGAGCTAGCTGCATGTTCTGTTCTGCATTTACATTGCAGGCAGCAGCTAGCAACA  
GTTTGCAGGAACAATCGATAATCCATTGTGTCAGGGAGGAACATGGAGAAAAACCGGGGCTGG  
AGACGAACGGGAGCAGCTGTACCGTACGTTTCTGAAGGCTGAACCCATCTGCGAAATCCGCAG  
10 ATTGGTTTGTTCAATTCCAACCTGCAGTCCTTCAGATTGGTTGCATGTTCAACCGTAGTACAT  
CTGAAAAATGAAGTGTTAAATACCTTGAGAAGACCTTCATGGAAGCATGCCTGCAGGCGATTA  
GCTAAGAAAAAATAAATGTACTTTTCGAACTTAATTTTGGAGTTAGATTTTAGGGTGT  
TTCCATCGTAGTGATTTTCTACTATTGCAGTTTAAACCGCTAATAGTCAGATATAAAATTTT  
ATCTATAGATCATTTATAAATCATTTTTTAGTTGCTTCGTTTCATTTTTCTACCACTTATCAACC  
15 ATAGCTCAACTGATCAATTGACAATAAAAGTTACTAAACGACATCGCTCATCACACACCCAAC  
GCTCACCGATGGGTGCCTCTCGACCACGAGTTTAGCACTTGTGCAACATATATGCGTGCGATG  
AACATCTACTGATGCGCCATGCGAATTTTAGCGTTCGTTTCATGACGCTTCCAACGGCACAGAG  
GCTGAGCAGCAGCATGCATGCATGGCTCTTGTGAAAACAAAAAGGTTACTGGTAAATGACAT  
GCTGCTGTAGCTAGTTAGCAGAATGCAAGGCCCATGCATATGCAATGCTATGCAACAAGTATA  
20 GTACCAGCATGTATGGTAGCCAGCTAACTAATCTATCAGCAGAGGCAGCAAGCTCGTGATGG  
TGTGATGCACTTCTCTCCAGTAATCTAGTGGTAATTTTCACCCAAAGCGTTGCTCATATGGAC  
AGTAATTAGTAATATTACCAAGGTTTACAATCCCGTTACCTGACCAAATACTACTCACGAATG  
GTATCTCTGGTTTTTCGTTAAAACCGTTGGTAAACCAGCAAAAATAGACAAAATTTGTCAAAAT  
TTTAAATTTTAGTTTTTTTTTTTAACTTAGCCGGGAAACCTTGAAGTTTGTGCTGTGAGCTGT  
25 CCTGGGAAGGACGGTTTTGGTTGGGATTGTGAACCCTGGTTACTGCACCTTCATTTTTGAACAG  
ATATTAGTGCAACAGACAAATGCCAACGCATTTTTTTCTGTTTACCGGCAAGCTGAAGCTTTT  
ACGATCCCCATACCGCCGTTGCTGCAAACTGCCAAGAAAGAGCAGCAGAAACAGGTGTCATT  
TTGTGGTGGAAGCCAAGTAAAGTAAACAGAAGATGGAAGATAGTGAGGACCAGGGAGTGAGG  
CAGGGGACACATGGCCACGCCTCCCTGCACATTTTCGTGTATAAATACAGGTGGATGCATCG  
30 CTCTCCAGCATCCATCGGTTCTCTGCTCTGTTTCATCCATAGAGTTTCCTCCTCTTCTCCTTC  
AGTGCAAGGCTTGAGGATCCAAC TAGAAGATAGCAATGG

## SEQ ID NO. 4

35 CAGGTGGATGCATCGCTCTCCAGCATCCATCGGTTCTCTGCTCTGTTTCATCCATAGAGTTTC  
CTCCTCTTCTCCTTCAGTGCAAG

## SEQ ID NO. 5 - SECOND PART OF EXON SEQUENCE

GCTTGAGGATCCAACTAGAAGATAGCAATGG

## 5 SEQ ID NO 6

ACTTTAGATAATAAAGTAAGTCACAAGAAAAATAAATAAATTCCAAATTTTTTTTAATAAGA  
CGAGTGGTCAAACAGTACAAGTAAAACTCAAATTCCTTATATTATGGGACTTATATTATGG  
GACGGAGGAAGTAGAAGATTGTAGCCAAGAAAAAACAAAAACAAACACACCGCCACCTGGCA  
10 GGCATGCATCTTAGGTCGGCACATTGAGAGGTCGGCAGTAGACGAGTTACCCTACACAACTGC  
TTCTTCAGTGAGCTAGCTGCATGTTCTGTTCTGCATTTACATTGCAGGCAGCAGCTAGCAACA  
GTTTGCAGGAACAATCGATAATCCATTGTGTGAGGGAGGAACATGGAGAAAAACCGGGGCTGG  
AGACGAACGGGAGCAGCTGTACCGTACGTTTCTGAAGGCTGAACCCATCTGCGAAATCCGCAG  
ATTGGTTTGTTCAATTCCAACCTGCAGTCCTTCAGATTGGTTGCATGTTCAACCGTAGTACAT  
15 CTGAAAAATGAAGTGTTAAATACCTTGAGAAGACCTTCATGGAAGCATGCCTGCAGGCGATTA  
GCTAAGAAAAAATAAATGTACTTTTCGAACTTAATTTTGGAGTTAGATTTTAGGGTGT  
TTCCATCGTAGTGTATTTTCTACTATTGCAGTTTAAACCGCTAATAGTCAGATATAAAATTTT  
ATCTATAGATCATTTATAAATCATTTTTAGTTGCTTCGTTTCTATTTTCTACCACTTATCAACC  
ATAGCTCAACTGATCAATTGACAATAAAAGTTACTAAACGACATCGCTCATCACACACCCAAC  
20 GCTCACCGATGGGTGCCTCTCGACCACGAGTTTAGCACTTGTGCAACATATATGCGTGCATG  
AACATCTACTGATGCGCCATGCGAATTTTAGCGTTTCGTTTCATGACGCTTCCAACGGCACAGAG  
GCTGAGCAGCAGCATGCATGCATGGCTCTTGTGAAAACAAAAAGGTTACTGGTAAATGACAT  
GCTGCTGTAGCTAGTTAGCAGAATGCAAGGCCCATGCATATGCAATGCTATGCAACAAGTATA  
GTACCAGCATGTATGGTAGCCAGCTAACTAATCTATCAGCAGAGGCAGCAAGCTCGTGATGG  
25 TGTGATGCACTTCTCTCCAGTAATCTAGTGGTAATTTTCACCCAAAGCGTTGCTCATATGGAC  
AGTAATTAGTAATATTACCAAGGTTCACAATCCCGTTACCTGACCAAATACTACTCACGAATG  
GTATCTCTGGTTTTTCGTTAAAACCGTTGGTAAACCAGCAAAAATAGACAAAATTTGTCAAAAT  
TTTAAATTTTAGTTTTTTTTTTAACTTAGCCGGGAAACCTTGAAGTTTGTGCTGTGAGCTGT  
CCTGGGAAGGACGGTTTTTGGTTGGGATTGTGAACCCTGGTTACTGCACTTCATTTTTGAACAG  
30 ATATTAGTGCAACAGACAAATGCCAACGCATTTTTTTCTGTTTACCGGCAAGCTGAAGCTTTT  
ACGATCCCCATACCGCCGTTGCTGCAACCTGCCAAGAAAGAGCAGCAGAAACAGGTGTCATT  
TTGTGGTGGAAGCCAAGTAAAGTAAACAGAAGATGGAAGATAGTGAGGACCAGGGAGTGAGG  
CAGGGGACACATGGCCACGCCTCCCTGCACATTTTCGTGTATAAATA

27 ppts

WO 00/78975

10/009570

PCT/GB00/02641

10 Rev 12 DEC 2001

## PROMOTER

### FIELD OF THE PRESENT INVENTION

- 5 The present invention relates to a promoter, including a construct and an expression vector comprising the same and a transformed cell comprising the same. In addition the present invention relates to a plant cell, as well as a plant, comprising the same.

### BACKGROUND OF THE PRESENT INVENTION

10

Expression of plant genes is controlled in a complex pattern during the life cycle of a plant. Several processes are involved in this regulation of gene expression. The main steps are; the initiation of transcription; the termination of transcription; the processing of transcripts; the transport of mRNA to the ribosomes; and the translation.

15

Three examples of plant genes that are expressed are found in Huang *et al* (1996 Biosci Biotech Biochem 60 (2) 233-239) who report on three rice sucrose synthase isogenes, which are called *RSus1*, *RSus2* and *RSus3*. The authors also report on their differential regulation of their expression. The authors state that the gene organisation patterns of *RSus2* and *RSus3* were the same.

20

One of the major processes controlling gene expression is initiation of transcription. The transcription is initiated by binding of RNA polymerase together with several transcription factors to the promoter region. Specific regulatory DNA sequences (cis-elements) in the promoter serve as binding sites for these transcription factors (trans-acting factors).

25

The cis-elements found in plant gene promoters can be divided in two categories. The first category comprises those cis-elements which are involved in initiation of transcription. The TATA box and the CAAT box are examples of proximal cis-elements involved in initiation of transcription. The CAAT box defines the binding site for the RNA polymerase, and the TATA box directs the RNA polymerase to the correct transcription start site. Presence of multiple CAAT boxes normally indicate a constitutive promoter. The TATA box and CAAT box are conserved among prokaryotes and eukaryotes, but are not essential for the function of some plant gene promoters. The second category is composed of cis-elements which are involved in

30

35

temporal and spatial regulation of gene expression. Genes encoding seed storage proteins (Glutamins, Legumins, Prolamins etc.) are examples of genes which are temporally and spatially regulated, and are thereby expressed in a tissue-specific and developmental manner. Examples of endosperm-specific cis-elements are the AACA motif and the endosperm box. These cis-elements, that contribute to tissue-specific and developmental expression of endosperm storage protein genes, are conserved among a wide range of seed storage protein genes.

The manner in which complex patterns of transcription factors act on specific cis-elements determines whether genes are more or less constitutively expressed, or are expressed at specific times during development. Furthermore, these interactions determine whether expression occurs in a specific tissue e.g. the endosperm, is displayed by several tissues e.g. those of the seed, or is common to all parts of the plant. Multiple trans-acting factors can recognise variants of the cis-element consensus sequences and compete for binding, yielding complex expression patterns. Each plant gene promoter has a set of transcription factors and other trans-acting factors, which interact with the promoter sequence and the RNA polymerase and thereby regulate gene expression in an unique pattern.

It is known that it is desirable to direct expression of a nucleotide sequence of interest ("NOI") in certain tissues of an organism - such as a plant. The NOI will typically encode a product of interest ("POI"). For example, it may be desirable to produce crop protein products with an optimised amino acid composition and so increase the nutritive value of the crop. It may even be desirable to use the crop to express non-plant genes such as genes for mammalian products. Examples of the latter products include interferons, insulin, blood factors and plasminogen activators.

However, whilst it may be desirable to achieve expression of a NOI in certain tissues it is sometimes important (if not necessary) to ensure that the NOI is not expressed in other tissues in such a manner that detrimental effects may occur. Moreover, it is important not to upset the normal metabolism of the organism to such an extent that detrimental effects occur. For example, a disturbance in the normal metabolism in a plant's leaf or shoot could lead to stunted growth of the plant.

An example of the use of plant promoters to cause expression of an NOI in plant tissue may be found in CA-A-2006454, which describes a DNA sequence of an expression cassette in which the potato tuber specific regulatory regions are localised. The

expression cassette contains a patatin-gene with a patatin-gene promoter. The DNA sequence is transferred into a plant genome using *Agrobacterium*. According to CA-A-2006454, the DNA sequence enables heterologous products to be prepared in crops.

5 However, in plant transformation processes, it is generally the low efficiency of both transformation and regeneration that seriously slow vector development, since they limit the number of genetic constructs which can be tested. Investigations of the strength and tissue specificity of different transcriptional promoters, which can greatly influence the effect of the genetic manipulation, can be unmanageably labour-intensive  
10 if performed in stable transformants. This has resulted in a tendency to use strong constitutive promoters which are not tissue-specific to direct transgenic expression in stable transformants, e.g. from viruses (cauliflower mosaic virus 35S promoter) and *Agrobacterium* (nopaline synthase promoter (NOS)). Not the least problematic element of this approach occurs when lowering of gene expression by antisense transcription is  
15 attempted, because gratuitous suppression of gene expression in all tissues can result in developmental retardation of non-target tissues, or other weakening of the transformant. Under such circumstances, only those transformants, in which the genetic construct poorly suppresses gene expression, would be expected to survive selection. There is, therefore, a strong argument for the use of tissue-specific  
20 transcriptional promoters for directing antisense transcription, but, in many crop species, characterising such promoters in stable transformants is not feasible owing to low efficiency of transformation and regeneration.

Despite the fact that there are already some promoters available in the art, there is  
25 still a need to have additional promoters, in particular promoters that are efficient and/or selective in their ability to allow for the expression of a NOI.

Thus, the present invention seeks to provide a promoter that is capable of causing the expression (transcription) of a NOI.  
30

More in particular, the present invention seeks to provide a promoter that is capable of directing the expression (transcription) of a nucleotide sequence of interest in specific tissues, or in just a specific tissue, of an organism, typically a plant.  
35

## SUMMARY ASPECTS OF THE PRESENT INVENTION

Aspects of the present invention are presented in the claims and in the following commentary.

5

In brief, some aspects of the present invention relate to:

1. A novel promoter capable of selective expression.
2. Novel promoter nucleotide sequences.
- 10 3. Expression systems comprising said promoters.
4. Methods of expression using said promoters.
5. Transformed hosts/host cells comprising said promoters.

As used with reference to the present invention, the terms "expression", "expresses",  
15 "expressed" and "expressable" are synonymous with the respective terms  
"transcription", "transcribes", "transcribed" and "transcribable". Hence, if the NOI is a  
coding sequence, then the product of its expression may also be called the  
transcription product and *visa versa*. Likewise, if the NOI is an anti-sense nucleotide  
sequence then the product of its transcription may also be called the expression  
20 product and *visa versa*.

In the following commentary references to "nucleotide sequence of the present  
invention" include references to the "promoter of the present invention" and *vice*  
*versa*. Also, the term "nucleotide sequence of the present invention" is synonymous  
25 with the phrase "polynucleotide sequence of the present invention".

Other aspects concerning the promoter and/or the nucleotide sequence of the present  
invention include: a construct comprising the sequences of the present invention; a  
vector comprising the sequences of the present invention; a plasmid comprising the  
30 sequences of present invention; a transformed cell comprising the sequences of the  
present invention; a transformed tissue comprising the sequences of the present  
invention; a transformed organ comprising the sequences of the present invention; a  
transformed host comprising the sequences of the present invention; a transformed  
organism comprising the sequences of the present invention. The present invention  
35 also encompasses methods of expressing NOIs using the same, such as expression in  
a host plant cell; including methods for transferring same.



For convenience, the promoter of the present invention is sometimes referred to as the *RSus3* promoter (or even the *Rsus3* promoter or even the *RSus3* promoter). However, it is important to note that the promoter of the present invention is not disclosed in the teachings of Huang *et al* (*ibid*). Moreover, and contrary to the authors statement that "*the gene organisation patterns of RSus2 and RSus3 were the same*" we found that the promoter of *RSus3* was quite different to that of *RSus2*.

In this respect, we found a very low degree of homology (i.e. identity) between the *RSus3* promoter and the *RSus2* promoter and also the *RSus3* and *RSus1* promoter - as evidenced by the following Table.

#### Homology scores of *RSus1*, *RSus2*, *RSus3*

Alignment	% Homology <sup>1</sup>	% Homology <sup>2</sup>
<i>RSus3</i> and <i>RSus1</i>	7.7 %	5.4 %
<i>RSus3</i> and <i>RSus2</i>	4.6 %	5.4 %
<i>RSus1</i> and <i>RSus2</i>	4.6 %	8.8 %

<sup>1</sup>Homology scores based on multiple alignment (all of the promoter region upstream of the translational start codon including the intron: *RSus1* (2663bp), *RSus2* (2900bp), *RSus3* (2667bp)).

<sup>2</sup>Homology scores based on multiple alignment (*RSus1*, *RSus2*, *RSus3* following excision of intron 1).

The homology scores presented in the above table show the low degree of similarity between the promoter regions of *RSus1*, *RSus2* and *RSus3*.

The percentage homologies were calculated using the multiple alignment feature in DNASIS<sup>TM</sup> (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).

In addition, and as a result of a sequence analysis of the sequences of the *RSus3* promoter and the *RSus1* promoter and the *RSus2* promoter, we found that apart from the conserved TATA box and intron splice sites, they have no motifs in common.

Thus, contrary to the prior art teachings, we found that the gene organisation patterns of *RSus2* and *RSus3* are not the same.

For ease of reference, aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.

#### DETAILED ASPECTS OF THE PRESENT INVENTION

According to a first aspect of the present invention there is provided a promoter having the nucleotide sequence presented as SEQ ID No. 1, or a variant, homologue, fragment or derivative thereof.

Alternatively expressed, the present invention provides a nucleotide sequence selected from:

- (a) the nucleotide sequence presented as SEQ ID No. 1;
- (b) a nucleotide sequence that is a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1;
- (c) a nucleotide sequence that is the complement of the nucleotide sequence set out in SEQ ID No. 1;
- (d) a nucleotide sequence that is the complement of a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1;
- (e) a nucleotide sequence that is capable of hybridising to the nucleotide sequence set out in SEQ ID No. 1;
- (f) a nucleotide sequence that is capable of hybridising to a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1;
- (g) a nucleotide sequence that is the complement of a nucleotide sequence that is capable of hybridising to the nucleotide sequence set out in SEQ ID No. 1;
- (h) a nucleotide sequence that is the complement of a nucleotide sequence that is capable of hybridising to a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1;
- (i) a nucleotide sequence that is capable of hybridising to the complement of the nucleotide sequence set out in SEQ ID No. 1;
- (j) a nucleotide sequence that is capable of hybridising to the complement of a variant, homologue, derivative or fragment of the nucleotide sequence presented as SEQ ID No. 1;

(k) a nucleotide sequence comprising any one of (a), (b), (c), (d), (e), (f), (g), (h), (i), and/or (j).

In a preferred aspect, the promoter is obtainable from (though it does not have to be actually obtained from) a plant of the genus *Oryza*, preferably from *Oryza sativa*.

Another aspect of the present invention includes an isolated nucleotide sequence according to the present invention.

Additional aspects of the present invention include uses of the promoter for expressing NOIs *in vitro* (e.g. in culture media such as a broth) and/or *in vivo* (e.g. in a transformed organism).

In a highly preferred aspect the present invention provides a method for expressing an NOI in endosperm (preferably selectively expressing in endosperm), the method comprising expressing the NOI when it is operably linked to the promoter of the present invention.

The terms "selective" and "selectively" as used herein with respect to the present invention are synonymous respectively with the terms "specific" and "specifically". In this respect, selective or specific expression by the promoter of the present invention in the endosperm layer means that higher levels of expression occur in the endosperm relative to other tissue types or cells.

In some instances, the NOI is highly selectively expressed in the endosperm. In this respect, highly selective or specific expression by the promoter of the present invention in the endosperm layer means that expression occurs predominantly in the endosperm relative to other tissue types or cells and in some cases almost exclusively in the endosperm layer.

Preferably the transformed host/host cells is/are plant/plant cells.

The plant can be any suitable monocot plant (such as maize) or any suitable dicot plant (such as soya or guar).

Preferably the plant is an endospermous cereal or a legume.

In a preferred aspect, the plant is a member of the grass family - such as any one of wheat, maize, barley, oats, rye, or rice.

5 In an alternative preferred aspect, the plant is a legume - such as any one of guar or locus bean.

Hence, preferably, the transformed host is a transformed member of the taxonomic groups *Gramineae* (which may be known as *Poaceae*) or *Leguminosae* (which may be known as *Fabaceae*) or is a cell or tissue thereof.

10 Hence, preferably, the transformed plant is a transformed grass or a transformed legume.

Also, preferably, the transformed plant cell is a transformed grass cell or a transformed legume cell.

15 The present invention is advantageous for a number of reasons.

By way of example, the present invention is advantageous because desirable levels of the expression product of a NOI can be obtained. Here, the NOI expression product may be, for example, a desired compound of benefit to humans or animals, e.g. a desirable foodstuff or an enzyme having a beneficial effect, such as a foodstuff processing effect or even a pharmaceutical effect. Furthermore, that product may be easily retrievable.

25 Alternatively, the NOI expression product may affect metabolism within the host. In some cases, the NOI expression product may be a component that is essential for metabolism within the host. In these instances, it may not be important for the POI to be retrieved from the host. In some cases, it may be important that the POI is not retrieved from the host.

30 The present invention is also advantageous because it allows transformed plants or plant cells to express desirable levels of the product of expression of a NOI.

35 The present invention is also advantageous because it allows transformed plants or plant cells to express in selective tissues or cell types desirable levels of the expression product of a NOI.

The promoter of the present invention is further advantageous as it can provide good expression levels of a NOI under conditions of transient expression in plant cells.

- 5 In a preferred aspect, the promoter is linked to the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or fragment thereof. The term "linked" includes direct or indirect (such as with the provision of suitable spacer sequence(s)) linkages.

10 Preferably the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or fragment thereof is located in between the promoter of the present invention and the NOI.

15 In this respect, we have found that in some transformed hosts, such as transformed plants (such as transformed guar), expression levels of the NOI can be elevated. This is important if it is desirable to have such an elevated expression.

The promoter may be used in conjunction with one or more other expression elements - which may be alternatively called "functional elements". These additional expression elements may be linked to the promoter of the present invention. The term "linked" includes direct or indirect (such as with the provision of suitable spacer sequence(s)) linkages.

25 The additional expression element may enhance expression or inhibit undesirable expression.

The additional expression element may even be a promoter, wherein that promoter may be the same as or different to the promoter of the present invention, or even a part thereof.

30 The present invention also encompasses repeating units of promoters - such as tandem repeats that comprise at least two promoter elements - one of which will be the promoter of the present invention - such as three promoter elements.

35 Preferably the additional expression elements are located intermediate the promoter of the present invention and the NOI. Should it be desirable, the additional expression elements and the promoter of the present invention may be separated by suitable restriction sites.

In this respect, we have found that in some transformed hosts, such as transformed plants (such as transformed guar), expression levels of the NOI can be elevated. This is important if it is desirable to have such an elevated expression.

5

In one aspect, the NOI is an antisense nucleotide sequence.

In this respect, preferably the NOI is a sequence that is antisense to all or part of the gene encoding an epimerase, in particular a UDP galactose epimerase, more in particular a UDP galactose-4-epimerase (EC 5.1.3.3).

10

If the NOI is a sequence that is antisense to all or part of the gene encoding a UDP galactose epimerase - more in particular a UDP galactose-4-epimerase (EC 5.1.3.3) - then expression of that antisense sequence by the promoter of the present invention could affect the galactose units (such as causing a decrease thereof) on a galactomannan or other extracellular polysaccharides.

15

In an alternative aspect, the NOI is a sense nucleotide sequence.

Here, the NOI may be a sequence that constitutes all or part of the gene encoding a UDP galactose epimerase, more in particular a UDP galactose-4-epimerase (EC 5.1.3.3).

20

#### PROMOTER

25

Thus, the present invention relates to a novel regulatory sequence, namely a promoter - which we have called the RSus3 promoter.

30

The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.

The promoter may be the same as the naturally occurring form - for this aspect, preferably the promoter is not present in its natural environment. In addition, or in the alternative, the promoter is in an isolated and/or in a purified form. The promoter of the present invention can be a variant, homologue, fragment or derivative of the naturally occurring promoter. The promoter can be obtainable from or produced by

35

any suitable source, whether natural or not, or it may be synthetic, semi-synthetic or recombinant.

5 A nucleotide sequence comprising the promoter of the present invention and other associated nucleotide sequences is schematically presented in Figure 1 (which is not to scale).

10 In this respect, the promoter sequence SEQ ID No. 1 is shown as Box A. As can be seen, Box A comprises two units - which have been shown diagrammatically as Box B and Box C. Box B corresponds to SEQ ID No. 6 and Box C corresponds to SEQ ID No. 4. SEQ ID No. 6 is the sequence up to the TATA box. SEQ ID No. 4 is the first part of an exon sequence.

15 In accordance with the present invention we have found that expression may still be achieved in some host cells with the promoter of the present invention in the absence of all or part of SEQ ID No. 4. In this respect, the promoter of the present invention would be represented as SEQ ID No. 6 and the comments concerning SEQ ID No. 1 would equally apply to SEQ ID No. 6.

20 Figure 1 also shows Box D - which corresponds to SEQ ID No. 2. SEQ ID No. 2 is an intron sequence. In accordance with the present invention we have found that surprisingly expression can still be achieved with the promoter of the present invention in the absence of all or part of SEQ ID No. 2. Thus, in one embodiment of the present invention the promoter of the present invention is not used in conjunction  
25 with all or part of SEQ ID No. 2.

However, in some instances we have surprisingly found that SEQ ID No. 2 can elevate expression levels of an NOI and/or increase the selectivity of the expression. Hence, in an alternative preferred embodiment of the present invention the promoter  
30 of the present invention is used in conjunction with all or part of SEQ ID No. 2.

Figure 1 also shows Box E - which corresponds to SEQ ID No. 5. SEQ ID No. 5 is the second part of the exon sequence associated with SEQ ID No. C. For some applications, the promoter sequence of the present invention is contained within a  
35 nucleotide sequence wherein SEQ ID No. 4 is fused to SEQ ID No. 5.

Thus, schematically, and by way of example, the promoter of the present invention may be represented as any one or more of: Box A; Box B with or without Box C; Box A with Box D; Box B - with or without Box C - with Box D; Box A with Box E; Box B - with or without Box C - with Box E; Box A with Box D and Box E; Box B - with or without Box C - with Box D and Box E.

It is to understood that: Box A represents SEQ ID No. 1 or a variant, homologue, fragment or derivative thereof, preferably, Box A represents SEQ ID No. 1; Box B represents SEQ ID No. 6 or a variant, homologue, fragment or derivative thereof, preferably, Box B represents SEQ ID No. 6; Box C represents SEQ ID No. 4 or a variant, homologue, fragment or derivative thereof, preferably, Box C represents SEQ ID No. 4; Box D represents SEQ ID No. 2 or a variant, homologue, fragment or derivative thereof, preferably, Box D represents SEQ ID No. 2; Box E represents SEQ ID No. 5 or a variant, homologue, fragment or derivative thereof, preferably, Box E represents SEQ ID No. 5.

In our analysis of the promoter of the present invention we have identified a number of interesting expression elements/functional elements which resemble consensus sequences or parts thereof.

These identified sequences are presented in Table 1 below.



TABLE 1

Functional elements in the RSus3 promoter region	Position	Position (-intron)	RSus3 sequence <sup>1</sup>	Consensus sequence	Reference (Consensus sequence)
Translation start site	+1	+1	CAATGG	CAATGG	[Joshi 1987]
Intron 1 (Acceptor splice site)	-27		TCCAG GC	TGCAG GT	[Simpson & Filipowicz 1996], consensus for monocots
Intron 1 (Donor splice site)	-892		AG GTAGAG	AG GTAAGT	
TATA box	-986	-121	TATAAATA	TATATATA	[Joshi 1987]
CAAT box	-999	-134	GCACATTTT	GGNCAATCT	
GCN4 box	-1032	-167	GTGAGGCAG	(G/A)TGA(G/C)TC A(T/G)	[Müller & Knudsen 1993], cis-element involved in endosperm specificity
Endosperm boxes	-1072	-207	AGTAAAG	TG(T/C/A)AAA(G/A)	[Marzábal et al. 1998], cis-element involved in endosperm specificity
	-1130	-265	TGCAAAAC		
	-1349	-484	TGTCAAA		
Legumin boxes (RY repeats)	-1539	-674	CGTGCATG	CATGCATG	[Bäumlein et al. 1992] cis-element involved in seed specificity
	-1586	-721	CATGTATG		
	-1624	-759	CATGCATA		
	-1707	-842	CATGCATGCATG		
	-2115	-1250	CATGCCTG		
	-2480	-1615	CAGGCATGCATC		

1. Deviations from the consensus sequence are in cursive.

5

We currently believe that at least one or more, such as all, of those identified sequences that are the same as or similar to the consensus sequences should be present in the promoter sequence of the present invention.

As indicated above, the promoter can additionally include or be used with features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box.

- 5 The promoter may even contain or be used with other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the nucleotide sequence of the present invention. For example, suitable other sequences may include the Sh1-intron or an ADH intron. Other sequences may include inducible elements - such as temperature, chemical, light or stress inducible elements. Also, suitable elements to  
10 enhance transcription or translation may be present. An example of the latter element is the TMV 5' signal sequence (see Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).

- 15 The promoter of the present invention may be used in combination with one or more other expression elements or functional elements or regulatory elements.

- 20 The terms "expression elements", "functional elements" and "regulatory elements" include enhancers, expression regulation signals, secretion leader sequences, promoter consensus sequences, terminator sequences, and may even include other promoters.

The present invention also encompasses hybrid promoters that comprise at least a part of the promoter of the present invention and at least a part of another promoter.

- 25 Hybrid promoters may also be used to improve inducible regulation of the expression construct.

- 30 As indicated above, the present invention also encompasses tandem promoters wherein at least one of the promoters is the promoter of the present invention. If the other promoter is a promoter of the present invention or part thereof then that combination may be called a tandem repeat.

- 35 The other promoter may even be another promoter or part thereof. By way of example, the other promoter may be selected for its efficiency in directing the expression of the NOI in the desired expression host.

In one embodiment, a constitutive promoter may be selected to direct the expression of the NOI. Such an expression construct may provide additional advantages since it may circumvent the need to culture the expression hosts on a medium containing an inducing substrate. Examples of strong constitutive and/or inducible promoters which are preferred for use in, for example, fungal expression hosts are those which are obtainable from the fungal genes for xylanase (*xlnA*), phytase, ATP-synthetase, subunit 9 (*oliC*), triose phosphate isomerase (*tpi*), alcohol dehydrogenase (*AdhA*),  $\alpha$ -amylase (*amy*), amyloglucosidase (AG - from the *glaA* gene), acetamidase (*amdS*) and glyceraldehyde-3-phosphate dehydrogenase (*gpd*) promoters. Examples of strong yeast promoters are those obtainable from the genes for alcohol dehydrogenase, 3-phosphoglycerate kinase and triosephosphate isomerase. Examples of strong bacterial promoters are the  $\alpha$ -amylase and *SP02* promoters as well as promoters from extracellular protease genes. Examples of strong plant promoters are the CaMV promoter and the SV40 35S promoter and the NOS promoter.

For some applications, preferably the promoter is stably incorporated within the transformed organism's genome.

The term "transformed" is synonymous with the term "transgenic".

In a preferred aspect, the promoter is linked to the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or fragment thereof.

## NATURALLY OCCURRING

As used herein "naturally occurring" refers to the promoter sequence found in nature - i.e. the wild type promoter.

**ISOLATED/PURIFIED**

As used herein, the terms "isolated" and "purified" refer to nucleic acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

**BIOLOGICALLY ACTIVE**

As used herein "biologically active" refers to a promoter according to the present invention - such as a recombinant promoter - having a similar structural function (but not necessarily to the same degree), and/or similar regulatory function (but not necessarily to the same degree), and/or similar biochemical function (but not necessarily to the same degree) of the naturally occurring promoter. Specifically, a promoter of the present invention has the ability to express a NOI in endosperm, preferably selectively in endosperm.

**DELETION**

As used herein, a "deletion" is defined as a change in the nucleotide sequence in which one or more nucleotides are absent.

**INSERTION/ADDITION**

As used herein, an "insertion" or "addition" is a change in the nucleotide sequence which has resulted in the addition of one or more nucleotides as compared to the naturally occurring promoter.

**SUBSTITUTION**

As used herein, "substitution" results from the replacement of one or more nucleotides or by one or more different nucleotides.

**VARIANT/HOMOLOGUE**

The terms "variant" or "homologue" with respect to the nucleotide sequence of the present invention are synonymous with allelic variations of the sequences.

In particular, the term "homology" as used herein may be equated with the term "identity". Here, sequence homology with respect to the nucleotide sequence of the present invention can be determined by a simple "eyeball" comparison (i.e. a strict comparison) of any one or more of the sequences with another sequence to see if  
5 that other sequence has at least 75% identity to the sequence(s). Relative sequence homology (i.e. sequence identity) can also be determined by commercially available computer programs that can calculate % homology between two or more sequences. A typical example of such a computer program is CLUSTAL.

10 Sequence homology (or identity) may even be determined using any suitable homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html), which is incorporated herein by reference. The search parameters are defined as  
15 follows, and are advantageously set to the defined default parameters.

Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in  
20 BLAST searching is usually 10.

BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin and  
25 Altschul (see [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html)) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al* (1994) Nature  
30 Genetics 6:119-129.

The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks:

35 **blastp** compares an amino acid query sequence against a protein sequence database;

**blastn** compares a nucleotide query sequence against a nucleotide sequence database;

**blastx** compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

**tblastn** compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

**tblastx** compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

**HISTOGRAM** Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

**DESCRIPTIONS** Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also EXPECT and CUTOFF.

**ALIGNMENTS** Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

**EXPECT** The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

**CUTOFF** Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database

sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds  
5 can be more intuitively managed using EXPECT.

MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate  
10 scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just  
15 reading frames on the top or bottom strand of the query sequence.

FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity  
20 internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or proline-rich regions), leaving the more  
25 biologically interesting regions of the query sequence available for specific matching against database sequences.

Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") and the letter "X" in protein  
30 sequences (e.g., "XXXXXXXXXX").

Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

35 It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety,

indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

- NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

Preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>.

- Other computer program methods to determine identify and similarity between the two sequences include but are not limited to the GCG program package (Devereux *et al* 1984 Nucleic Acids Research 12: 387 and FASTA (Atschul *et al* 1990 J Molec Biol 403-410).
- Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used:

<b>FOR BLAST</b>	
GAP OPEN	0
GAP EXTENSION	0

<b>FOR CLUSTAL</b>	DNA
WORD SIZE	2
GAP PENALTY	10
GAP EXTENSION	0.1

- Most preferably, sequence comparisons are conducted using DNASIS™.

As used herein, the terms "variant", "homologue", "fragment" and "derivative" embrace allelic variations of the sequences.

- The term "variant" also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.



## HYBRIDISATION

The term "hybridisation" (sometimes written as "hybridization") as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY) as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies as described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

10

Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

15

Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na<sup>+</sup> at 65-68 °C

Maximum stringency typically occurs at about  $T_m - 5^\circ\text{C}$  (5°C below the  $T_m$  of the probe).

30

High stringency typically occurs at about 5°C to 10°C below the  $T_m$  of the probe. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na<sup>+</sup> pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

35

Moderate, or intermediate, stringency typically occurs at about 10°C to 20°C below the T<sub>m</sub> of the probe.

- 5 Low stringency typically occurs at about 20°C to 25°C below the T<sub>m</sub> of the probe.

As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences, while an intermediate (or low) stringency hybridization can be used to identify or detect similar  
10 or related polynucleotide sequences.

Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.  
15

Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

- 20 It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, *et al.*, eds. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York or Ausubel, *et al.*, eds.  
25 (1990) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the probe also play a role.

#### NUCLEOTIDE SEQUENCE

- 30 The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variants, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin which may be double-stranded or single-  
35 stranded whether representing the sense or antisense strand.

Preferably, the term "nucleotide sequence" means DNA.

In a preferred embodiment, the nucleotide sequence *per se* of the present invention does not cover the native nucleotide sequence according to the present invention in its natural environment when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence".

Typically, the nucleotide sequence of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers MH *et al* (1980) Nuc Acids Res Symp Ser 215-23, Horn T *et al* (1980) Nuc Acids Res Symp Ser 225-232).

The present invention also encompasses nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar sequences in other organisms etc.

The present invention also encompasses nucleotide sequences that are capable of hybridising to the sequences presented herein, or any derivative, fragment or derivative thereof.

The present invention also encompasses nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.

The term "variant" also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.

Preferably, the term "variant" encompasses sequences that are complementary to sequences that are capable of hybridising under stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na<sub>3</sub> citrate pH 7.0}) to the nucleotide sequences presented herein.

The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).

- 5 The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).

Also included within the scope of the present invention are polynucleotide sequences  
10 that are capable of hybridizing to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency.

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions  
15 (e.g. 65°C and 0.1xSSC).

Advantageously, the invention provides nucleic acid sequences which are capable of hybridising, under stringent conditions, to a fragment of SEQ. ID. No. 1. Preferably, the fragment is between 15 and 50 bases in length. Advantageously, it is about 25  
20 bases in length.

By knowledge of the nucleic acid sequences set out herein it is possible to devise partial and full-length nucleic acid sequences such as cDNA and/or genomic clones. Nucleic acid sequences obtained by PCR - such as fragments of the full length  
25 sequence, preferably fragments having unique sequences - may then be used to obtain same or similar sequences using hybridization library screening techniques. The fragments may be from 10 to 100 nucleotides long. Preferably, the fragments may be from 15 to 90 nucleotides long. More preferably, the fragments may be from 20 to 80 nucleotides long.

30

By way of example, a PCR clone may be labelled with radioactive atoms and used to screen a genomic library from other species, preferably other plant species. Hybridization conditions will typically be conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to  
35 about 60°C).

Degenerate nucleic acid probes encoding all or part of the amino acid sequence may also be used to probe cDNA and/or genomic libraries from other species, preferably other plant species or fungal species. However, it is preferred to carry out PCR techniques initially to obtain a single sequence for use in further screening procedures.

Polynucleotide sequences of the present invention obtained using the techniques described above may be used to obtain further homologous sequences and variants using the techniques described above.

Thus, polynucleotides of the present invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the present invention as used herein.

Polynucleotides or primers of the present invention may carry a revealing label. Suitable labels include radioisotopes such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , enzyme labels, or other labels such as biotin or digoxigenin. The DIG<sup>TM</sup> system (Boehringer Mannheim) is useful as it offers a very attractive non-radioactive system. The DIG system is based on the steroid hapten digoxigenin, which occurs exclusively in Digitalis plants and thus avoids endogenous background problems as in the case of other haptens, such as biotin. Such labels may be added to polynucleotides or primers of the present invention and may be detected using by techniques known *per se*.

Polynucleotides such as a DNA polynucleotide and primers according to the present invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using PCR cloning techniques. This will involve making a pair of primers

(e.g. of about 15-30 nucleotides) to a region of the nucleotide sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from a fungal, plant or prokaryotic cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

The nucleotide sequence of the present invention may be engineered in order to alter its activity for a number of reasons, including but not limited to, alterations which modify the processing and/or expression. For example, mutations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns or to change codon preference. By way of further example, the nucleotide sequence of the present invention may also be modified to optimise expression in a particular host cell - such as the inclusion of additional promoter(s) or parts thereof, such as the provision of tandem repeats, and/or the provision of other expression elements such as the intron sequence. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites.

#### VARIANT, HOMOLOGUE AND FRAGMENT OF THE PROMOTER NUCLEOTIDE SEQUENCE

The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a promoter, preferably being at least as biologically active as the promoter having the sequence shown as SEQ ID No. 1. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as a promoter. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as SEQ ID No. 1. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as SEQ ID No. 1.

The present invention also relates to DNA segments comprising the DNA sequence of SEQ ID No. 1 or allelic variations of such sequences. These segments are capable of acting as a regulatory region/unit.

5 VARIANT, HOMOLOGUE AND FRAGMENT OF NUCLEOTIDE SEQUENCE SEQ ID NO. 2

The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence of the present invention include any substitution of, variation of, modification of, 10 replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to increase expression levels, preferably being at least as biologically active as the sequence shown as SEQ ID No. 2. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the 15 ability to increase expression levels. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as SEQ ID No. 2. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as SEQ ID No. 2.

20

The present invention also relates to DNA segments comprising the DNA sequence of SEQ ID No. 2 or allelic variations of such sequences. These segments are capable of increasing expression levels.

25 VARIANT, HOMOLOGUE AND FRAGMENT OF ANY ONE OR MORE OF THE IDENTIFIED NUCLEOTIDE SEQUENCES IN TABLE 1

The terms "variant", "homologue" or "fragment" in relation to any one of the nucleotide sequences presented in Table 1 include any substitution of, variation of, modification 30 of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to influence expression. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to influence expression. With respect to sequence homology, preferably there is at least 35 75%, more preferably at least 85%, more preferably at least 90% homology to the respective sequence shown in Table 1. More preferably there is at least 95%, more preferably at least 98%, homology to the respective sequence shown in Table 1.

## NOI/POI

In a preferred aspect, the present invention relates to the use of the promoter of the present invention to express one or more suitable NOIs.

Thus, in a preferred aspect, the promoter is operably linked to a NOI.

The term "operably linked" refers to a relationship - such as in a suitable juxtaposition - wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a NOI is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The NOI can encode for a POI.

The NOI can be any suitable sequence encoding a polypeptide of interest, other than the complete natural sequence normally associated with the promoter of the present invention when the NOI is operably linked to the promoter in their natural environment.

Preferably, the NOI does not include all of the nucleotide sequence naturally associated with the wild type promoter of the present invention.

The NOI can be any nucleotide sequence that is either foreign (heterologous) or natural (homologous) to the organism in question - which may be a filamentous fungus or a plant.

Typically, the POI may be any suitable prokaryotic or eukaryotic heterologous or homologous peptide or protein of interest.

For some applications, the POI may be secreted and/or retrieved.

For some applications, it is important that the POI is secreted and/or retrieved.

For some applications, the POI may not be secreted and/or retrieved.

For some applications, it is important that the POI is not secreted and/or retrieved.



The NOI may even be a sequence which is capable of expressing a nucleic acid, for example a regulatory RNA such as an antisense RNA or a ribozyme, an mRNA, or a tRNA or rRNA capable of regulating the metabolism of an organism.

5

The NOI may also be a homologous nucleotide sequence which has been mutated, such as by insertion, addition, deletion or alteration, such that it is no longer identical with the natural homologous nucleotide sequence.

10 The POI can be a single-chain polypeptide molecule as well as a multiple-polypeptide complex where individual constituent polypeptides are linked by covalent or non-covalent means. Here, the term "polypeptide" includes peptides of two or more amino acids in length, typically having more than 5, or more than 10 or more than 20 amino acids.

15

Typical examples of a NOI include sequences coding for proteins and enzymes that modify metabolic and catabolic processes. The heterologous nucleotide sequence may code for an agent for introducing or increasing pathogen resistance. The heterologous nucleotide sequence may be an antisense construct for modifying the  
20 expression of natural transcripts present in the relevant tissues.

The heterologous nucleotide sequence may be a protein giving nutritional value to a food or crop. Typical examples include plant proteins that can aid human or animal digestion, inhibit the formation of anti-nutritive factors and those plant proteins that  
25 have a more desirable amino acid composition (e.g. a higher lysine content than a non-transgenic plant).

Non-limiting examples of POIs include, for example, proteins involved in the regulation of cell division, for example growth factors including neurotrophic growth factors, cytokines (such as  $\alpha$ -,  $\beta$ - or  $\gamma$ -interferon, interleukins including IL-1, IL-2, tumour  
30 necrosis factor, or insulin-like growth factors I or II), protein kinases (such as MAP kinase), protein phosphatases and cellular receptors for any of the above.

The POI may also be an enzyme involved in cellular metabolic pathways, for  
35 example enzymes involved in carbohydrate biosynthesis or degradation, amino acid biosynthesis or degradation (such as tyrosine hydroxylase), purine or pyrimidine biosynthesis or degradation, and the biosynthesis or degradation of

neurotransmitters, such as dopamine, or a protein involved in the regulation of such pathways, for example protein kinases and phosphatases.

The POI may also be effective in the post-harvest processing of plants - e.g. in the  
5 brewing or baking processes.

The POI may also be a transcription factors or proteins involved in their regulation, for example pocket proteins of the Rb family such as Rb or p107, membrane proteins, structural proteins or heat shock proteins such as hsp70.

10

The NOI may code for an intron of a particular nucleotide sequence, wherein the intron can be in sense or antisense orientation.

Non-limiting examples of POIs include: proteins or enzymes involved in starch  
15 metabolism, proteins or enzymes involved in glycogen metabolism, acetyl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carboxypeptidases, catalases, cellulases, chitinases, chymosin, cutinase, deoxyribonucleases, epimerases, esterases,  $\alpha$ -galactosidases,  $\beta$ -galactosidases,  $\alpha$ -glucanases, glucan lysases, endo- $\beta$ -glucanases, glucoamylases, glucose oxidases,  $\alpha$ -glucosidases,  $\beta$ -glucosidases,  
20 glucuronidases, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, lipases, lyases, mannosidases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, rhamno-galacturonases, ribonucleases, thaumatin, transferases, transport proteins,  
25 transglutaminases, xylanases, or combinations thereof. The NOI may even be an antisense sequence for any of those sequences.

The NOI can be the nucleotide sequence coding for the exo-amylase enzyme which is the subject of PCT patent application PCT/IB99/00649 (incorporated herein by  
30 reference).

The NOI can be the nucleotide sequence coding for the xylanase enzymes and mutants thereof which are the subject of UK patent application GB 99078057 (incorporated herein by reference).

35

The NOI can be the nucleotide sequence coding for the arabinofuranosidase enzyme which is the subject of PCT patent application PCT/EP96/01009 (incorporated herein by reference).

- 5 The NOI can be any of the nucleotide sequences coding for the ADP-glucose pyrophosphorylase enzymes which are the subject of PCT patent application PCT/EP94/01082 (incorporated herein by reference).

- The NOI can be any of the nucleotide sequences coding for the  $\alpha$ -glucan lyase enzyme  
10 which are described in PCT patent application PCT/EP94/03397 (incorporated herein by reference).

The NOI can be any of the sequences coding for *T. lanuginosus* amylase, as described in PCT patent application PCT/EP95/02607, incorporated herein by reference.

15

The NOI can be any of the nucleotide sequences coding for the glucanase enzyme which are described in PCT patent application PCT/EP96/01008 (incorporated herein by reference).

- 20 The NOI can be any of the nucleotide sequences coding for the UDP-galactose epimerase enzyme, as well as anti-sense sequences therefor, - such as those which are described in PCT patent application WO-A-98/54335 (incorporated herein by reference).

- 25 The NOI can be *hox* from the red algae *Chondrus crispus* or *lipA* from *Aspergillus niger*.

- The POI can be a PME as disclosed in WO-A-97/03574 or the PME disclosed in either WO-A-94/25575 or WO-A-97/31102 as well as variants, derivatives or homologues of  
30 the sequences disclosed in those patent applications.

The POI may even be a fusion protein, for example to aid in extraction and purification.

- 35 Examples of fusion protein partners include the maltose binding protein, glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation

domains) and  $\beta$ -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion components.

The POI may even be fused to a secretion sequence. Examples of secretion leader sequences are those originating from the amyloglucosidase gene, the  $\alpha$ -factor gene, the  $\alpha$ -amylase gene, the lipase A gene, the xylanase A gene.

Other sequences can also facilitate secretion or increase the yield of secreted POI. Such sequences could code for chaperone proteins as for example the product of *Aspergillus niger cyp B* gene described in UK patent application 9821198.0.

The NOI may be engineered in order to alter their activity for a number of reasons, including but not limited to, alterations which modify the processing and/or expression of the expression product thereof. For example, mutations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns or to change codon preference. By way of further example, the NOI may also be modified to optimise expression in a particular host cell. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites.

The NOI may include within it synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the NOI may be modified by any method available in the art. Such modifications may be carried out in to enhance the *in vivo* activity or life span of the NOI.

The NOI may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule.

## CONSTRUCTS

The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes the nucleotide sequence according to the present invention

directly or indirectly attached to a NOI. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the NOI. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In each case, the terms do not cover the natural combination of the wild type gene promoter and its associated nucleotide sequence when they are both in their natural environment.

The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a plant cell into which it has been transferred.

The selectable marker means may reside on an additional vector or may be included in the nucleic acid molecule which contains the expression system. The nature of the selectable marker means will depend on the nature of the host and the culture conditions. The most suitable selection systems for industrial micro-organisms are those formed by the group of selection markers which do not require a mutation in the host organism.

US-A-5358864 provides a short list of suitable selectable marker genes that may be used in the present invention - examples of which include fungal selection markers such as those that are the genes for acetamidase (*amdS*), ATP synthetase, subunit 9 (*oliC*) and benomyl resistance (*benA*).

Examples of non-fungal selection markers are the bacterial G418 resistance gene (this may also be used in yeast, but not in fungi), the ampicillin resistance gene (*E. coli*), the neomycin resistance gene (*Bacillus*) and the *E.coli uidA* gene, coding for  $\beta$ -glucuronidase (GUS).

In certain aspects of the present invention, use of the *ble* marker - which confers resistance to phleomycin/bleomycin/zeocin - may be preferred. However, other selection markers, known in the art, could be used. Examples of auxotrophic markers are *pyrG* selecting for uridine prototrophs, *argB* selecting for arginine prototrophs, *niaD* selecting for nitrate prototrophs, *trpC* selecting for tryptophan prototrophs, *amdS* selecting for increased utilisation of acetamide as sole nitrogen source. Dominant resistance markers could be chosen from *oliC3* conferring resistance to oligomycin, *hph* conferring resistance to hygromycin B, *bar* conferring resistance to bialaphos or *NPTII* conferring resistance to G418.

The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a bacterium, preferably of the genus *Bacillus*, such as *Bacillus subtilis*, or plants, such as potatoes, sugar beet etc., into which it has  
5 been transferred.

The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a plant. Various markers exist which may be used, such as for example those encoding mannose 6-phosphate isomerase,  
10 glucosamine 6-phosphate deaminase/ketoisomerase, xylose isomerase, or those markers that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin.

#### VECTORS

15

The term "vector" includes expression vectors, replicable vectors, transformation vectors and shuttle vectors, including vector combinations thereof.

20

The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

Preferably the expression vector is incorporated in the genome of the organism. The term "incorporated" preferably covers stable incorporation into the genome.

25

Preferably, the vector of the present invention comprises a construct according to the present invention. Alternatively expressed, preferably the promoter of the invention is present in a vector and wherein the promoter is operably linked to a NOI such that the promoter is capable of providing for the expression of the coding sequence by a suitable host organism, i.e. the vector is an expression vector.

30

The term "transformation vector" means a construct capable of being transferred from one entity to another entity - which may be of the species or may be of a different species. If the construct is capable of being transferred from one species to another - such as from an *E.coli* plasmid to a bacterium, such as of the genus *Bacillus*, then the  
35 transformation vector is sometimes called a "shuttle vector". It may even be a construct capable of being transferred from an *E.coli* plasmid to an *Agrobacterium* to a plant.

The vectors of the present invention may be transformed into a suitable host cell to provide for expression of a POI.

5 Thus, in a further aspect the invention provides a process for preparing a POI invention which comprises cultivating a host cell transformed or transfected with an expression vector under conditions to provide for expression by the promoter of the present invention of a NOI encoding the POI, and optionally recovering the expressed POI.

10

Typically, the nucleotide sequences of the invention may be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host organism.

15 Thus, in a further embodiment, the invention provides a method of introducing a nucleotide sequence of the invention into a replicable vector, introducing the vector into a compatible host organism, and growing the host organism under conditions which bring about expression of a NOI by the promoter of the present invention. The POI may then be recovered from the host organism. Suitable host organisms include  
20 plants or plant cells.

The NOI may be incorporated into a replicable vector, for example a cloning or expression vector, which comprises a promoter of the present invention. The vector may be used to replicate the NOI in a compatible host cell.

25

Thus, in a further embodiment, the invention provides a method of making NOIs by introducing a NOI into a replicable vector which comprises the promoter of the present invention, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may  
30 be recovered from the host cell.

The vectors may be for example, plasmid, virus or phage vectors. In addition to the promoter of the present invention, the vectors may be provided with any one or more of an origin of replication, a NOI operably linked to the promoter for the expression of  
35 the NOI, and a regulator of the promoter.

Vectors may be used, for example, to transfect or transform a host organism either *in*

*vitro* or *in vivo*.

Such vectors may be transformed or transfected into a suitable host organism to provide for expression of a protein of the invention. This process may comprise  
5 culturing a host organism transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein.

Vectors of the invention may be introduced into host organisms for the purpose of  
10 replicating the vectors/nucleotide sequences and/or expressing the NOI. In one preferred aspect, the host organism is a plant cell.

Vectors of the present invention may introduced into suitable host organisms using a variety of techniques known in the art, such as transfection, transformation and  
15 electroporation. Another technique is the protoplast transformation method (Winer *et al.*, Microbiology, 1985, 468, American Society for Microbiology).

Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell.

20

#### TISSUE

The term "tissue" as used herein includes tissue *per se* and organ.

25

#### HOST CELLS

The term "host cell" - in relation to the present invention includes any cell that could comprise the promoter of the present invention and/or products obtained therefrom, wherein the promoter can allow expression of a NOI when present in the host cell.

30

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a promoter of the present invention. Preferably the promoter is carried in a vector for the replication and expression of NOIs. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for  
35 example bacterial), fungal, yeast or plant cells.

Preferably, the host cell is a plant cell.



The gram-negative bacterium *E. coli* is widely used as a host for heterologous gene expression. However, large amounts of heterologous protein tend to accumulate inside the cell. Subsequent purification of the desired protein from the bulk of *E. coli* intracellular proteins can sometimes be difficult.

In contrast to *E. coli*, bacteria from the genus *Bacillus* are very suitable as heterologous hosts because of their capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera *Streptomyces* and *Pseudomonas*.

Depending on the nature of the NOI encoding the POI, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a fungal host organism should be selected.

Examples of suitable expression hosts within the scope of the present invention are fungi such as *Aspergillus* species (such as those described in EP-A-0184438 and EP-A-0284603) and *Trichoderma* species; bacteria such as *Bacillus* species (such as those described in EP-A-0134048 and EP-A-0253455), *Streptomyces* species and *Pseudomonas* species; and yeasts such as *Kluyveromyces* species (such as those described in EP-A-0096430 and EP-A-0301670) and *Saccharomyces* species. By way of example, typical expression hosts may be selected from *Pichia pastoris*, *Hansenula polymorpha*, *Aspergillus niger*, *Aspergillus niger* var. *tubigenis*, *Aspergillus niger* var. *awamori*, *Aspergillus aculeatis*, *Aspergillus nidulans*, *Aspergillus oryzae*, *Trichoderma reesei*, *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Kluyveromyces lactis* and *Saccharomyces cerevisiae*.

The use of suitable host cells - such as yeast, fungal and plant host cells - may provide for post-translational modifications (e.g. myristolation, glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

Thus, the present invention also provides a method of transforming a host cell with a nucleotide sequence shown as SEQ ID No. 1 or a derivative, homologue, variant or fragment thereof.

5 Host cells transformed with a promoter according to the present invention operably linked to a NOI may be cultured under conditions suitable for the expression and recovery of the POI from cell culture. The POI may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing a promoter  
10 according to the present invention operably linked to a NOI can be designed with signal sequences which direct secretion of the NOI/POI through a particular prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join the NOI to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll *DJ et al* (1993) *DNA Cell Biol* 12:441-53).

15

#### ORGANISM

The term "organism" in relation to the present invention includes any organism that could comprise the nucleotide sequence of the present invention, wherein the promoter  
20 can allow expression of a NOI when present in the organism. Examples of organisms may include a fungus, yeast or a plant.

The term "transgenic organism" in relation to the present invention includes any organism that comprises the nucleotide sequence of the present invention, wherein the  
25 promoter can allow expression of a NOI within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

The term "transgenic organism" does not cover the native nucleotide sequence according to the present invention in its natural environment when it is operably linked  
30 to its associated coding sequence which is also in its natural environment.

Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence of the present invention, constructs according to the present invention (including combinations  
35 thereof), vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof. The transformed cell or organism could prepare

acceptable quantities of the POI. In some instances, the POI may be easily retrievable from, the cell or organism.

#### TRANSFORMATION OF HOST CELLS/HOST ORGANISMS

5

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook *et al* (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press) and Ausubel *et al.*, Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

10

If a prokaryotic host is used then the NOI may need to be suitably modified before transformation - such as by removal of introns.

15

#### TRANSFORMED FUNGUS

A host organism may be a fungus - such as a mold. Examples of suitable such hosts include any member belonging to the genera *Thermomyces*, *Acremonium*, *Aspergillus*, *Penicillium*, *Mucor*, *Neurospora*, *Trichoderma* and the like - such as *Thermomyces lanuginosis*, *Acremonium chrysogenum*, *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus awamori*, *Penicillium chrysogenum*, *Mucor javanicus*, *Neurospora crassa*, *Trichoderma viridae* and the like.

20

In one embodiment, the host organism may be a filamentous fungus.

25

For almost a century, filamentous fungi have been widely used in many types of industry for the production of organic compounds and enzymes. For example, traditional Japanese koji and soy fermentations have used *Aspergillus sp.* Also, in this century *Aspergillus niger* has been used for production of organic acids particular citric acid and for production of various enzymes for use in industry.

30

There are two major reasons why filamentous fungi have been so widely used in industry. First filamentous fungi can produce high amounts of extracellular products, for example enzymes and organic compounds such as antibiotics or organic acids. Second filamentous fungi can grow on low cost substrates such as grains, bran, beet

35

pulp etc. The same reasons have made filamentous fungi attractive organisms as hosts for heterologous expression according to the present invention.

In order to prepare the transgenic *Aspergillus*, expression constructs are prepared by inserting the nucleotide sequence according to the present invention (and optionally the NOI) into a construct designed for expression in filamentous fungi.

Several types of constructs used for heterologous expression have been developed. These constructs preferably contain one or more of: a signal sequence which directs the POI to be secreted, typically being of fungal origin, and a terminator (typically being active in fungi) which ends the expression system.

Another type of expression system has been developed in fungi where the nucleotide sequence according to the present invention (and optionally the NOI) can be fused to a smaller or a larger part of a fungal gene encoding a stable protein. This can stabilise the POI. In such a system a cleavage site, recognised by a specific protease, can be introduced between the fungal protein and the POI, so the produced fusion protein can be cleaved at this position by the specific protease thus liberating the POI. By way of example, one can introduce a site which is recognised by a KEX-2 like peptidase found in at least some *Aspergilli*. Such a fusion leads to cleavage *in vivo* resulting in production of the expressed product and not a larger fusion protein.

Heterologous expression in *Aspergillus* has been reported for several genes coding for bacterial, fungal, vertebrate and plant proteins. The proteins can be deposited intracellularly if the nucleotide sequence according to the present invention (or even the NOI) is not fused to a signal sequence. Such proteins will accumulate in the cytoplasm and will usually not be glycosylated which can be an advantage for some bacterial proteins. If the nucleotide sequence according to the present invention (or even the NOI) is equipped with a signal sequence the protein will accumulate extracellularly.

With regard to product stability and host strain modifications, some heterologous proteins are not very stable when they are secreted into the culture fluid of fungi. Most fungi produce several extracellular proteases which degrade heterologous proteins. To avoid this problem special fungal strains with reduced protease production have been used as host for heterologous production.

Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to *N. crassa* is found, for example in Davis and de Serres, Methods Enzymol (1971) 17A:79-143. Standard procedures are generally used for the maintenance of strains and the preparation of conidia. Mycelia are typically grown in liquid cultures for about 14 hours (25°C), as described in Lambowitz *et al.*, J Cell Biol (1979) 82:17-31. Host strains can generally be grown in either Vogel's or Fries minimal medium supplemented with the appropriate nutrient(s), such as, for example, any one or more of: his, arg, phe, tyr, trp, p-aminobenzoic acid, and inositol.

Further teachings on transforming filamentous fungi are reviewed in US-A-5674707 which states that once a construct has been obtained, it can be introduced either in linear form or in plasmid form, e.g., in a pUC-based or other vector, into a selected filamentous fungal host using a technique such as DNA-mediated transformation, electroporation, particle gun bombardment, protoplast fusion and the like. In addition, Ballance 1991 (*ibid*) states that transformation protocols for preparing transformed fungi are based on preparation of protoplasts and introduction of DNA into the protoplasts using PEG and Ca<sup>2+</sup> ions. The transformed protoplasts then regenerate and the transformed fungi are selected using various selective markers.

To allow for selection of the resulting transformants, the transformation typically also involves a selectable gene marker which is introduced with the expression cassette, either on the same vector or by co-transformation, into a host strain in which the gene marker is selectable. Various marker/host systems are available, including the pyrG, argB and niaD genes for use with auxotrophic strains of *Aspergillus nidulans*; pyrG and argB genes for *Aspergillus oryzae* auxotrophs; pyrG, trpC and niaD genes for *Penicillium chrysogenum* auxotrophs; and the argB gene for *Trichoderma reesei* auxotrophs. Dominant selectable markers including amdS, oliC, hyg and phleo are also now available for use with such filamentous fungi as *A. niger*, *A. oryzae*, *A. ficuum*, *P. chrysogenum*, *Cephalosporium acremonium*, *Cochliobolus heterostrophus*, *Glomerella cingulata*, *Fulvia fulva* and *Leptosphaeria maculans* (for a review see Ward in Modern Microbial Genetics, 1991, Wiley-Liss, Inc., at pages 455-495). A commonly used transformation marker is the amdS gene of *A. nidulans* which in high copy number allows the fungus to grow with acrylamide as the sole nitrogen source.

For the transformation of filamentous fungi, several transformation protocols have been developed for many filamentous. Among the markers used for transformation are a number of auxotrophic markers such as *argB*, *trpC*, *niaD* and *pyrG*, antibiotic resistance markers such as benomyl resistance, hygromycin resistance and  
5 phleomycin resistance.

In one aspect, the host organism can be of the genus *Aspergillus*, such as *Aspergillus niger*.

10 A transgenic *Aspergillus* according to the present invention can also be prepared by following the teachings of Rambosek, J. and Leach, J. 1987 (Recombinant DNA in filamentous fungi: Progress and Prospects. CRC Crit. Rev. Biotechnol. 6:357-393), Davis R.W. 1994 (Heterologous gene expression and protein secretion in *Aspergillus*. In: Martinelli S.D., Kinghorn J.R.( Editors) *Aspergillus*: 50 years on. Progress in  
15 industrial microbiology vol 29. Elsevier Amsterdam 1994. pp 525-560), Ballance, D.J. 1991 (Transformation systems for Filamentous Fungi and an Overview of Fungal Gene structure. In: Leong, S.A., Berka R.M. (Editors) Molecular Industrial Mycology. Systems and Applications for Filamentous Fungi. Marcel Dekker Inc. New York 1991. pp 1-29) and Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D., Kinghorn  
20 J.R.( Editors) *Aspergillus*: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666).

#### TRANSFORMED YEAST

25 In another embodiment the transgenic organism can be a yeast.

In this regard, yeast have also been widely used as a vehicle for heterologous gene expression.

30 By way of example, the species *Saccharomyces cerevisiae* has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in *Saccharomyces cerevisiae* has been reviewed by Goodey *et al* (1987, Yeast Biotechnology, D R Berry *et al*, eds, pp 401-429, Allen and Unwin, London) and by King *et al* (1989, Molecular and Cell Biology of Yeasts, E F Walton and  
35 G T Yarronton, eds, pp 107-133, Blackie, Glasgow).

For several reasons *Saccharomyces cerevisiae* is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability.

5 Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of *Saccharomyces cerevisiae*.

A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

10

Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.

15

In order to prepare the transgenic *Saccharomyces*, expression constructs are prepared by inserting the nucleotide sequence of the present invention into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs may contain a promoter active in yeast, such as a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.

20

For the transformation of yeast several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen *et al* (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H *et al* (1983, J Bacteriology 153, 163-168).

25

30

The transformed yeast cells may be selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, eg G418.

35

## TRANSFORMED PLANTS/PLANT CELLS

A preferred host organism suitable for the present invention is a plant.

- 5 In this respect, the basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.

10 Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).

- 15 Even though the promoter of the present invention is not disclosed in EP-B-0470145 and CA-A-2006454, those two documents do provide some useful background commentary on the types of techniques that may be employed to prepare transgenic plants according to the present invention. Some of these background teachings are now included in the following commentary.

20 The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.

- 25 Thus, in one aspect, the present invention relates to a vector system which carries a nucleotide sequence or construct according to the present invention and which is capable of introducing the nucleotide sequence or construct into the genome of an organism, such as a plant.

30 The vector system may comprise one vector, but it can comprise two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An *et al.* (1980), Binary Vectors, *Plant Molecular Biology Manual* A3, 1-19.

- 35 One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from *Agrobacterium tumefaciens* or a Ri plasmid from *Agrobacterium rhizogenes* An *et al.*



(1986), *Plant Physiol.* 81, 301-305 and Butcher D.N. *et al.* (1980), *Tissue Culture Methods for Plant Pathologists*, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.

Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above. A non-limiting example of such a Ti plasmid is pGV3850.

The nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome.

As will be understood from the above explanation, if the organism is a plant, then the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant (e.g. the *vir* region) and at least one border part of a T-DNA sequence, the border part being located on the same vector as the genetic construct. Preferably, the vector system is an *Agrobacterium tumefaciens* Ti-plasmid or an *Agrobacterium rhizogenes* Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.

In the construction of a transgenic plant the nucleotide sequence or construct of the present invention may be first constructed in a micro-organism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful micro-organism is *E. coli.*, but other micro-organisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in *E. coli.* it is transferred, if necessary, into a suitable *Agrobacterium* strain, e.g. *Agrobacterium tumefaciens*. The Ti-plasmid harbouring the nucleotide sequence or construct of the invention is thus preferably transferred into a suitable *Agrobacterium* strain, e.g. *A. tumefaciens*, so as to obtain an *Agrobacterium* cell harbouring the nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified.

As reported in CA-A-2006454, a large amount of cloning vectors are available which contain a replication system in *E. coli* and a marker which allows a selection of the

transformed cells. The vectors contain for example pBR 322, the pUC series, the M13 mp series, pACYC 184 etc.

In this way, the nucleotide or construct of the present invention can be introduced into a  
5 suitable restriction position in the vector. The contained plasmid is used for the transformation in *E.coli*. The *E.coli* cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered. As a method of analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the  
10 used DNA sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in the same or different plasmid.

After each introduction method of the desired promoter or construct or nucleotide sequence according to the present invention in the plants the presence and/or insertion  
15 of further DNA sequences may be necessary. If, for example, for the transformation the Ti- or Ri-plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transformation of plant cells has been intensively studied and is described in EP-A-  
20 120516; Hoekema, in: The Binary Plant Vector System Offset-drukkerij Kanters B.B., Alblasserdam, 1985, Chapter V; Fraley, *et al.*, Crit. Rev. Plant Sci., 4:1-46; and An *et al.*, EMBO J. (1985) 4:277-284.

Direct infection of plant tissues by *Agrobacterium* is a simple technique which has been  
25 widely employed and which is described in Butcher D.N. *et al.* (1980), *Tissue Culture Methods for Plant Pathologists*, eds.: D.S. Ingrams and J.P. Helgeson, 203-208. For further teachings on this topic see Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). With this technique, infection of a plant may be done on a certain part or tissue of  
30 the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant.

Typically, with direct infection of plant tissues by *Agrobacterium* carrying the promoter and/or the GOI, a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound  
35 is then inoculated with the *Agrobacterium*. The inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.

When plant cells are constructed, these cells may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc. Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.

- Other techniques for transforming plants include ballistic transformation, the silicon whisker carbide technique (see Frame BR, Drayton PR, Bagnaall SV, Lewnau CJ, Bullock WP, Wilson HM, Dunwell JM, Thompson JA & Wang K (1994) Production of fertile transgenic maize plants by silicon carbide whisker-mediated transformation, The Plant Journal 6: 941-948) and viral transformation techniques (e.g. see Meyer P, Heidmann I & Niedenhof I (1992) The use of cassava mosaic virus as a vector system for plants, Gene 110: 213-217).

Further teachings on plant transformation may be found in EP-A-0449375.

## BALLISTIC TRANSFORMATION OF PLANTS AND PLANT TISSUE

Originally developed to produce stable transformants of plant species which were recalcitrant to transformation by *Agrobacterium tumefaciens*, ballistic transformation of plant tissue, which introduces DNA into cells on the surface of metal particles, has found utility in testing the performance of genetic constructs during transient expression. In this way, gene expression can be studied in transiently transformed cells, without stable integration of the gene in interest, and thereby without time-consuming generation of stable transformants.

In more detail, the ballistic transformation technique (otherwise known as the particle bombardment technique) was first described by Klein *et al.* [1987], Sanford *et al.* [1987] and Klein *et al.* [1988] and has become widespread due to easy handling and the lack of pre-treatment of the cells or tissue in interest.

The principle of the particle bombardment technique is direct delivery of DNA-coated micro-projectiles into intact plant cells by a driving force (e.g. electrical discharge or

compressed air). The micro-projectiles penetrate the cell wall and membrane, with only minor damage, and the transformed cells then express the promoter constructs.

One particle bombardment technique that can be performed uses the Particle Inflow Gun (PIG), which was developed and described by Finer *et al.* [1992] and Vain *et al.* [1993]. The PIG accelerates the micro-projectiles in a stream of flowing helium, through a partial vacuum, into the plant cells.

One of advantages of the PIG is that the acceleration of the micro-projectiles can be controlled by a timer-relay solenoid and by regulation the provided helium pressure. The use of pressurised helium as a driving force has the advantage of being inert, leaves no residues and gives reproducible acceleration. The vacuum reduces the drag on the particles and lessens tissue damage by dispersion of the helium gas prior to impact [Finer *et al.* 1992].

In some cases, the effectiveness and ease of the PIG system makes it a good choice for the generation of transient transformed guar tissue, which were tested for transient expression of promoter/reporter gene fusions.

## GUAR

As indicated above, in one aspect, a preferred transformed organism is transformed guar.

Guar (*Cyamopsis tetragonoloba*) is a drought-tolerant species, which originated in India and Pakistan, but is cultivated for industrial use in a number of other countries e.g. USA. Guar is taxonomically arranged with the peas and beans in the family of grain legumes. Legumes are dicotyledonous plants (dicots), which are characterised by having broad leaves and two cotyledons, in contrast to monocotyledonous plants (monocots) which display 'grass like' morphology and only have one. Examples of other dicots are tobacco and potato, and examples of monocots are cereals such as wheat, rice, maize and barley. Guar differs from most crop legumes such as peas and beans, however, in that its seed carbohydrate reserve is not starch in the cotyledons, but is galactomannan accumulated in the endosperm. The endosperm is a non-photosynthetic tissue, which envelopes the cotyledons in the seed immediately beneath the seed coat, and can be dissected away from the other seed tissues.

## GUAR GUM

Guar is grown as crop for animal feed and human consumption. However, an important use of guar is the extraction of guar gum or 'guaran', which is used as a functional ingredient in foods e.g. as thickener in ice cream. Guar gum consists of galactomannan - which is an extracellular cell-wall polysaccharide located in the endosperm.

In a preferred aspect, the present invention relates to the use of the promoter of the present invention to cause expression of an NOI that can affect guar gum synthesis.

## GALACTOMANNAN

Galactomannan consists of a mannan backbone with substituted galactosyl-groups, the bonding of which is (1→6)-α-D-galacto-(1→4)-β-D-mannan, and the polymer has an molecular weight of 220,000 daltons (Whistler & Hymowitz 1979).

The degree of substitution, and thereby the ratio between galactose and mannose residues in galactomannan, varies between leguminous species. The ratio is approx. 0.56 in guar, and mature seeds contains approx. 35-42 % galactomannan (Whistler & Hymowitz 1979).

In a preferred aspect, the present invention relates to the use of the promoter of the present invention to cause expression of an NOI that can affect galactomannan synthesis.

## ENDOSPERM EXPRESSION

In a preferred aspect, the promoter of the present invention is active in the endosperm of plant tissue.

In this respect, endosperm - as well as the embryo - are formed early in seed development of flowering plants. In particular, the endosperm is formed during double fertilisation in which, one sperm nucleus fuses with an egg to produce the embryo, and a second sperm nucleus fuses with two polar nuclei to form the triploid endosperm [Lopes & Larkin 1993]. In some, but by no means all, plants this tissue serves as a storage reservoir for the seeds, and guar and the cereals are among

these. In other species, however, the cotyledons have assumed the status of the principal storage tissue of the seed, and the endosperm has become vestigial.

In cereals such as rice, wheat, barley, and maize the chief carbohydrate reserve in the endosperm is starch which accumulates intracellularly in plastids known as amyloplasts. In guar endosperm, however, the principal storage carbohydrate is galactomannan which accumulates extracellularly in the intercellular spaces, and is therefore secreted out of the cell.

During maturation, the developing seed increases in volume and mass due to significant cell expansion and accumulation of carbohydrates, protein and lipids to be used as C and N sources during germination. After maturation, the seed enters dormancy [West & Harada 1993], imposed by plant hormones, such as abscisic acid (ABA), which prevent precocious germination [Thomas 1993]. On germination of guar seeds, mannanase, and galactosidase activities break down the galactomannan of the endosperm, and the mannose and galactose released support the development of the seedling.

#### CARBOHYDRATE METABOLISM

20

In a preferred aspect, the present invention relates to the use of the promoter of the present invention to cause expression of an NOI that can affect carbohydrate metabolism, such as sucrose metabolism, particularly in a plant tissue.

In this respect, sucrose is the major photoassimilate which is transported long distances in plants from the photosynthetic 'source' tissue to the heterotrophic energy-consuming 'sink' tissues, in which it is the mainstay of carbohydrate nutrition.

The initial precursor for the synthesis of sucrose is triose-phosphate which is synthesised in the carbon-fixation (Calvin) cycle in chloroplast in photosynthetic cells. This triose phosphate (glyceraldehyde 3-phosphate) is transported to the cytoplasm and converted to fructose 6-phosphate (Fructose-6-P) and glucose 1-phosphate (Glucose-1-P). The Glucose-1-P is converted to UDP-glucose which together with Fructose-6-P are converted to sucrose 6-phosphate (Sucrose-6-P) by sucrose phosphate synthase. S-6-P is the immediate precursor for sucrose and the conversion is catalysed by sucrose phosphatase.

After its synthesis in the cytoplasm of mesophyll cells, sucrose is loaded by the companion cells into the phloem and distributed to sink tissues. The transport process is a 'mass flow' facilitated by osmotic pressure, due to a concentration gradient of sucrose between source and sink. Photosynthesis is slowed by build up of sucrose in green tissues, and so it is seen by many as a demand-led process, with the vascular tissue communicating requirement for carbohydrate by unloading of sucrose into developing sink tissues.

The developing seed is a storage-active sink organ, and is therefore a large user of sucrose. Developing seeds utilise sucrose for several purposes, one example of which is synthesis of storage polysaccharides as galactomannan in guar endosperm.

Sucrose is degraded by sucrose synthase to fructose (F) and UDP-galactose (UDPG) and through a series of conversions GDP-mannose (GDPM) and UDPG are formed. GDPM and UDPG are the immediate precursors for galactomannan and the synthesis is catalysed by mannan synthase and galactosyl transferase. Galactomannan is synthesized and transported from the golgi apparatus to the extracellular space. Another key enzyme in the synthesis of galactomannan is UDP galactose 4-epimerase.

Breakdown of sucrose in plants can be achieved through the activity of two enzymes: Invertase (E.C. 3.2.1.26) and sucrose synthase (E.C. 2.4.1.13). The name 'sucrose synthase' implies that the enzyme catalyses the synthesis of sucrose, but the metabolic role of sucrose synthase is catabolic rather than anabolic, and sucrose synthase preferentially cleaves sucrose *in vivo*. Consistent with this role, sucrose synthase is abundant in sink tissues such as developing seeds, but not in fully competent photosynthetic tissues. Sucrose synthase catalyses the cleavage of sucrose in the presence of UDP into UDP-glucose and fructose. By cleavage of sucrose in the presence of UDP the high energy of the sucrose glycosidic link is conserved in UDP-glucose, which can then serve as a glycosidic donor for further reactions. Invertase, on the other hand, catalyses the hydrolysis of sucrose into glucose and fructose, and probably serves less to provide carbohydrate for storage, but may furnish the immediate energy requirements of development.

In a preferred aspect, the present invention relates to the use of the promoter of the present invention to cause expression of an NOI that can affect the *in situ* activity of UDP galactose 4-epimerase.

## GUS REPORTER GENE

In some of the studies of the present invention, the *E.coli uidA* gene (otherwise known as the GUS gene) is used as a reporter gene. Here, the *E.coli uidA* gene is used as proof that the promoter of the present invention can cause expression of an NOI. However, it is to be noted that the present invention is not limited to the NOI just being the *E.coli uidA* gene.

In more detail, the *uidA* gene codes for the  $\beta$ -glucuronidase enzyme (GUS) which is a hydrolase that catalyses the cleavage of  $\beta$ -glucuronides, e.g. X-gluc and MUG. The GUS reporter gene system for higher plants was developed by Jefferson 1987.

The system utilises that the *uidA* gene can be fused to a promoter and introduced in to plant cells for expression. By assaying the activity of the GUS protein in transgenic tissue, the activity of a given promoter can be monitored. In some of our studies, the *E.coli uidA* gene has been modified to prevent glycosylation in plants, which enables GUS to retain activity when targeted to the endoplasmatic reticulum (ER).

For transient expression studies, X-Gluc (5-bromo-4-chloro-3-indolyl  $\beta$ -D-glucuronide) is used as a substrate in histochemical detection of GUS (qualitative), and MUG (4-methyl umbelliferyl glucuronide) as a substrate for fluorometrical detection (quantitative). The enzymatic cleavage of the colourless X-Gluc substrate produces a blue indigo precipitate at the site of cleavage. The precipitation is caused by oxidative dimerisation of the indoxyl derivative produced by the cleavage of X-Gluc. The activity of GUS can therefore be detected and analysed in transgenic tissue without extracting the enzyme before running the assay.

## PRODUCTION OF POI

Host organisms comprising the vectors of the present invention may be used to express the POI by use of the promoter of the present invention. In this respect, host organisms may be cultured under suitable conditions which allow expression of the POI. In some instances, expression of the POI may be constitutive such that they are continually produced, or inducible, requiring an inducer to initiate expression. In the case of inducible expression, protein production can be initiated when required



by, for example, addition of an inducer substance to the culture medium.

Once the vector has been transformed or transfected into a suitable host organism then the host organism can be cultivated. Here reference can be made briefly to US-A-5543322 which says that for cultivation of a transformant, a culture medium containing carbon and nitrogen sources assimilable by the transformant and the like can be used. Any carbon source assimilable by the transformant can be used. Examples thereof include glucose, sucrose, starch, soluble starch, dextrin, glycerin, n-paraffin and the like as well as organic acids (e.g., acetic acid, fumaric acid, benzoic acid, etc.), alcohols (e.g., methanol, ethanol, butanol, etc.), fats and oils (soybean oil, lard, etc.) and the like. They can be used alone or in combination thereof. As the nitrogen sources, there are, for example, peptone, soybean flour, cotton seed flour, meat extract, yeast extract, dried yeast, corn steep liquor, corn gluten meal, urea, ammonium salts (e.g., ammonium chloride, ammonium sulfate, etc.), nitrates (e.g., potassium nitrate, ammonium nitrate, etc.), other organic or inorganic nitrogen-containing materials and the like. They can be used alone or in combination thereof. In addition, inorganic salts (e.g., phosphates, etc.), trace metal salts (e.g., magnesium salt, calcium salt, manganese salt, etc.) can be appropriately added.

20

If desired, the POI can be extracted from host organisms by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption. For some applications, a preferred extraction/purification protocol may involve a centrifugation step followed by, if necessary using, column chromatography such as ion-exchange or affinity chromatography.

25

Thus, after the desired product (e.g. the POI) has accumulated in a culture medium, a supernatant fluid containing the POI can be obtained by centrifugation or filtration. On the other hand, when the POI has accumulated in the organisms, after the cultivation, the organisms can be collected by a known method and the desired product is recovered by an appropriate method. For example, the organisms can be suspended in a buffer containing a protein denaturant such as guanidine hydrochloride, the suspension is stirred in a cold place, and then the supernatant fluid containing the desired product is obtained by centrifugation or the like.

35

Alternatively, after the organisms have been suspended in a buffer, the organisms can be ground by glass beads, or broken by French press, sonication, enzymatic

treatment or the like, and then the supernatant fluid is obtained by centrifugation or the like.

For separation and purification of the POI from the above supernatant fluid reference  
5 can be made to US-A-554332 where it is stated that *per se* known separation and  
purification methods can be appropriately combined. As the known separation and  
purification methods, there are, for example, a method utilizing a difference in  
solubilities (e.g., salting out, precipitation with a solvent, etc.), a method mainly  
utilizing a difference in molecular weights (e.g., dialysis, ultrafiltration, gel filtration,  
10 etc.), a method utilizing a difference in charges (e.g., ion exchange chromatography,  
etc.), a method utilizing specific affinity (e.g., affinity chromatography, etc.), a method  
utilizing a difference in hydrophobicities (e.g., reverse phase high performance liquid  
chromatography, etc.), a method utilizing a difference in isoelectric points (e.g.,  
isoelectric focusing, etc.) and the like.

15

#### SECRETION

In some cases, it is desirable for the POI to be secreted from the expression host  
into the culture medium from where the POI may be more easily recovered.  
20 According to the present invention, the secretion leader sequence may be selected  
on the basis of the desired expression host. Hybrid signal sequences may also be  
used with the context of the present invention.

Typical examples of heterologous secretion leader sequences are those originating  
25 from the fungal amyloglucosidase (AG) gene (*glaA* - both 18 and 24 amino acid  
versions e.g. from *Aspergillus*), the  $\alpha$ -factor gene (yeasts e.g. *Saccharomyces* and  
*Kluyveromyces*) or the  $\alpha$ -amylase gene (*Bacillus*).

#### DETECTION

30

A variety of protocols for detecting and measuring the expression of the POI are  
known in the art. Examples include enzyme-linked immunosorbent assay (ELISA),  
radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site,  
monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-  
35 interfering epitopes on the POI may be used or a competitive binding assay may be  
employed. These and other assays are described, among other places, in Hampton

R *et al* (1990, Serological Methods, A Laboratory Manual, APS Press, St Paul MN) and Maddox DE *et al* (1983, J Exp Med 15 8:121 1).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting POI include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled nucleotide. Alternatively, the NOI, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A-4,277,437; US-A-4,275,149 and US-A-4,366,241. Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.

Additional methods to quantitate the expression of a POI include radiolabeling (Melby PC *et al* 1993 J Immunol Methods 159:235-44) or biotinylating (Duplaa C *et al* 1993 Anal Biochem 229:36) nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or calorimetric response gives rapid quantitation.

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the NOI is inserted within a marker gene sequence, recombinant cells containing NOIs can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a NOI under the control of the promoter of the present invention or an alternative promoter (preferably the same

promoter of the present invention). Expression of the marker gene in response to induction or selection usually indicates expression of the POI as well.

Alternatively, host cells which contain the NOI may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane-based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein.

#### SUMMARY

In summation, the present invention relates to a promoter and, also to a construct comprising the same. In particular the present invention relates to the use of a promoter for the expression of a NOI in an organism.

In a preferred aspect, the present invention relates to the modification of carbohydrate metabolism by the transformation (genetic manipulation) of a plant by use of the novel promoter of the present invention to cause expression of an NOI that affects carbohydrate metabolism.

In one preferred aspect, the present invention relates to the modification of galactomannan synthesis by the transformation (genetic manipulation) of the leguminous plant *Cyamopsis tetragonoloba* (guar) by use of the novel promoter of the present invention to cause expression of an NOI that affects the galactomannan synthesis.

## DEPOSITS

The following sample was deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on 15 March 1999:

Microorganism	Strain Number	NCIMB Number
<i>E. coli</i>	TOP10 (Invitrogen) + pTBR-ScaK3	NCIMB 41011

NCIMB 41011 comprises the novel nucleotide sequence of the present invention.

10

A restriction map of the novel nucleotide sequence of the present invention is shown in Figure 3.

The present invention also encompasses sequences derivable from those deposits and embodiments comprising the same. The present invention also encompasses partial sequences derivable from those deposits and embodiments comprising the same, wherein those partial sequences code for regulatory elements.

The promoter of the present invention may be isolated from the deposit by use of any of the suitable restriction enzymes indicated in Figure 2. Alternatively, one could use PCR techniques to "PCR out" the promoter sequence. Here, suitable primers would be based on the sequence presented as SEQ ID No. 1.

By way of example, for amplification of the full-length RSus3 promoter (2700 bp) from pTBR-ScaK3, the primer-pair "M13 forward" and "RSusNcoI" can be used. The upper M13 forward primer anneals to the pCR2.1-TOPO part of the clone some 110 bp from the cloning site, and the lower RSusNcoI primer anneals to the translation start codon of RSus3. Alternatively the primer-pair "AP2" and "RSusNcoI" can be used to isolate a similar fragment (AP2 anneals to the adaptor part of the cloned fragment).

30

For amplification of the RSus3 promoter without intron 1 from pTBR-ScaK3, the primer-pair "AP2" and "Lowexon½" can be used. The lower Lowexon½ primer is designed as follows: The 3' end of the primer corresponds to a 24 bp sequence just

upstream of the 5' splicing site in intron 1. The 5' end of the primer corresponds to the 27 bp sequence between the 3' splicing site and the ATG-codon, and incorporates of a NcoI site.

- 5 Hence, in summation, the present invention relates to a promoter that is useful for causing selective expression of an NOI in the endosperm tissue/cells of a transformed plant. The NOI and/or the promoter may be heterologous to the transformed plant - in the sense that the NOI and/or the promoter may not naturally occur in the non-transformed plant. The promoter of the present invention is defined by having a
- 10 nucleotide sequence corresponding to that shown as SEQ ID No. 1 or a variant, homologue, fragment or derivative thereof.

#### INTRODUCTION TO THE EXAMPLES SECTION AND THE FIGURES

- 15 The present invention will now be described, by way of example only, with reference to the accompanying drawings in which:-

- Figure 1 is a schematic diagram  
Figure 2 is a schematic diagram  
20 Figure 3 is a schematic diagram  
Figure 4 is a photograph  
Figure 5 is a schematic diagram  
Figure 6 is a schematic diagram  
Figure 7 is a schematic diagram  
25 Figure 8 is a schematic diagram  
Figure 9 is a schematic diagram  
Figure 10 is a schematic diagram  
Figure 11 is a graph  
Figure 12 is a schematic diagram  
30 Figure 13 is a schematic diagram  
Figure 14 is a schematic diagram  
Figure 15 is a photograph  
Figure 16 is a series of photographs  
Figure 17 is a graph  
35 Figure 18 is a graph  
Figure 19 is a schematic diagram  
Figure 20 is a schematic diagram

Figure 21 is a schematic diagram

Figure 22 is a schematic diagram

Figure 23 is a schematic diagram

Figure 24 is a schematic diagram

5 Figure 25 is a schematic diagram

Figure 26 is a graph.

### Part I - Figures in more detail

10 Figure 1: A schematic representation (not to scale) of the promoter of the present invention and some of its associated sequences.

Figure 2: Map of the RSus3 sequence in pScaK3 (pTBR-ScaK3) with the surrounding restriction sites. The other clones are analogues to this, but some have the opposite  
15 orientation.

Figure 3 is a restriction map of the promoter of the present invention.

Figure 4: Agarose gel showing the result of the semi-nested PCR. Lane 1 and 12  
20 marker II; lane 2-6 EcoRV, DraI, PvuII, ScaI and SspI with buffer F; lane 7-11 same with buffer H.

Figure 5. The promoter region from pScaK3 and pSspK3 were amplified from the primers M13 forward and RSusNco. The amplified products contain XhoI and NcoI  
25 sites for directional cloning into the unique Sall and NcoI in pGUSNOST as XhoI/NcoI fragments.

Figure 6 is a schematic diagram of a construct.

30 Figure 7 is a schematic diagram of a construct.

Figure 8 is a schematic diagram of a construct.

Figure 9 is a schematic diagram of a construct.

35

Figure 10 is a schematic diagram of a construct.

Figure 11 shows a time course of sucrose synthase activity during development of guar endosperm. The specific activity of sucrose synthase were measured in extracts from guar endosperm at various developmental stages from 7-41 days after flowering. The value of each point is the mean sucrose synthase activities obtained from 3 to 4 independent measurements in which at least 5 endosperms from each pod were pooled.

Figure 12: Presentation of sequencing plan for pTBR-ScaK3. The arrows represent sequencing primers, and the numbers indicates approximate position of 5'end of the sequencing primers relative to the RSus3 ATG codon.

Figure 13: Schematic presentation of various RSus3/GUS/NOS<sub>t</sub> constructs. The numbers indicates the base pairs relative to the translational start codon.

Figure 14: Schematic presentation of various tandem Rsus3 constructs. The numbers indicates the base pairs relative to the translational start codon.

Figure 15: Agarose gel showing the result of control digest of tandem repeat clones. Lane 1: HindIII digest of pTandem leg/pro, which gives a specific fragment of 740 bp. Lane 2: NheI digest of pTandem legumin, which gives a specific fragment of 570 bp. Lane 3: DNA marker VI. Lane 4: HindIII digest of pTandem prolamin, which gives a specific fragment of 160 bp.

Figure 16a is a photograph of cotyledon tissue of guar that has been ballistically transformed with the ENOS control plasmid that contains the GUS expression nucleotide sequence. This is a control study. As can be seen, high levels of transient expression of GUS are observed.

Figure 16b is a photograph of endosperm tissue of guar that has been ballistically transformed with the ENOS control plasmid that contains the GUS expression nucleotide sequence. This is a control study. As can be seen, transient expression of GUS is observed.

Figure 16c is a photograph of cotyledon tissue of guar that has been ballistically transformed with the RSus3 construct plasmid p1730 (which contains a single copy of the nucleotide sequence of the present invention) that contains the GUS



expression nucleotide sequence. As can be seen, very low levels of transient expression of GUS are observed.

Figure 16d is a photograph of endosperm tissue of guar that has been ballistically transformed with the RSus3 construct plasmid p1730 (which contains a single copy of the nucleotide sequence of the present invention) that contains the GUS expression nucleotide sequence. As can be seen, good levels of transient expression of GUS are observed.

Figure 16e is a photograph of cotyledon tissue of guar that has been ballistically transformed with the RSus3 construct plasmid pTandem leg/pro (which contains a tandem copy of the nucleotide sequence of the present invention) that contains the GUS expression nucleotide sequence. As can be seen, very low levels of transient expression of GUS are observed.

Figure 16f is a photograph of endosperm tissue of guar that has been ballistically transformed with the RSus3 construct plasmid pTandem leg/pro (which contains a tandem copy of the nucleotide sequence of the present invention) that contains the GUS expression nucleotide sequence. As can be seen, high levels of transient expression of GUS are observed.

Figure 17. Histogram showing the transient GUS expression in guar endosperms after bombardment with the RSus3 constructs. The data are presented as mean number of blue spots per endosperm together with the calculated standard error.

Figure 18. Histogram showing the transient GUS expression in guar tissue after correction for tissue size. The data are presented as mean number of blue spots per cotyledon together with the calculated standard error.

## MATERIALS AND METHODS

### Isolation of DNA

The plasmids used in this work were isolated using Qiaprep Spin Miniprep Kit and Plasmid Maxi Kit from Qiagen (Hilden, Germany). These kits give very clean plasmid preparations which are ready for use in cloning, sequencing, and transient

expression assays. Further purification are therefore not necessary. 10 mM Tris-Cl, pH 8.5 was used as elution buffer and storage buffer. All DNA was stored at -20°C.

The concentration of plasmid preparations was determined, by measuring the absorbance at 260 nm in a Powerwave™ 200 spectrophotometer. An OD<sub>260</sub> of 1 corresponds to about 50µg/mL DNA. The amounts of DNA in isolated fragments was estimated by comparative fluorescence of Ethidium-bromide (Etbr) stained DNA in agarose gels.

## 10 Restriction enzymes

Enzyme digestion was performed using restriction enzymes from NEB and Boehringer M. The buffer provided by the supplier was used in the reactions. When double digestions were performed, a buffer compatible with both enzymes was chosen (e.g. digestions with both NheI and NcoI was performed in NEBuffer 2 with BSA).

## Electrophoresis

20 Electrophoresis was used to separate and identify DNA. The DNA was stained with the fluorescent dye Ethidium bromide (EtBr) incorporated in the gel in a concentration of 0.6 µg/mL. Appropriate amount of DNA was mixed with loading buffer (0.1 % bromophenol blue, 16% Ficoll 400) loaded on to the either Nusieve or Seakem agarose gels (FMC Bioproducts). TBE Buffer (0.1 M Tris, 0.09 M Boric acid, 0.001 M EDTA) was used as electrophoresis buffer. DNA were separated by electrophoresis in a 0.5 - 2 % (w/v) agarose gel, dependent upon the sizes of the bands of interest. For bands <1000 bp 2 % Nusieve GTG agarose gels, and for bands >1000 bp 0.5-1.5 % Seakem LE agarose gels were used.

30 DNA molecular weight marker I, II, IV, VI and VII (Boehringer M) were used for evaluation of electrophoreses DNA. The markers were provided at a concentration of 0.25 µg/µL and diluted as follows: 2 µL DNA marker; 2 µL loading buffer and 8 µL H<sub>2</sub>O. Either 4 µL or 10 µL of this mixture was loaded on to gels depending upon the well size.

Selected bands were isolated from the gel, by minimal UV radiation, using Qiaquick Gel Extraction (Qiagen).

### Ligation

5

All ligations were performed using T4 DNA ligase in the reaction buffer (66 mM Tris-HCl, pH 7.6, 6.6 MgCl<sub>2</sub>, 10 mM dithiothreitol, 66 μM ATP) supplied by the manufacturer (Amersham Life Science). Fragment with Cohesive ends were ligated using 1 U T4 ligase, whereas blunt-ended fragment were ligated using 5 U of the enzyme.

10

To prevent intramolecular religation of open plasmid, it was treated with alkaline phosphatase from the psychrophilic shrimp *Pandalus borealis* (Boehringer M). This enzyme catalyses the dephosphorylation of 5' phosphates from the plasmid DNA, but is easily prevented from interfering with the subsequent ligation by heating to 60°C for 15 minutes.

15

### Transformation

All the plasmids were used to transform, and propagated in, supercompetent TOP10 One Shot™ Cells (Invitrogen) Genotype: F<sup>-</sup> *mcrA* Δ(*mrr-hsdRMS-mcrBC*) Φ80/*lacZ*ΔM15 Δ*lacX74* *deoR* *recA1* *araD139* Δ(*ara-leu*)7697 *galU* *galK* *rpsL* *endA1* *nupG*.

20

50μL of supercompetent cells were carefully mixed with 1-5 μL of ligation mixture, and incubated on ice for 30 minutes, after which a 30 second heat shock was performed, followed by a 2 minute recovery period on ice. Finally, 250μL of SOC medium were added, and the cells were incubated in an orbital shaker at 37°C for 30 minutes, before spreading on to LB plates containing 100μg/ml ampicillin.

25

30

### Polymerase Chain Reaction (PCR)

Polymerase chain reaction (PCR) is a technique which is based on *in vitro* amplification of a specific DNA sequence using synthetic primers flanking the sequence, and a thermostable DNA polymerase (e.g. Taq DNA Polymerase) for replication of the DNA.

35

A wide range of PCR techniques were extensively used in this study, e.g. Hot Start, Touch Down, Long PCR, Nested PCR and Sequencing PCR.

5 For optimization of PCR reactions the PCR optimizer™ Kit (Invitrogen) was applied. This kit comprises 16 buffers of four different pH values, each supplied with a range of four different magnesium ion concentrations, and eases optimization of PCR reactions.

10 The following polymerases were used:

- AmpliTaq Gold™ (Perkin-Elmer)
- Expand™ High Fidelity PCR system (Boehringer M)
- Taq DNA polymerase (Pharmacia Biotech)

15

Expand™ High Fidelity PCR system is a polymerase mix of the Taq and Pwo polymerases, and is designed for amplification of PCR products up to 12 kb with high specificity. Taq possesses 5'→3' transferase activity and generates ends with single 3' A overhang, whereas Pwo possesses 3'→5' exonuclease activity and generate products with blunt ends.

20

With the exception of cycle sequencing, all PCR reactions reported here used the Hot Start technique, which minimizes binding of primers to poorly matched sites on the template at low temperatures, and the subsequent amplification of the spurious extension products formed in the first cycle of the reaction. This is achieved by preventing polymerisation before a substantial period of denaturation of the template has elapsed, and this was effected in two different ways depending on the type of polymerase.

25

30 When the Expand™ or AmpliTaq Gold™ DNA polymerase were used, a wax pellet was placed over the reaction mixture containing all components except for polymerase. The wax was melted by 95°C for 2 min, followed by cooling to 4°C, which results in its hardening to form a thin surface on top of the reaction mixture. On to this surface 1 µL of the polymerase was added and the tube was then placed in the thermocycler, which was preheated to 95°C beforehand, and the PCR programme was started immediately.

35

AmpliTaq Gold™ is a thermally activated polymerase mixture which allows a hot start, without the inconvenience of overlaying polymerase on to a solid wax surface. The enzyme is provided with an inactivating antibody bound to it. The polymerase is activated by a preliminary heating step, whereby the antibodies denatures, thus rendering the enzyme active. This allows a hot start PCR without the inconvenience of overlaying polymerase on to a solid wax surface, and the denaturation time is significant longer, and therefore more thorough. In these reactions all the components were added together with wax pellet, and the reaction started as described above.

When amplification of long PCR products was desired, a time increment was added to the extension step in the PCR program.

The PCR reactions were performed in a Mastercycler (Eppendorf).

A typical example of such a reaction is summarised in the table below.

PCR reaction		PCR program		
Reagent	μL/reac.	Step	Temp (°C)	Time
Template (1:100)	1	1	94	2'
5*Buffer	10	2	94	30"
dNTP mix	4	3	68	30"
Upper primer 4 μM	5	4	go to 2, 29 times	
Lower primer 4 μM	5	5	68	10'
Water	to 50	6	4	infinite
Expand	0.75			

seconds:" and minutes:.'

### Cloning of PCR products

Under most circumstances, isolated PCR products were cloned in pCR2.1-TOPO (Invitrogen) which was provided as a linearized fragment with single 3'-T overhangs and TOPO isomerase. This system exploits the tendency of Taq polymerase to add a single overhanging 3'-A in both ends of the amplified product. The TOPO isomerase has both cleavage and ligation activity, it cleaves the vector at a CCTTT site thereby

generating a single 3'-T overhang, which will religate with a PCR product with single 5'-A overhangs. This system therefore allows cloning of Taq amplified PCR products without the use of ligation with T4 ligase.

- 5 The cloning site of pCR2.1-TOPO resides in a disruptive locus of the lacZ gene, which allows clones with inserts to be selected by blue/white screening in the presence of the chromogenic substrate for  $\beta$ -galactosidase (x-gal). Miniprep DNA from white colonies was analysed by restriction digests, PCR and/or sequencing.
- 10 Some PCR-fragments were digested with enzymes and cloned directly into plasmid vectors without a sub-cloning step. When cohesive ends could be generated by restriction enzymes in this way, and exploited for direct cloning, substantial savings in time were achieved.

#### 15 **Primers**

The relevant primers are shown in the Tables presented below.

**Primers and oligos**

Listed in alphabetic order (Storage name, size)

**AP1:** (Walking AP1a, 27-mer)

5'- GGA TCC TAA TAC GAC TCA CTA TAG GGC

**AP2:** (Walking AP2, 17-mer)

5'- AAT AGG GCT CGA GCG GC

**Dellow1:** (Dellow 1, 22-mer)

5' GCT TTC CAC CAC AAA ATG ACA C

**E356:** (E356, 26-mer)

5'- GGA ATT CTA GTA ACA TAG ATG ACA CC

**E357:** (E357, 28-mer)

5'- GGA ATT CCC CGA TCG TTC AAA CAT TTG G

**HindGCN4:** (HindGCN4, 24-mer)

5' GGA AGC TTG CGA AAA TGT GCA GGG

**Lowexon $\frac{1}{2}$ :** (Low exon 1/2, 56-mer)

5' CCC ATG GCT ATC TTC TAG TTG GAT CCT CAA GCC TTG CAC TGA AGG GGA  
AGA GGA GG

**M13 forward :** (M13 forward, 16-mer, TOPO Cloning Kit (Invitrogen))

5' CAT TTT GCT GCC GGT C

**M13 reverse:** (M13 reverse, 17-mer, TOPO Cloning Kit (Invitrogen))

5' CAG GAA ACA GCT ATG AC

**Nhedel1:** (Nhedel 1, 23-mer)

5' CCG CTA GCA CAG AGG CTG AGC AG

**Nhedel2:** (Nhedel.2, 27-mer)

5' TGC TAG CTG GTA AAT GAC ATG CTG CTG

**Nhedel3:** (Nhedel.3, 22-mer)

5' CGC TAG CAG AGG CAG CAA GCT C

**NheGCN4:** (Nhe GCN4, 22-mer)

5' GGG CTA GCG AAA ATG TGC AGG G

**Oligo 1:** (Walking Adaptor, 44-mer):

5' CTA ATA CGA CTC ACT ATA GGG CTC GAG CGG CCG CCC GGG CAG GT

**Oligo 2:** (Walking AP1b, 8-mer)

5'phosphate- AC CTG CCC - 3'amine

**pGUS lower:** (pGUS lower, 22-mer)

5' CTG GCG AAA GGG GGA TGT GCT G

**Rsus3:** (Lower RSus 3 Spe, 25-mer)

5' ACG ACG GAA TGG ATA ATA GCA GAT A

**RsusNco:** (RsusNco1, 21-mer)5' GTT TCC CCC ATG GCT ATC TTC**RsusTATA:** (RSusTATA, 21-mer)5' CCT CCC TGA AGC TTT TCG TGT**UppCR2.1:** (UppCR2.1, 44-mer)

5' ATT AGG CAC CCC AGG CTT TAC ACT TTA TGC TTC CGG CTC GTA TG

**Lower sequencing primers:**

(Listed in numerical order)

**RSusseq 1**

5' Cy5- GT TTC CCC CAT TGC TAT CTT C

**RSusseq 2**

5' Cy5- AG TGC CAG GTT CAA GGA CA

**RSusseq 700**

5' Cy5- AC CAA TCC CAG AAA CCC AAG C

**RSusseq 1000**

5' Cy5- GT GTC CCC TGC CTC ACT CC

**RSusseq 3**

5' Cy5- CC GGC TAA GTT AAA AAA AAA

**RSusseq 4**

5' Cy5- CT GTG CCG TTG GAA GCG TCA T

**RSusseq 5**

5' Cy5- CG CAG ATG GGT TCA GCC TTC A



**Upper sequencing primers:**  
(Listed in numerical order)**Scaseq 1**

5' Cy5- GG TCG GCA CAT TGA GAG GTC

**Scaseq 2**

5' Cy5- CA CAC CCA ACG CTC ACC GAT G

**Scaseq 3**

5' Cy5- AG GAC GGT TTT GGT TGG GAT T

**Scaseq 4**

5' Cy5- TC CTC CTC TTC CCC CTT CAG TG

**Scaseq 5**

5' Cy5- AT CTG GCA ACC TTT TGT TTC T

**M13 sequencing primers:****M13 Reverse**

5' Cy5- CA GGA AAC AGC TAT GAC

**M13 Universal**

5' Cy5- CG ACG TTG TAA AAC GAC GGC CAG T

**Sequencing**

5

The Rsus 3 promoter region was sequenced with a ALFexpress DNA sequencer. The ALFexpress is designed for automated detection of fluorescently labelled DNA molecules separated by electrophoresis.

- 10 Cy5-labelled fluorescent M13 reverse and forward primers for the pCR2.1-TOPO vector was used for sequencing of 5' and 3' ends of cloned PCR products. In addition Cy5-labelled sequencing primers was designed for specific regions of the Rsus3 promoter region, using the described OLIGO™ program - Version 5.0 for Windows (National BioSciences Inc, Plymouth, Ma).

15

### Materials for sequencing

- ALFexpress™ DNA Sequencer (Pharmacia biotech AB)
- Thermo Sequenase fluorescent labelled primer cycle sequencing kit with 7-deaza-dGTP (Amersham Pharmacia biotech)
- ReproGel™ Long Read, for polyacrylamide gel electrophoresis with the ALF® family of instruments (Amersham Pharmacia Biotech)
- ReproSet™, for UV polymerisation of ReproGel™ (Amersham Pharmacia Biotech)
- ALFwin™ Sequence Analyser 2.00, Windows 95 based program that controls ALFexpress (Amersham Pharmacia Biotech)

Diodeoxy chain terminator sequencing was performed in a thermocycled reaction using the special mutant polymerase ThermoSequence supplied by Amersham Pharmacia Biotech which has been selected both to accept fluorescently labelled primers and to have equal affinity for the four diodeoxy chain terminators. Band compressions on the gel were limited by the use of 7-deaza-dGTP in the reaction.

### Sequence analysis

The resulting sequences was assembled using Winseq 1.01, developed by F.G. Hansen, Department of Microbiology, DTU, Denmark. After this preliminary sequence assembling, the sequence analysis was performed using the same program.

### Isolation of the RSus 3 promoter region from rice genomic DNA

The rice sucrose synthase 3 (RSus3) promoter region was isolated from rice genomic DNA using the chromosome walking technique described by Siebert *et al.* 1995, which is an adaptor mediated PCR method, designed to amplify an unknown sequence which is flanking a known sequence.

Genomic DNA is first digested with enzymes which produce blunt ended products (DraI, EcoRV, PvuII, ScaI or SspI) on to which adaptors are ligated. The result is the generation of 5 DNA-libraries, which can serve as templates for a PCR, using one

primer specific to the known sequence and an adaptor-specific primer which is described in Siebert *et al* (*ibid*).

5 The adaptor sequence and the adaptor primer (AP1) and the nested adaptor primer (AP2) was provided. The adaptor was designed with an aminogroup in 3' end, which prevents amplification from the AP1 primer binding site, unless there is an initial round of amplification from e.g. a gene-specific primer [After Siebert *et al*. 1995].

10 The adaptor incorporates two features which ensure that template with adaptor binding sites at both ends will not be amplified. Firstly, due to an amino group in the 3'end of the adaptor, the generation of an AP1 primer binding site by extension of the lower strand 3' end is prevented. Thus, the only circumstances in which an AP1 primer binding site is formed during the PCR, are those in which there is an initial round of amplification from a primer which binds within the restriction fragment.

15 Secondly, amplification of template, formed by unspecific priming from AP1, will be suppressed. Fragments formed in this manner contain inverted terminal repeats in the single stranded product, which will form a secondary stem-loop structure, which is more stable than the template-primer hybrid. The formation of the stem-loop structure prevents annealing of primer, which suppresses amplification of unspecific

20 PCR products. The specificity of the method is further improved by reamplification of the product using a nested PCR primer.

#### Preparation of genomic DNA

25 Genomic DNA was obtained from rice. 1  $\mu$ g of this DNA was digested with 20 U of either of the following blunt end enzymes: DraI, EcoRV, PvuII, ScaI and SspI in a total volume of 50  $\mu$ L.

30 The digestions were run through an enzyme remover column (Amicon) and concentrated by alcohol precipitation followed by dissolving in 20  $\mu$ L TE.

The adaptor was prepared by mixing 800 pmol of each of Oligo 1 and Oligo 2 in a total volume of 22  $\mu$ L. The mix was denatured by treatment at 94°C for 1 min., and transferred on to ice.

35

An excess of the adaptor was ligated with the blunt-end digests using T4 DNA ligase. 4 µL adaptor and 13 µL digest were mixed with 10 U T4 DNA ligase in a total volume of 30 µL, and incubated at room temperature for 24 hours.

- 5 Excess adaptors were removed after ligation with the Qiaquick PCR purification kit (Qiagen), which recovers >100 bp PCR products and thereby also will remove excess adaptor.

#### PCR screening for the RSus3 promoter region

10

For isolation of the RSus3 promoter region, the following sequence-specific primer was designed:

5'-ACG ACG GAA TGG ATA ATA GCA GAT A-3'

15

The 3' end of this antisense primer anneals approx. 300 bp downstream of the ATG of *RSus3*.

20 The amplification was performed in a Mastercycler (Eppendorf) as a hot started, two step, PCR (68°/94°C). To ensure optimal product length and limitation of errors the proof-reading thermostable DNA polymerase mixture Expand™ (Boehringer M) was used.

25 For additional optimisation of the amplification, a PCR with one nested primer was performed. After the initial PCR (primer-pair AP1/Rsus3), a secondary semi-nested amplification (primer-pair AP2/Rsus3) was performed, using the product from the initial amplification as template.

30 The composition and reaction conditions for the initial PCR are summarised in the table below.

Initial PCR reaction		PCR program		
Reagent	$\mu\text{L}/\text{reac.}$	Step	Temp ( $^{\circ}\text{C}$ )	Time
Template (1:20)	5	1	94	1' 45"
5xBuffer (E, F, G and H)	10	2	94	15"
dNTP mix (10 mM)	4	3	68	4'
AP1 (4 $\mu\text{M}$ )	5	4	go to step 2, 9 times	
Rsus3 (4 $\mu\text{M}$ )	5	5	94	15"
Water	20	6	68	4' + 20"/cycle
Expand <sup>TM</sup>	0.75	7	go to step 5, 19 times	
		8	4	infinite

\*minutes:' and seconds:''

- 5 Buffer E, F, G, and H for the PCR optimizer<sup>TM</sup> Kit (Invitrogen) were chosen for optimisation of the buffer conditions.

The semi-nested PCR was performed as Outlined in the table below.

Secondary PCR reaction		PCR program		
Reagent	$\mu\text{L}/\text{reac.}$	Step	Temp ( $^{\circ}\text{C}$ )	Time
Template (1:100)	1	1	94	1' 45"
5xBuffer (F and H)	10	2	94	15"
dNTP mix (10 mM)	4	3	68	4'
AP2 (4 $\mu\text{M}$ )	5	4	go to step 2, 9 times	
Rsus3 (4 $\mu\text{M}$ )	5	5	94	15"
Water	25	6	68	4' + 20"/cycle
Expand <sup>TM</sup>	0.5	7	go to step 5, 19 times	
		8	4	infinite

10 minutes:' and seconds:''

compatible with Sall and, since no internal XhoI sites are present in the RSus3, this XhoI site represents the 5' end of all of the native RSus3 fragments.

Sequencing revealed that the sequence around the ATG start codon in RSus3 was CAATGG. So a introduction of the NcoI (CCATGG) in the consensus sequence around the ATG only affects a single basepair. For generation of the 3' end of the promoter region, the RSus3Nco primer was therefore designed with a NcoI site positioned at the ATG start codon for translational fusion of amplified promoter fragments with the *uidA* gene in pGUSNOST.

For amplification of the two RSus3 fragments (1450 bp and 2700 bp ) the primer-pair M13 forward/ RSusNco was used and the RSus3 fragments were amplified from pSspK3 and pScaK3. The M13 primer anneals to the pCR2.1-TOPO part of the pSsp and pSca clones some 110 bp from the cloning site.

The two RSus3 fragments were amplified according to the following scheme:

PCR reaction		PCR program		
Reagent	$\mu$ L/reac.	Step	Temp (°C)	Time
Template (1:20)	5	1	95	2'
5xBuffer (G and H)	10	2	95	1'
dNTP mix (10 mM)	4	3	55	1'
M13 forward (4 $\mu$ M)	5	4	72	2'
RsusNcoI (4 $\mu$ M)	5	5	go to 2, 25 times	
Water	20	6	72	10'
Expand™	0.5		4	0'

\*Qiagen miniprep of pSspK3 or pScaK3

The resulting products were cloned in pCR2.1-TOPO and then subcloned into pGUSNOST as XhoI/NcoI fragments. Positive clones was identified by restriction mapping of miniprep DNA. Although the pGUSTNOST was linearised with both Sall and NcoI, the vector was treated with phosphatase before ligation to prevent religation of plasmid that was cut with only one enzyme due to the close placement of the Sall and NcoI sites (G/TCGAC/CATGG).

The NOS terminator was amplified from pDB2 as a 266 bp fragment with the E357/E356 primerpair, each of which contained an EcoRI site 5' to the annealing region. The amplified fragment was cloned in pCR2.1-TOPO, a positive clone was identified, and named pNOST9. This was sequenced in both directions with universal  
5 and reverse sequencing primers (pCR2.1-TOPO) and the resulting sequence was verified using the BLAST function in the Entrez search engine. NOST was excised from pCR2.1-TOPO with EcoRI and cloned into the unique site for this enzyme in pGUSN358→S. The orientation of the fragment in pGUSN358→S was tested by  
10 PCR using the primer pairs E357/pGUSlower for the correct orientation, and E356/pGUSlower for reverse orientation (product of 350 bp). A clone with NOST in the correct orientation was selected, and named pGUSNOST 2 (5253 bp), which was later just referred to as pGUSNOST, whereas a clone with NOST in reverse orientation was selected and named pGUSNOST1.

#### 15 Cloning of the RSus3 promoter in pGUSNOST

The initial goal was to clone as much as possible of RSus3 promoter into pGUSNOST, without any change of the promoter sequence.

20 Restriction mapping of the RSus3 promoter localised the following features:

1. An internal HindIII site approx. 1200 bp upstream the ATG codon.
2. A PstI site in clones originating from rice DNA template digested with Sca I (pSca clones), but not in those digested with Ssp I (pSsp clones).
- 25 3. Several SphI sites in both pSca and pSsp clones.
4. No Sall and NcoI sites were found in any of the cloned fragments.

These characteristics limited the number of unique restriction sites for cloning of the RSus3 promoter in pGUSNOST. Only Sall and NcoI were available for cloning of the  
30 RSus3 promoter.

The cloning strategy was to generate two RSus3 upstream fragments (1450 bp and 2700 bp) with ends compatible to the Sall and NcoI sites for directional and translational fusion of the RSus3 promoter with the *uidA* gene. The cloning strategy  
35 is outlined in figure 5.

The adaptor from the chromosome walking technique contains a XhoI site and therefore the isolated RSus3 promoters in the pSsp and pSca clones all contain this XhoI site in the 5' end of the promoter region. Overhanging ends generated from cutting with XhoI are compatible with Sall and, since no internal XhoI sites are present in the RSus3, this XhoI site represents the 5' end of all of the native RSus3 fragments.

Sequencing revealed that the sequence around the ATG start codon in RSus3 was CAATGG. So a introduction of the NcoI (CCATGG) in the consensus sequence around the ATG only affects a single basepair. For generation of the 3' end of the promoter region, the RSus3Nco primer was therefore designed with a NcoI site positioned at the ATG start codon for translational fusion of amplified promoter fragments with the *uidA* gene in pGUSNOST.

For amplification of the two RSus3 fragments (1450 bp and 2700 bp ) the primer-pair M13 forward/ RSusNco was used and the RSus3 fragments were amplified from pSspK3 and pScaK3. The M13 primer anneals to the pCR2.1-TOPO part of the pSsp and pSca clones some 110 bp from the cloning site.

The two RSus3 fragments were amplified according to the following scheme:

PCR reaction		PCR program		
Reagent	$\mu\text{L}/\text{reac.}$	Step	Temp (°C)	Time
Template (1:20)	5	1	95	2'
5xBuffer (G and H)	10	2	95	1'
dNTP mix (10 mM)	4	3	55	1'
M13 forward (4 $\mu\text{M}$ )	5	4	72	2'
RsusNcoI (4 $\mu\text{M}$ )	5	5	go to 2, 25 times	
Water	20	6	72	10'
Expand™	0.5		4	0'

\*Qiagen miniprep of pSspK3 or pScaK3

The resulting products were cloned in pCR2.1-TOPO and then subcloned into pGUSNOST as XhoI/NcoI fragments. Positive clones was identified by restriction



mapping of miniprep DNA. Although the pGUSTNOST was linearised with both Sall and NcoI, the vector was treated with phosphatase before ligation to prevent religation of plasmid that was cut with only one enzyme due to the close placement of the Sall and NcoI sites (G/TCGAC/CATGG).

5

A positive 1450 bp clone was named "p1450" and a positive 2700 bp clone was named "p2700".

### Deletions of the RSus3 promoter

10

In order to identify those parts of the cloned promoter regions which confer activity and specificity, we performed a molecular dissection of the cloned fragments, by effecting serial deletions of regions which were deemed from the DNA sequence to contain motifs, identified in the promoters of other genes.

15

The generation of RSus3 promoter deletions involved PCR amplification of selected parts of the promoter region, and cloning of these fragments into a construction which was based on the p1450 construct. It was decided that all truncations of the promoter would be upstream of the TATA box, which is positioned 989 bp 5' to the translation start codon, and approximately 100bp upstream of intron 1. This strategy

20

gave the option of retaining or later removing intron 1 from constructs, while focussing deletions upon the region in which all the recognised promoter motifs are located.

25

As described above, there are a limited number of restriction sites available in the pGUSNOST MCS for cloning of truncated promoter inserts. In fact, there are no unique sites left in the pGUSNOST part of the resulting clones. But in the adaptor part of the cloned 1450 bp and 2700 bp fragments there are a number of restriction sites.

30

Only a few restriction sites are unique within the RSus3 part of the p2700 and the p1450 constructs. Of these, only BamHI, BglII, BsiWI and ClaI generate cohesive ends and are therefore convenient for cloning, but BamHI is located downstream of intron 1 and BglII within it. The BsiWI and ClaI on the other hand are located only 300-400 bp from the MCS and therefore leave very little sequence that can be

35

truncated.

So the lack of usable cloning sites led to the following strategy:

The MCS HindIII site was converted to a NheI site by partial digestion followed by fill-in with Klenow and religation of the resulting blunt ended fragment. PCR amplified fragments with NheI/HindIII could afterwards be cloned directionally in the resulting unique NheI and HindIII sites.

This strategy had several advantages, though it is quite laborious.

1) A standard test plasmid was created, which contained unique NheI and HindIII sites, into which PCR amplified products could be directionally cloned.

2) The sequence of the HindIII/NcoI fragment obtainable from all truncated clones was identical, so possible variations owing to PCR-generated mutations in this region were avoided.

#### HindIII→NheI conversion for directional cloning of PCR deletions

The conversion of the HindIII site in the MCS to a NheI site involved partial digestion with HindIII, filling-in of the 5' single stranded overhang with Klenow fragment, and religation which formed an NheI site. Reaction conditions for effecting a partial digestion with Hind III were established empirically, using the range of dilutions of enzyme in the tabel below and slowing the reaction by performing it at 25°C, rather than 37°C.

Reaction scheme for the partial digestion:

sample	Plasmid dilution <sup>1</sup> (μL)	NEBuffer 2 (μL)	HindIII dilution <sup>1</sup> (μL)	H <sub>2</sub> O (μL)
1	2	1,5	2	9,5
2	2	1,5	4	7,5
3	2	1,5	6	5,5
4	2	1,5	8	3,5
5	2	1,5	10	1,5
6	2	1,5	12	0

Dilutions: 0.25 μg/μL plasmid and 0.02 U/μL HindIII

The partial digests were incubated in a Mastercycler (Eppendorf) for 15 min at 25°C followed by 10 min at 65°C. The result was evaluated on a 1% Seakem agarose gel and sample 2 and 3 gave the best result. In these two samples there were 4 bands: 2  
5 bands from uncut plasmid, a band from a single HindIII cut and a faint band from cutting of both HindIII sites. The latter band increased in intensity in the subsequent samples, at the expense of the single cut band.

The partially HindIII-digested 1450bp construct was filled in using DNA Polymerase I  
10 Large Fragment (Klenow) (NEB) before ligation. In the presence of dNTP's, Klenow fragment retains the polymerization fidelity of the *E.coli* DNA Polymerase I without degrading 5' termini. Treatment with Klenow fragment was performed as follows:

14 µL partial digested plasmid  
15 2 µL 10 mM dNTP mix (Invitrogen)  
0.6 µL NEBuffer 2 (NEB)  
2.9 µL H<sub>2</sub>O  
0.5 µL Klenow fragment (NEB)

20 The reaction was incubated for 15 min at 25°C and 10 min at 75°C. After the filling-in reaction the singly cut plasmid band was isolated from the gel, ligated and positive clones were isolated. This strategy gives rise to two different types of clones, one with an upstream NheI site (p2700(upNheI) 1 and 3), and one with a downstream NheI site (p2700(downNheI) 7 and 10). Although the latter type of clone was not  
25 suitable for promoter truncation studies, it found utility later during the construction of tandem repeats of promoter motifs.

Additionally, the HindIII site in the MCS of the parent plasmid pGUSNOST, which contained no RSus3 sequence, was modified to an NheI site in a similar manner, to  
30 form pGUSNOSTNheI 2 and 3, but the partial digestion was of course not necessary for the unique HindIII site in this plasmid.

### Cloning of three RSus3 deletions in p2700(upNheI)

See Figure 6.

5

Three deletions were generated using the three primer-pairs with different upper primers, but the same lower primer: Nhedel1/Dellow1, Nhedel2/Dellow1 and Nhedel3/Dellow1. The Nhedel1-3 primers was designed with a NheI site and the Dellow1 primer was designed to anneal downstream of the internal HindIII site. Thus  
 10 these primer-pairs results in generation of 3 different PCR products (650 bp, 590 bp and 480 bp), with the 2700bp construct as template, each with NheI/HindIII sites for cloning in p2700(upNheI).

The amplification was performed in a Mastercycler (Eppendorf) as a 2-step PCR  
 15 (68/94°C) described in the table below.

PCR reaction		PCR program		
Reagent	$\mu\text{L}/\text{reac.}$	Step	Temp (°C)	Time
Template (1:100)	1	1	95	2'
5xBuffer (E,F,G or H)	10	2	94	45"
dNTP mix (10 mM)	4	3	68	45"
Nhedel1,2,3 (4 $\mu\text{M}$ )	5	4	go to 2, 25 times	
Dellow1 (4 $\mu\text{M}$ )	5	5	68	10'
Water	24,5	6	4	infinite
Expand™	0.5			

The PCR products were cloned in pCR2.1-TOPO and positive clones were identified  
 20 by restriction mapping. NheI/HindIII fragments from these were isolated and cloned into p2700(upNheI) 1.

Three positive clones were identified and named "p1730" clone 3, "p1670" clone 3 and "p1560" clone 3.

### The p1160 construct

See Figure 7.

5

This deletion was generated by cutting the p2700 construct HindIII. The vector was religated and two positive clones were named "p1160" clone 1 and 2.

### The p2700-prolamin construct

10

See Figure 8.

Whereas all the RSus3 deletions described above are 5' end deletions, this truncation comprises an internal deletion of 161 bp between the internal HindIII site and the TATA-box in the RSus3 promoter. Based on the RSus3 sequence, a primerpair (RsusTATA/RsusNco) was designed for amplification of a 1020 bp fragment, with a HindIII site at one end and an NcoI site at the other. This product therefore comprises Intron 1 flanked by the TATA box, and the ATG translational start codon. The primer RsusTATA contained an internal HindIII site and annealed just upstream the TATA-box. The primer RsusNco, which contains a NcoI site positioned at the ATG start codon for translational fusion of amplified promoter fragments with the *uidA* gene, was the same as described above in section 5.

The PCR reaction was performed as a 2-step PCR (68/94°C) after the following scheme in a Mastercycler (Eppendorf).

25

PCR reaction		PCR program		
Reagent	$\mu\text{L}/\text{reac.}$	Step	Temp (°C)	Time
Template (1:100)	1	1	95	2'
5xBuffer (A and B)	10	2	94	45"
dNTP mix (10 mM)	4	3	68	45"
RsusTATA (4 $\mu\text{M}$ )	5	4	go to 2, 30 times	
RsusNco (4 $\mu\text{M}$ )	5	5	68	10'
Water	24,5	6	4	infinite
Expand™	0.5			

The 1020 bp HindIII/NcoI product was generated by PCR and cloned into pCR2.1-TOPO. Positive clones was identified, and the HindIII/NcoI fragment was cloned into 2700bp(upNheI) (linearized with HindIII and NcoI for substitution of a corresponding 1160 bp fragment). A positive clone was isolated and named "p2700-prolamin" clone

5 1.

### Removal of Intron 1 within the RSus3 promoter region

In order to create a promoter lacking Intron1, screening for the 5'-untranslated region  
10 of an RSus3 clone in a rice cDNA library, and splicing of this to the upstream promoter motifs already cloned, were initially considered. However, sequence analysis revealed the 3' acceptor splice site of intron 1 to be located only 27 bp upstream of the ATG-codon. In light of this, a preferred strategy was formulated in which the sequence of this 27 bp downstream non-coding exon was incorporated in  
15 the lower strand PCR primer used to amplify the promoter.

See Figure 9.

A primer pair was designed for PCR amplification of the RSus3 promoter region from  
20 pSca and pSsp clones. The lower primer (Lowexon $\frac{1}{2}$ ) was designed as follows: The 3' end of the primer corresponded to a 24 bp sequence just upstream for the putative 5' splicing site in intron 1. The 5' end of the primer corresponded to the 27 bp sequence between the 3' splicing site and the ATG-codon (NcoI). The upper primer UppCR2.1 was designed to anneal to a 44 bp sequence of pCR2.1-TOPO, upstream  
25 of the M13 reverse primer site, for amplification of the RSus3 promoter without intron 1 from pSca and pSsp clones.

Both primers were quite long (Lowexon $\frac{1}{2}$  is 56 bp and UppCR2.1 is 44 bp), and to ensure that they were full length, they were ordered HPLC purified. Lowexon $\frac{1}{2}$  has  
30 the possibility to form a hairpin loop with a melting temperature of 56°C and an internal BamHI site gives a stable primer dimer, so the PCR amplification was performed using AmpliTaq Gold an a two step program (68°C/94°C).

Due to the potential of these long primers to form partially miss-matched double-  
35 stranded secondary structures at their 3' end, AmpliTaq gold was used instead of Expand™ polymerase, in order to avoid the modification of the oligonucleotides by the proof-reading Pwo polymerase.

The result was a very faint band of the right size, so a semi-nested PCR amplification with M13 reverse/RsusNco1 was performed using purified product as template.

- 5 This nested PCR gave a more intense band, which was cloned in pCR2.1-TOPO. A positive clone was identified and a XhoI/NcoI fragment was subcloned in pGUSNOST (Analogous to subcloning of XhoI/NcoI fragments from pScaK3 and pSsp3). A positive clone was named "p1450-intron" clone 2.

#### 10 **Generation of tandem-repeat RSus3 promoters**

In an attempt to enhance the activity of the RSus3 promoter, a range of sequences upstream the TATA-box in RSus3 were doubled. This strategy resulted in 3 tandem-repeat RSus3 promoters, in which different parts of the RSus3 promoter region had  
15 been doubled.

See Figure 10.

DNA sequence analysis located the majority of putative cis-elements to be within 700  
20 bp (-1709 bp to -1027 bp), upstream of the TATA box. Therefore these 700 bp contained the elements to be doubled.

The three tandem-repeat promoters were constructed by amplification of specific sequences of the promoter, cloning of these into pCR2.1-TOPO, and finally  
25 subcloning the cloned fragments in either the NheI site or the HindIII site in the p1730 construct.

#### **Tandem legumin**

- 30 The repeated sequence in the tandem legumin promoter were amplified after same description as NheI/HindIII product in p1730, but with p2700(downNheI) as template. This gave a similar product, only with two NheI sites, which after cloning into pCR2.1-TOPO, was subcloned as an Nhe I fragment into the NheI site of p1730. A positive clone was identified by NheI digestion, and the orientation was established by  
35 repeating the PCR using the subclone as template. The resulting clone was named "pTandem legumin"

**pTandem leg/pro**

This tandem-repeat promoter was constructed in a similar approach. A primer pair was designed for amplification of a 750 bp fragment from the p2700 construct. The primer pair each had an NheI site (NheI1 used for p1730, and NheGCN4). Amplification of the primer pair NheI1/NheGCN4, was again performed, after same description as for the p1730 construct, and resulted in a 750 bp product (with NheI sites in both ends), which were cloned in pCR2.1-TOPO, and afterwards subcloned into the NheI site of the p1730 construct. A positive clone was identified by restriction digest, the orientation was determined in the same manner, and the clone was named "pTandem leg/pro".

**pTandem prolamin**

This tandem-repeat promoters was generated in almost the same manner as the tandem leg/pro. The primerpair had same upper primer, and an analogous lower primer with a HindIII site (HindGCN4). The resulting product was cloned into pCR2.1-TOPO and a 170 bp HindIII/HindIII fragment from this was subcloned in the HindIII site in the p1730 construct. A positive clone was identified by restriction digest, the orientation of which was determined by repeating the PCR using the subclone as template. The resulting clone was named "pTandem prolamin".

**Transient ballistic transformation with the Particle Inflow Gun (PIG)**

The Particle Inflow Gun (PIG) used in this study was in accordance with Finer et al. 1992 and Vain et al. 1993. The PIG - which is placed on a sterile-bench for minimizing contaminants - comprises a vacuum chamber with a digital vacuum sensor, an electronically operated solenoid gas valve attached to a helium cylinder regulator (1-16 bar), and a three-way valve connected to a vacuum pump. The solenoid regulates the helium flow, and is controlled by a timer relay which allows gated flow in pulses down to 25 milliseconds. The PIG is operated from a control panel with a timer relay, a digital display vacuum gauge and a fire-button.

The vacuum chamber is constructed from 3 mm stainless steel with a 20 mm acrylic door and a 10 mm inner lining of polypropylene with grooves at every 20 mm for a shelf. A silicone foam gasket between the chamber and the door seals the vacuum chamber.



A ballistic transformation device, similar to the PIG, was used in a preliminary experiment to test the feasibility of transformation of guar endosperms by particle bombardment.

5

#### **Preparation of guar tissue for transformation**

The primary target for particle bombardment in this study was the guar endosperm, but both emerged and pre-emerged cotyledons, as well as juvenile leaves, were also used as comparative tissue. Endosperms and emerged cotyledons were isolated from 3-4 weeks old guar pods, pre-emerged cotyledons were harvested from 12 and 20 day old *in vitro* grown seedlings, and juvenile leaves were harvested from mature guar plants.

#### **Isolation of guar tissue**

Endosperms were isolated from guar seeds, under aseptic conditions, after the following procedure:

The sterilised guar pods were opened, and the seeds taken out. For each seed, the coat was carefully removed, and the remaining part was divided in endosperm and embryo. The endosperm was divided in two identical halves, and the convex dorsal side of both halves was the target surface for particle bombardment. This bisection and orientation minimised dispersal of the tissue by the helium blast. The pre-emerged cotyledons were separated from the embryo, whereas emerged cotyledons were isolated from seedlings grown *in vitro* in a 12 hour day/night regime. Young guar leaves were excised from full-grown plants.

The isolated tissue was transferred to the 60 mm petri dishes containing solid agarose medium and a filter paper disc (see section 1.4.3). The tissue were placed as follows: Endosperms in the centre of the petri dish with dorsal side up; cotyledons from seedlings with the upper side facing up in the centre of the petri dish; Embryo cotyledons together with endosperms.

A particle bombardment experiment consisted of 5 to 6 repeated bombardments per construct. 6-8 endosperms, 2-3 cotyledons from seedlings, or 6-7 endosperms plus 4-5 pre-emerged cotyledons were bombarded in each discharge of the PIG. For

comparative analysis, both cotyledons and endosperms were bombarded in same experiment.

#### **Sterilisation of guar tissue**

5

No antibiotics were used in the transformation, so microbial contamination must be avoided. Therefore a fastidious sterilisation procedure was very important.

10 Sterilisation of guar pods from mature guar plants were accomplished as follows: The pods were washed in sterile water, submerged for 1 min in 96 % EtOH, and finally washed 3 times with sterile water. Further sterilisation of the guar pods and seeds was not necessary.

15 Sterilisation of new leaves from mature guar plants was accomplished as follows: The leaves were washed in sterile water, submerged for 10s in 96 % EtOH and for 20 min in 0.15 % NaOCl and 0.05 % Triton X-100. Finally the leaves were washed 3 times with sterile water, and stored in water until use.

20 Cotyledons from *in vitro* grown seedling were sterile and no sterilisation was necessary.

**Medium**

The tissue was bombarded and incubated on the following medium. The medium was a solid medium, and was based on a recipe from Donovan & Lee 1977, with a few modifications in the concentration of the ingredients.

	Compound	Concentration (mg/L)
Salts	Sucrose	20,000
	M&S mix <sup>1</sup>	4,300
Vitamins	Myo-inositol	100
	Thiamine	0.4
Aminoacids	L-Alanine	89
	L-Arginine	126.5
	L-Asparagine	117
	L-Aspartic acid	100
	L-cysteine	69
	L-glutamic acid	664.5
	L-Glutamine	665.5
	Glycine	156
	L-Histidine	112
	L-Isoleucine	174
	L-Leucine	274.5
	L-Lysine	77
	L-Methionine	67
	L-Phenylalanine	287.5
	L-Proline	443.5
	L-Serine	202.5
	L-Threonine	96
	L-Tryptophane	164
	L-Tyrosine	144
	L-Valine	161.5
Agar	Agar type A 1296	8,000

<sup>1</sup> Murashige & Skoog basal salt mixture M5524

## 10 The particle bombardment procedure

The particle bombardment experiments in this study had been performed as described below.

### DNA coating of gold particles

A typical transformation with a single plasmid, comprising five repeated discharges of the PIG, employed 3 mg of gold particles. In practice, a larger batch of gold particles than this was freshly prepared at one time, and used for several transformations immediately afterwards. The procedure described below for the preparation of 3mg of gold particles was adjusted such that amounts and volumes increased in proportion to amount of material.

10

1. 3 mg of gold particles (1.6 $\mu$ m, Biorad) were treated with 50  $\mu$ L 99.9 % EtOH (Danisco Distillers).

2. The gold particles were vortexed in the ethanol for 3 min (full speed) and centrifuged at 10.000 g for 1 min.

15

3. The supernatant was removed and resuspended in 50  $\mu$ L of sterile H<sub>2</sub>O .

4. The particles were centrifuged at 10.000 g for 1 min, the supernatant was removed and this washing with water repeated.

5. The particles were resuspend in 50  $\mu$ L 50% w/v glycerol (sterile).

20

The gold particles were then coated with plasmid DNA in the following manner.

1. 50  $\mu$ L of gold particle suspension were removed during vortexing (14.000 min<sup>-1</sup>) on an thermomixer (Eppendorff).

25

2. While vortexing (14.000 min<sup>-1</sup>) this 50  $\mu$ L sample of gold particles, the following components were sequentially added.

10  $\mu$ L of plasmid (10  $\mu$ g/ $\mu$ L)

50  $\mu$ L 2.5 M CaCl<sub>2</sub>

20  $\mu$ L 0.1 M Spermidine

30

3. Vortexing was continued for 3 min at 16.000 min<sup>-1</sup>. The sample was then sedimented at 10.000 g for 10 s. and the supernatant was removed.

4. The sample was resuspended in 250  $\mu$ L 99.9 % EtOH, and centrifuged at the same force for 10s.

35

5. The supernatant was removed and the particles resuspended in 40  $\mu$ L 99.9 % EtOH.

6. The DNA coated microprojectiles were stored at ice until use.

Because the gold particles tend to agglomerate irreversible in aqueous solutions, it was necessary to prepare them immediately prior to use [Kikkert 1993].  $\text{CaCl}_2$  can be store at 4°C, but spermidine (N-[3-aminopropyl]-1,4-butanediamine) deaminates with time, and solutions must be freshly made every month and be stored frozen at -20°C.

The purpose of the spermidine in the coating procedure is to condense the DNA by shielding the negative charges on the DNA phosphate backbone, thereby allowing hydrophobic interactions to predominate [Bloomfield 1991].

### Operating the PIG

The PIG was operated in accordance with the following procedure

1. A petri-dish (60 mm in diameter) with the target tissue was placed in the vacuum chamber.
2. A stainless steel mesh (250  $\mu\text{m}$ -mesh, 13 mm in diameter) was placed in the filter unit.
3. 5  $\mu\text{L}$  of a suspension of DNA-coated micro-projectiles were loaded on to the centre of the steel mesh.
4. The filter unit was assembled and attached to the helium solenoid valve.
5. The 250  $\mu\text{m}$ -mesh stainless steel protection screen was placed on top of the petri-dish.
6. The door and the valves were closed and evacuation of the chamber was begun.
7. The helium burst was released by pressing the fire button exactly at the point when the desired vacuum was reached.
8. The vacuum was released by opening the evacuation port, and the tissue was removed .
9. The cycle was repeated until all the samples had been bombarded. The filter unit, mesh and protection screen were changed for every new construct.

### Bombardment conditions

Good results for ballistic transformation of guar endosperms, embryos, and  
5 cotyledons were obtained with the following bombardment conditions.

- The vacuum chamber was evacuated to a partial vacuum of 0.1 bar .
- The target was placed at a distance of 16 cm, measured from the mesh in the filter unit to the target tissue.
- 10 • The helium pressure on the regulator was set at 5 bar.
- The timer relay was set at 50 milliseconds.
- A stainless steel protective screen (250  $\mu\text{m}$ -mesh) was placed approx. 2 cm above the target tissue
- Gold micro-projectiles with a diameter of 1.6  $\mu\text{m}$  (Biorad) were used to carry the  
15 plasmid DNA.

### Post bombardment

After bombardment the petri-dishes, containing bombarded tissue, were sealed and  
20 incubated for 48 hour at 25°C. Endosperms and embryos were incubated in the dark, leaves and cotyledons were incubated in a 12 hour day/night regime.

### GUS assay

25 The histochemical GUS assay was performed as described by Jefferson 1987. After the incubation period the bombarded tissues were transferred to microtitre plates, submerged in GUS-assay buffer and incubated in dark for 24 hours at 37°C.

GUS-assay buffer:

30

100 mM Sodium-phosphate buffer, pH 7.5

0.5 mM Potassium ferricyanide (III)

0.5 mM Potassium ferrocyanide (II)

10 mM  $\text{Na}_2\text{EDTA}$  (Titriplex III)

35 1.9 mM X-Gluc

A method for determination of GUS expression, and thereby promoter activity, by counting the number of blue spots was adapted from Knudsen & Müller [1991]. After bombardment, incubation and GUS-assay the number of blue spots (expression units) was counted under a microscope, and expressed relative to the area examined.

The cotyledons and leaves were cleared in 96 % EtOH in several washing steps, and were stored in 70 % EtOH until counting of blue spots.

Blue spots in endosperms had to be counted immediately after the GUS incubation period. Neither storage in alcohol nor water were applicable, due to high content of galactomannan and water. The water caused swelling of the endosperm and ethanol made the endosperm shrink. These changes destroyed the expression pattern on the surface of the endosperm.

#### Presence of sucrose synthase in guar endosperm

A typical developmental increase in sucrose synthase, that coincides with seed-fill, was verified in extracts from guar endosperm using a continuous sucrose synthase assay (see Figure 11). Details on the sucrose synthase assay are as follows.

#### Sucrose synthase assay

The sucrose synthase activity in developing guar endosperms was assayed in the direction of sucrose cleavage. The sucrose synthase catalyses the cleavage of sucrose in the presence of UDP into fructose and UDP-glucose:



The activity of sucrose synthase was assayed by monitoring the formation of UDP-glucose in a continuous enzyme reaction described by Keller et al. (Keller F, Frehner M & Wiemken A (1988) Sucrose Synthase, a Cytosolic Enzyme in Protoplasts of Jerusalem Artichoke Tubers (*Helianthus tuberosus* L.) Plant Physiol. 88, 239-241). The formation of UDP-glucose was coupled to the reduction of NAD<sup>+</sup> in the presence of UDP-glucose dehydrogenase (E.C. 1.1.1.22), which catalysis oxidation of UDP-glucose to UDP-glucuronic acid:



The endosperms were dissected from the developing seeds, pooled and homogenised in Hepes/KOH buffer (20 mM, pH 8.00) using a rotating pestle. During this procedure enzymatic breakdown of the galactomannan backbone was effected by addition of  $\beta$ -mannase (E.C. 3.2.1.78, Megazyme). The sample was centrifuged at 20,000 g for 20 minutes and the resulting supernatant was desalted using Sephadex® G-25 columns (NAP™-5, Pharmacia Biotech), for removal of endogenous sugars from the crude extract.

10

An appropriate amount of enzyme extract was added to the sucrose synthase assay buffer (1 ml):

20 mM Hepes/KOH (pH 8.0)  
15 200 mM sucrose  
2 mM UDP  
1.5 mM NAD<sup>+</sup>  
20 mU UDP-glucose dehydrogenase (Sigma)

20 The reduction of NAD<sup>+</sup> to NADH was followed by continuous measurement of the absorbance at 340 nm in a spectrophotometer (25°C,  $\epsilon_{\text{NADH}} = 6300 \text{ l mol}^{-1} \text{ cm}^{-1}$ ). The amount of UDP-glucose produced ( $\mu\text{mol min}^{-1}$ ) was calculated from the slope of the resulting absorbance curve. The total amount of protein, in the remaining supernatant, was determined using the Biorad Protein Assay with bovine serum  
25 albumin as standard, and the specific activity of sucrose synthase was calculated (Units sucrose synthase per mg protein, or  $\mu\text{mol min}^{-1} \text{ mg}^{-1}$ ).

The activity of sucrose synthase was measured in extracts from guar endosperms at various developmental stages from 7-41 days after flowering. The mean sucrose  
30 synthase activity for each developmental stage was obtained from 3 to 4 independent measurements, each of which was made with extract obtained from at least 5 endosperms from same pod.



## RESULTS

### Isolation of the RSus3 promoter region

The rice sucrose synthase 3 (RSus3) promoter region was isolated from rice genomic DNA using the chromosome walking technique described by Siebert et al. 1995. After the semi-nested PCR reaction, 3 bands appeared in the following reactions: *Dra*I ( $\approx$ 700 bp), *Sca*I ( $\approx$ 3000 bp) and *Ssp*I ( $\approx$ 1800 bp).

The 1800bp and 3000bp products were verified, as specific products obtained from the primer-pair AP2/RSus3, by single primer control reactions.

Template\Primer	AP2	RSus3	AP2/RSus3
<i>Sca</i> I (buffer H)	-	-	$\approx$ 3000 bp
<i>Ssp</i> I (buffer H)	-	-	$\approx$ 1800 bp

- The result of this single primer control reaction shows that the 1800 bp and 3000 bp originated from specific amplification from the AP2/RSus3 primer-pair and are not single primer products. Single primer product from the AP2 is most likely the result of amplification from two adaptors.
- The 1800 bp and 3000 bp products were cloned into pCR2.1-TOPO. Nine clones of the 1800 bp ligation and seven clones of the 3000 bp ligation were isolated. Restriction mapping with *Eco*RI showed that of these, four 1800 bp clones and six 3000 bp clones had insert between the two *Eco*RI sites.
- The resulting pCR2.1 clones with 1800 bp and 3000 bp inserts were partially sequenced using M13 universal and reverse sequencing primers specific for pCR2.1-TOPO. Downstream sequences for the 1800 bp and 3000 bp clones were compared to the published part of the RSus3 sequence [Huang et al. 1996 (GenBank accession number: L03366)] using the alignment feature in the Winseq program.

All four 1800 bp clones were shown to have the upstream part of transcribed region of RSus3 inserted (two clones of each orientation). These clones were named pSsp A2, K1, K3 and K4.

Four 3000 bp clones were also shown to have the upstream part of the transcribed region of RSus3 inserted (with both orientations represented). These clones were named pSca K3, K5, New1 and New5.

5

See Figure 2.

### Presentation of sequence data

- 10 The clone pTBR-ScaK3 (pScaK3) was chosen for total sequencing of the RSus3 promoter region. This clone was sequenced on both strands after the sequencing plan outlined in figure 12.

- 15 The other positive RSus3 clones described above was partially sequenced. The sequencing of the RSus3 clones resulted in determination of 2700 bp upstream the ATG codon (see SEQ ID No. 1).

### DNA sequence analysis

- 20 The sequence for the RSus3 promoter region was analysed for the presence of putative cis-elements involved in the regulation of gene expression. The region upstream of the translational start codon was examined for the conserved TATA and CAAT consensus sequences, and the region was examined for the presence of putative endosperm or seed specific elements.

25

Additionally the region between the TATA box and the translational start codon was examined for the presence of intron donor and acceptor splice sites.

- 30 The translational start codon was chosen as basis for assigning bases in the RSus3 promoter, i.e. the A in ATG was numbered +1 (E.g. the base-pairs around the CAATGG are numbered -2, -1, +1, +2, +3 and +4).

- 35 Alignment of the RSus3 promoter region, with the promoter region region from RSus1 (GenBank accession number: X59046) and from RSus2 (GenBank accession number: X64770), gave no obvious similarity.

The results of the DNA sequence analysis are summarised in Table 1 (see earlier).

The GCN4 box and the three endosperm boxes are cis-elements involved in endosperm specificity and the legumin boxes are cis-elements involved in seed specificity. Additionally the -1072 bp endosperm box and the GCN4 motif constitutes a putative prolamin element, which also is involved in endosperm specificity, although the distance between the endosperm box and GCN4 motifs in RSus3 is greater than this (34 bp), the sequence shows high similarity to the consensus sequence.

The GCN4 box, the two endosperm boxes and the majority of the legumin boxes are located within 700 bp spanning from -1023 bp to -1707 bp. This 700 bp sequence are located just upstream the TATA box.

A restriction map of the RSus3 promoter region is presented herein as Figure 3.

#### 15 **Presentation of RSus3/GUS/NOST constructs**

In this study, various RSus3 promoter sequences were fused with the *uidA* gene for generation of a series of RSus3/GUS expression cassettes. Specific deletions of the RSus3 promoter were constructed in an attempt to identify those parts of the promoter that are involved in tissue-specificity. A series of tandem-repeat promoters were constructed in an attempt to enhance the promoter activity, and the intron 1 was removed from the promoter region, in order to establish whether it is necessary for expression in guar endosperm.

25 The constructs were generated either by amplification of specific fragments by PCR or by subcloning. For verification of the resulting constructs, control restriction digests, typically with HindIII, Nhe I, and NcoI were performed. Additionally, control PCR or sequencing reactions were performed in some cases.

30 Common features in all variants of the RSus3 promoter were, translational fusion to the *uidA* gene, presence of the TATA box, and conservation of region downstream of this (with the exception of the single construct from which the intron was removed). The series of RSus3 promoter constructs centred around the upstream 700 bp region distal to the TATA box. As described above, this sequence contains the majority of putative cis-elements involved in specificity.

The various RSus3 promoter constructs are summarised in figure 13.

**p2700 construct (plasmid size 7938 bp)**

An RSus3 promoter of 2700 bp was initially constructed. This construct constituted the full-length RSus3 promoter, and was prepared by amplification of a 2700 bp XhoI/NcoI fragment from pTBR-ScaK3 into Sall/NcoI in pGUSNOST. Positive clones were verified by NcoI/HindIII digests, which resulted in 2 specific fragments, of 1160 bp and 1540 bp, in addition to the 5230 bp NcoI/HindIII fragment from the pGUSNOST part.

10

**p1730 construct (plasmid size 6963 bp)**

This 5' truncation of RSus3 was constructed by generation of a 571 bp NheI/HindIII fragment spanning from -1160 bp to -1730 bp. After changing of the upstream HindIII site to a NheI site in p2700, the NheI/HindIII fragment generated was subcloned into this p2700(upNheI). Positive clones were identified by an NheI/HindIII control digest, and this resulted in a specific fragment of same size as the subcloned fragment.

**p1670 construct (plasmid size 6907 bp)**

This 5' truncation was analogous to p1730, comprising a 515 bp instead of 571 bp NheI/HindIII fragment, positive clones of which were identified in the same way.

**p1560 construct (plasmid size 6791 bp)**

This 5' truncations was also analogous to p1730, comprising a 400 bp instead of 571 bp NheI/HindIII fragment, positive clones of which were identified in the same way.

**p1450 construct (plasmid size 6704 bp)**

This construct was analogues to p2700, with ligation of a 1450 bp XhoI/NcoI fragment amplified from pSspK3 template, instead of the same amplified from pScaK3. A NcoI/HindIII digest resulted in two specific bands of 1160 bp and 290 bp, besides the 5230 bp pGUSNOST fragment.

**p1160 construct (plasmid size 6390 bp)**

This truncated promoter constitutes removal of 1540 bp upstream the internal HindIII site, and was generated by cutting p2700 with HindIII, followed by religation. Positive clones were identified by HindIII digest, which gave a single fragment in positive clones.

**p2700-prolamin construct (plasmid size 7777 bp)**

This internal truncation of 161 bp was produced by amplification of a 1020 bp fragment comprising the TATA box to the ATG codon. This fragment was cloned in p2700(upNheI) as a HindIII/NcoI fragment. Positive clones were verified by a HindIII/NcoI digest, which resulted in a specific fragment of 1000 bp and a fragment of 6770 bp.

**p1450-intron (plasmid size 5837 bp)**

In this construct, the intron 1 was removed by exactly splicing of the putative intron 1 acceptor and donor splice sites. This internal deletion of the intron 1 was generated by amplification of a region of p1450 which corresponded to RSus3 lacking the intron 1. After cloning in pCR2.1-TOPO, an XhoI/NcoI fragment containing this was subcloned in pGUSNOST. A positive clone was identified by restriction digestion with HindIII/NcoI, and the 3' promoter end was verified by sequencing.

**pTandem legumin (plasmid size 7536 bp)**

This tandem repeat promoter was constructed by generation of a 570 bp NheI fragment spanning from -1160 bp to -1730 bp by PCR. This fragment was subcloned in the NheI site in p1730. A positive clone was identified by control digests and a control PCR reaction with NheI1/Dellow1 verified the orientation. The right orientation resulted in two bands of 650 bp and 1300 bp, whereas the reverse orientation only resulted in a 650 bp product.

**pTandem leg/pro (plasmid size 7704 bp)**

This tandem-repeat promoter was constructed by PCR amplification of a 740 bp NheI fragment spanning from -990 bp to -1730 bp. This fragment was subcloned in the NheI site in p1730. Positive clones were first identified by an NheI digest, and those

of appropriate orientation were determined by HindIII digest. This was possible due to the internal HindIII site in the promoter, which was duplicated in this construct. Correct orientation resulted in a 740 bp HindIII fragment, whereas the reverse orientation resulted in a 1140 bp HindIII fragment.

5

#### **pTandem prolamin (plasmid size 7135 bp)**

This tandem-repeat promoters was constructed by generation of a 170 bp HindIII fragment, spanning from -990 to -1160 bp by PCR, which was subcloned in the  
10 HindIII site in p1730. A Positive clone were identified by control digests, and the right orientation was determined by control PCR. Amplification with primer pair Nhede11/HindGCN4 resulted in two bands of 600 bp and 750 bp for clones with right orientation, and to bands for of 300 bp and 750 bp for clones of reverse orientation.

15 See Figure 15.

#### **Transient expression experiments**

The RSus3 expression cassettes described above were used to effect a transient  
20 transformation of guar tissue using the particle bombardment technique.

These experiments served several purposes. Firstly, for testing the usefulness of the method for generation of transient transformed guar tissue. Secondly, the purpose was to set up and optimise the Particle Inflow Gun (PIG) in Danisco Biotechnology,  
25 Holeby. Finally, the main purpose was to evaluate the strength and specificity of promoters, such as RSus3, in guar tissues.

#### **Control**

30 By way of a control experiment, a control plasmid comprising the *uidA* gene fused to the ENOS promoter was constructed. It is known that the ENOS promoter has high levels of expression in both endosperm and leaf tissue.

**Transient expression of RSus3/GUS/NOST in guar tissue**

A total of 11 sets of particle bombardment experiments were performed for testing the promoter strength and specificity of the RSus3 promoter region. The above  
5 described RSus3/GUS/NOST constructions had been tested in this period. The procedures for the bombardment, for the preparation of guar tissue and for the coating of gold particles are described above.

The first approach was to test whether the RSus3 promoter was active in guar  
10 endosperm or not. p2700 and p1450 were bombarded into guar endosperms, and the result showed significant expression of GUS in endosperm for both constructs, although the expression was lower than for the ENOS control. These results were so promising that the subsequent work was concentrated around this promoter.

15 The second approach was to test whether the RSus3 was specific for the endosperm or whether it had expression in other parts of the plant. The initial experiment, which was performed on cotyledons from *in vitro* grown seedlings, showed differences in expression between p2700 and p1450. p2700 had almost no expression of GUS in cotyledons, whereas some cotyledons transformed with p1450 displayed significantly  
20 higher expression.

To test whether this expression pattern for p2700 and p1450 was the same in leaves, these constructs were also used to perform transient transformation of juvenile  
25 leaves from mature plants. This transformation turned out to be difficult due to severe damage of the leaf tissue caused by the helium blast. Not only was the expression of RSus3 concentrated in the vascular tissue of the leaves, but also the ENOS control showed same expression pattern indicating that optimisation of the procedure for leaves were necessary. Due to limitations in time, however, these optimisation experiments were abolished after a while, and instead it was chosen  
30 exclusively to bombard cotyledons from seedlings and from seeds.

The transient GUS expression, directed by the two RSus3 promoter constructs, p2700 and p1450, justified further analysis of the promoter strength and tissue  
35 specificity. As described above a series of deletions of the RSus3 promoter were constructed and these were tested in guar endosperm, guar embryo cotyledons and cotyledons from 12 and 20 day old seedlings. Additionally, in an attempt to enhance the promoter activity, 3 tandem promoters were constructed and the resulting

constructs were also tested in same tissue for evaluation of promoter strength and specificity.

Figure 16 presents transient GUS expression data from the control ENOS promoter, the RSus3 promoter construct p1730 and the RSus3 promoter construct pTandem leg/pro (tandem repeat). The results, which are in accordance with the findings for the other RSus3 promoter constructs, have been discussed above. These results show selective endosperm expression of an NOI.

10 The results of transient GUS expression in guar endosperms, after bombardment with RSus3 constructs, are summarised in figure 17.

The data show that the promoter of the present invention causes selective expression of the NOI in endosperm. In addition, a tandem repeat of the promoter of the present invention causes an increase in the expression levels.

As can be seen at figure 17 the expression in guar endosperm are only slightly affected by deletion of the sequence between 2700 bp and 1160 bp. The 1160 bp has still significant expression indicating that the cis-elements which caused the main part of expression in guar endosperm are present between 1160 bp and the TATA box (+989 bp). This part has been removed in the p2700÷prolamin construct, and this result in a loss of 25 % of the promoter activity compared to p2700.

25 pTandem leg/pro gives highest expression in endosperms, 3 times higher than the 2700 construct and the level of expression is comparable to NOS expression in endosperms.

30 No blue spots were observed when GUAR tissues were bombarded with microprojectiles treated in the same manner, only without DNA, and when the PIG was discharged without microprojectiles. Bombardment with the promoterless GUS construct (pGUSNOST) gave only a few blue spots, presumably caused by illegitimate recombination into the chromosome adjacent to a promoter.

35 For comparative analysis of expression in endosperms versus cotyledons, values relative to the area of the bombarded tissue were calculated. An average 4 weeks old endosperm comprises an area of 0.2 cm<sup>2</sup>, and the same for an average pre-emerged cotyledon. An average 12 days cotyledon covers an area of 1.5 cm<sup>2</sup>, and



an average 20 days cotyledon an area of 2.8 cm<sup>2</sup>. Therefore the number of blue spots per 12 day or 20 days cotyledon were corrected to number of blue spots per 0.2 cm<sup>2</sup>.

- 5 Figure 18 shows that the only highly significant change in promoter strength was displayed by the Tandem leg/pro variant. Although this construct directed a level of GUS expression which was three-fold larger than that of the parent construct p2700, it retained specificity for the endosperm. Levels of expression in cotyledons was equally low with the Tandem leg/pro variant as it was with p2700.

## CO-TRANSFORMATION

The largest component of variance in data obtained by measurements of transient gene expression, following ballistic transformation, resides in the differences in the efficiency of delivery of the DNA to the target. It has been shown that one can compensate for this problem, and obtain more precise evaluation of transient gene expression, by co-transformation with a control expression vector containing a different reporter gene (Godon, C., Caboche, M, Daniel-Vedele, F. (1993) Biochimie 75: 591-595). By measuring the reporter activities and expressing results as the ratio of the test activity to that of the control, fluctuations that merely result from differences in the amount of DNA striking the target are accounted for.

The RSus3 promoter variants, were also tested in this manner. The firefly luciferase gene (*luc*) was fused to each of them, as a reporter, and ballistic transformation was repeated as described before, but two control plasmids were included in equal molar amounts to the test plasmid. The strength and tissue-specificities of the different promoter constructs were tested in modified transient expression studies of ballistically transformed endosperms, and pre-emerged cotyledons, from the same guar seeds. Each experiment involved simultaneous transformation with three separate plasmids. Of these, one was a test plasmid (p2700 + intron/*luc*+, p2700 - intron/*luc*+, pTandem leg/pro + intron/*luc*+, or pTandem leg/pro - intron/*luc*+ or pDB16/*luc*+), in which promoters were fused to the firefly luciferase gene (*luc*+) (Figures 19, 20, 21, 22, and 23). The remaining two were control plasmids, in which either the *uidA* (GUS) gene or the renilla luciferase gene (pDB16/Rluc) were under the control of the NOS promoter (Figures 24 and 25). 2µg of test plasmid were mixed with 2µg of each control plasmid, and coating of particles with this DNA, preparation, bombardment, and subsequent incubation of tissue, were all performed as described above.

Enzyme extracts of bombarded tissues were made by grinding these in liquid nitrogen, and extracting the frozen macerate with a buffer containing boric acid, that prevents gelling of the galactomannan in cryopreserved material. Approximately 400mg of each tissue were extracted with 800µl of extraction buffer (50mM NaH<sub>2</sub>PO<sub>3</sub>, 50mM H<sub>2</sub>BO<sub>3</sub>, 1mM dithiothreitol, 1mM EDTA disodium salt, 10mg/ml bovine serum albumin, pH was adjusted to 7.0 by addition of sodium hydroxide). Samples were centrifuged at 12,000 g, at 4°C, for 2minutes, and the resulting supernatants were used for analysis.

The activities of all three reporter genes were measured luminometrically using a Turner TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). The two luciferase activities were measured sequentially in the same reaction mixture, after the 'Dual -Luciferase ®' method described in Promega Technical Manual No. 40 (Promega Corporation, Madison, WI, USA). 20µl of guar tissue extract were rapidly mixed with 100µl of LARII reagent in the apparatus, which after 2 seconds measured and integrated the light evolved over the subsequent 10 seconds. Immediately after this, 100µl of 'Stop and Glo®' reagent were added to the reaction mixture and the renilla luciferase luminescence was measured in the same manner.

10

GUS activity was measured according to the GUS-Light™ system instruction manual (TROPIX Inc., Bedford, MA, USA). 20µl of guar tissue extract were added to 180µl of GUS reaction buffer, and incubated at 25°C for one hour. The tube was placed in the luminometer, 300µl of 'light emission accelerator' were added, and after 2 seconds the light emitted during the subsequent 10 seconds was measured and integrated.

15

The values obtained are summarised in the table below.

#### Relative Integrated Light Signal

20

Rsus3/luciferase experiment	Dual Luciferase® Reporter Assay system (Promega)				GUS-Light™ (Tropix)	
	Endosperm		Cotyledon		Endosperm	Cotyledon
	luc+	Rluc	luc+	Rluc	GUS	GUS
<b>p2700+intron/luc+</b> (pDB16/Rluc and pDB16/GUS)	7,7	352,0	1,2	248,7	194,5	208,2
	7,6	350,4	0,8	236,4	165,3	192,4
	7,6	353,2	0,8	256,7	189,8	206,7
<b>P2700-intron/luc+</b> (pDB16/Rluc and pDB16/GUS)	20,9	574,0	0,6	185,2	269,7	215,0
	20,9	585,1	0,5	179,3	252,1	151,3
	21,2	596,7	0,5	195,1		228,0

104

PTandem (leg/pro)+intron/luc+ (pDB16/Rluc and pDB16/GUS)	13,9	249,5	1,1	209,2	93,4	166,4
	13,3	248,8	0,9	202,3	99,6	142,0
	13,3	247,5	0,8	206,6	104,9	182,7
pTandem (leg/pro)-intron/luc+ (pDB16/Rluc and pDB16/GUS)	42,8	570,1	1,7	205,1	249,2	172,3
	43,2	591,8	1,5	202,6	225,2	156,3
	44,7	604,3	1,5	213,9		167,2
pDB16/luc+ (pDB16/Rluc and pDB16/GUS)	45,3	565,5	22,3	155,5	289,8	206,6
	43,4	582,0	21,4	176,2	205,8	191,8
	45,1	623,4	19,9	172,4	333,2	206,4

The same results are expressed in Figure 26 as 'relative strength of promoter', the value of which is calculated by the division of two ratios, the test ratio and the control ratio. The test ratio was calculated by dividing the luminescence generated by the firefly luciferase, under control of test promoter construct, by the value obtained from the control reporter gene (either uidA or Rluc) under the control of the NOS promoter. The control ratio was calculated by dividing the luminescence from the firefly luciferase by the value from the control reporter gene (either uidA or Rluc) when both genes were under the control of the NOS promoter. 'Relative strength of promoter' was calculated by dividing the test ratio by the control ratio and multiplying the value obtained by one hundred.

The results in Figure 26 show a pattern that mirrors that shown in Figure 17 insofar as the Tandem leg/pro configuration enhances the activity of the promoter while retaining tissue specificity. Although it appeared from the earlier results that the Tandem leg/pro promoter construct was twice as strong as the NOS promoter strength in endosperm tissue, the results in Figure 26 show that these two promoters in fact display similar strength in this tissue. These results also show that removal of the intron from constructs seems to enhance promoter strength in guar tissue. This is a preferred aspect for some embodiments of the present invention. Hence, preferably the NOI does not comprise an intron.

## SUMMARY

In summation, the present invention relates to a promoter and, also to a construct  
5 comprising the same. In particular the present invention relates to the use of a  
promoter for the expression of a NOI in an organism.

All publications mentioned in the above specification are herein incorporated by  
reference. Various modifications and variations of the described methods and system  
10 of the present invention will be apparent to those skilled in the art without departing  
from the scope and spirit of the present invention. Although the present invention  
has been described in connection with specific preferred embodiments, it should be  
understood that the invention as claimed should not be unduly limited to such specific  
embodiments. Indeed, various modifications of the described modes for carrying out  
15 the invention which are obvious to those skilled in biochemistry and biotechnology or  
related fields are intended to be within the scope of the following claims.

REFERENCES

- Bloomfield VA (1991)  
Condensation of DNA by multivalent Cations: Considerations on Mechanism  
5 Biopolymers 31: 1471-1481
- Donovan CR & Lee JW (1977)  
The Growth of Detached Wheat Heads in Liquid Culture  
10 Plant Science Letters 9: 107-113
- Kikkert JR (1993)  
The Biolistic PDS-1000/He device  
Plant cell, Tissue and Organ Culture 33: 221-226
- 15 Knudsen S & Müller M (1991)  
Transformation of the developing barley endosperm by particle bombardment  
Planta 185: 330-336
- Siebert PD, Chenchik A, Kellogg DE, Lukyanov KA and Lukyanov SA (1995)  
20 An improved PCR method for walking in uncloned genomic DNA  
Nucleic Acids Research, vol. 23, no.6; p.1087-1088
- Huang JW, Chen JT, Yu WP, Shyr LF, Wang AY, Sung HY, Lee PD and Su (1996)  
Complete Structures of Three Rice Sucrose Synthase Isogenes and Differential  
25 Regulation of Their Expressions  
Biosci. Biotech. Biochem. 60(2): p233-239
- Copeland L (1990)  
Methods in plant biochemistry Vol. 3, Kap. 4: Enzymes of Sucrose Metabolism  
30 Academic Press Limited
- Dörmann P & Benning C (1998)  
The role of UDP-glucose epimerase in carbohydrate metabolism of Arabidopsis  
The Plant Journal 13(5): 641-652  
35
- Finer JJ, Vain P, Jones MW & McMullen MD (1992)  
Development of the particle inflow gun for DNA delivery to plant cells  
Plant cell Reports 11: 323-328
- 40 Jefferson RA (1987)  
Assaying Chimeric Genes in Plant: The GUS Gene Fusion System  
Plant Molecular Biology Reporter vol.5, number 4
- Karrer EE & Rodriguez RL (1992)  
45 Metabolic regulation of rice alpha-amylase and sucrose synthase genes in planta  
Plant J 2(4): 517-523
- Klein TM, Wolf ED, Wu R & Sanford JC (1987)  
High-velocity microprojectiles for delivery nucleic acids into living cells  
50 Nature 327: 70-73
- Klein TM, Fromm M, Weissinger A, Tomes D, Schaaf S, Sletten M & Sanford JC  
(1988)  
Transfer of foreign genes into intact maize cells with high-velocity microprojectiles

Proc. Natl. Acad. Sci. USA 85: 4305-4309

Lopes MA & Larkin BA (1993)  
Endosperm origin, development, and function  
5 The Plant Cell 5: 1383-1399

Sanford JC, Klein TM, Wolf ED & Allen N (1987)  
Delivery of substances into cells and tissues using a particle bombardment process  
Particulate Science and Technology 5: 27-37

10

Thomas TL (1993)  
Gene expression during plant embryogenesis and germination: An overview  
The Plant Cell 5: 1401-1410

15 Vain P, Keen N, Murillo J, Rathus C, Nemes C & Finer JJ (1993)  
Development of the Particle Inflow Gun  
Plant cell, Tissue and Organ Culture 33: 237-246

West MAL & Harada JJ (1993)  
20 Embryogenesis in higher plants: An overview  
The Plant Cell 5: 1361-1369

Whistler RL & Hymowitz T (1979)  
GUAR: Agronomy, Production, Industrial use and Nutrition  
25 Purdue University Press, West Lafayette, Indiana

REFERENCES FOR TABLE 1

- Bäumlein H, Nagy I, Villarroel R, Inzé D & Wobus U (1992)  
Cis-analysis of a seed protein gene promoter: the conservative RY-repeat  
5 CATGCATG within the legumin box is essential for tissue-specific expression of a  
legumin gene  
The Plant Journal 2(2): 233-239
- Joshi CP (1987)  
10 An inspection of the domain between putative TATA box and translation start site 79  
plant genes  
Nuc. Acid. Res. 15(16): 6643-6653
- Marzabal P, Busk PK, Ludevid MD & Torrent M (1998)  
15 The bifactorial endosperm box of gamma-zein gene: characterisation and function of  
the Pb3 and GZM cis-acting elements.  
The Plant Journal 16(1): 41-52
- Müller M & Knudsen S (1993)  
20 The nitrogen response of a barley C-hordein promoter is controlled by positive and  
negative regulation of the GCN4 and endosperm box  
The Plant Journal 4(2): 343-355
- Simpson CG & Filipowicz W (1996)  
25 Splicing of precursors to mRNA in higher plants: mechanism, regulation and sub-  
nuclear organisation of the spliceosomal machinery  
Plant Molecular Biology 32: 1-41



109

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>55</u> , line S <u>12 - 20</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB)	
Address of depositary institution (including postal code and country)  23 St Machar Drive Aberdeen AB2 1RY United Kingdom	
Date of deposit 15 March 1999	Accession Number NCIMB 41011
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, and any other designated states having equivalent legislation, a sample of the deposited microorganism will only be made available (a) until the publication of the mention of grant of the patent or (b) for twenty years from the date of filing if the application has been refused, withdrawn or deemed to be withdrawn, by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received with the international application</div> <div style="border-top: 1px solid black; padding: 5px; margin-top: 10px;">Authorized officer</div>	<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on</div> <div style="border-top: 1px solid black; padding: 5px; margin-top: 10px;">Authorized officer</div>
--	--

**CLAIMS**

1. A promoter comprising a nucleotide sequence corresponding to that shown as SEQ  
5 ID No. 1 or a variant, homologue, fragment or derivative thereof.
2. A promoter having a nucleotide sequence corresponding to that shown as SEQ ID  
No. 1 or a variant, homologue, fragment or derivative thereof.
- 10 3. A promoter comprising a nucleotide sequence corresponding to that shown as SEQ  
ID No. 1.
4. A promoter having a nucleotide sequence corresponding to that shown as SEQ ID  
No. 1.
- 15 5. A promoter according to any one of claims 1 to 4 wherein the promoter is  
obtainable from a plant of the genus *Oryza*.
6. A promoter capable of causing endosperm specific expression, wherein the  
20 promoter is obtainable from a plant of the genus *Oryza*.
7. A promoter according to any one of claims 1 to 6, wherein the promoter is operably  
linked to a NOI.
- 25 8. A promoter according to any one of the preceding claims wherein the promoter is  
linked to the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative  
or fragment thereof.
9. A promoter according to claim 8 wherein if an NOI is operably linked to the promoter  
30 then the sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or  
fragment thereof is located intermediate the promoter of the present invention and the  
NOI.
10. A promoter according to any one of the preceding claims wherein the promoter  
35 comprises one or more of the identified sequences presented in Table 1 or a variant,  
homologue or fragment thereof.

11. A promoter according to claim 10 wherein the promoter comprises one or more of the identified sequences presented in Table 1.
12. A promoter according to claim 10 or claim 11 wherein the promoter comprises all  
5 of the identified sequences presented in Table 1
13. A promoter according to any one of the preceding claims wherein the promoter is linked to the sequence presented as SEQ ID No. 5, or a variant, homologue, derivative or fragment thereof.
- 10 14. A promoter according to claim 13 wherein if an NOI is operably linked to the promoter then the sequence presented as SEQ ID No. 5, or a variant, homologue, derivative or fragment thereof is located intermediate the promoter of the present invention and the NOI.
- 15 15. A construct comprising the promoter according to any one of claims 1 to 14 but wherein the promoter is operably linked to a NOI.
16. An expression vector comprising the invention according to any one of claims 1 to  
20 15.
17. A transformation vector comprising the invention according to any one of claims 1 to 16.
- 25 18. A transformed host or host cell comprising the invention according to any one of claims 1 to 16.
19. A transformed host or host cell according to claim 18 wherein the host or host cell is a plant or a plant cell.
- 30 20. A method of preparing a POI, the method comprising expressing an NOI which encodes at least a part of the POI, wherein the NOI is operably linked to a promoter, optionally isolating the expression product of the NOI, forming the POI if the expression product of the NOI is not all of the POI, optionally isolating the POI; wherein the  
35 promoter is the promoter according to any one of claims 1 to 19.
21. A method according to claim 20 wherein the NOI codes for all of the POI.

22. A method for expressing an NOI in endosperm, the method comprising expressing the NOI when it is operably linked to the promoter according to any one of claims 1 to 20.
- 5 23. A promoter sequence obtainable from Deposit No. NCIMB 41011.
24. Any one of the plasmids presented in the Experimental Section provided herein.
- 10 25. Use of a sequence presented as SEQ ID No. 2, or a variant, homologue, derivative or fragment thereof to increase expression levels of an NOI.
26. A promoter substantially as described herein and with reference to any one of the preceding claims.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number  
**WO 00/78975 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/54,  
9/10, 15/82, A01H 5/00

(21) International Application Number: PCT/GB00/02641

(22) International Filing Date: 15 June 2000 (15.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9914210.1 17 June 1999 (17.06.1999) GB

(71) Applicant (for all designated States except US):  
DANISCO A/S [DK/DK]; Langebrogade 1, P.O. Box 17,  
DK-1001 Copenhagen K (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DONALDSON,  
Iain, Alasdair [GB/DK]; Dalgas Have 27, 1 TV, DK-2000  
Frederiksberg (DK). RASMUSSEN, Thomas, Bruun  
[DK/DK]; Gormsvej 10, DK-4900 Nakskov (DK).

(74) Agents: HARDING, Charles, Thomas et al.; D Young &  
Co., 21 New Fetter Lane, London EC4A 1DA (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:  
31 May 2001

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: RICE SUCROSE SYNTHASE PROMOTER


(57) Abstract: A promoter is described. The promoter comprises a nucleotide sequence corresponding to that shown as SEQ ID  
No. 1 or a variant, homologue or derivative thereof.

WO 00/78975 A3



**FIG. 2**

RSus3 cloned in pCR2.1-TOPO



2 / 27

## FIG. 3

1  
ACTTTAGATAATAAAGTAAGTCACAAGAAAAATAATAATAATTCCAAATTTTTTTAATA  
TGAAATCTATTATTTTCATTTCAGTGTTCTTTTATTATTATTAAAGGTTAAAAAATTAT

Eam1105I

61  
AGACGAGTGGTCAAACAGTACAAGTAAAACTCAAATTCCTTATATTATGGGACTTATA  
TCTGCTCACCAGTTTGTTCATGTTTCATTTTTGAGTTTTAAGGAATATAATACCCTGAATAT

121  
TTATGGGACGGAGGAAGTAGAAGATTGTAGCCAAGAAAAAACAAAAACAAACACACCCGC  
AATACCCTGCCTCCTTCATCTTCTAACATCGGTTCTTTTTTTGTTTTTGTGTGGCG

Ppu10I  
NsiI  
SphI

181  
CACCTGGCAGGCATGCATCTTAGGTCGGCAGATTGAGAGGTCGGCAGTAGACGAGTTACC  
GTGGACCGTCCGTACGTAGAATCCAGCCGTGTAAGTCTCCAGCCGTCTGCTCAATGG

Eco57I NheI

241  
CTACACAACTGCTTCTTCAGTGAGCTAGCTGCATGTTCTGTTCTGCATTTACATTGCAGG  
GATGTGTTGACGAAGAAGTCACTCGATCGACGTACAAGACAAGACGTAAATGTAACGTCC

NheI ClaI

301  
CAGCAGCTAGCAACAGTTTGCAGGAACAATCGATAATCCATTGTGTCAGGGAGGAACATG  
GTCGTCGATCGTTGTCAAACGTCCTTGTTAGCTATTAGGTAACACAGTCCCTCCTTGATC

PvuII  
BpmI Esp3I BsiWI Eco57I

361  
GAGAAAAACCGGGGCTGGAGACGAACGGGAGCAGCTGTACCGTACGTTTCTGAAGGCTGA  
CTCTTTTTGGCCCCGACCTCTGCTTGCCCTCGTCGACATGGCATGCAAAGACTTCCGACT

Eco57I

421  
ACCCATCTGCGAAATCCGCAGATTGGTTTGTTCATTCCAACTTGCAAGTCTTTCAGATTG  
TGGGTAGACGCTTTAGGCGTCTAACCAACAAGTTAAGGTTGAACGTGAGGAAGTCTAAC

481  
GTTGCATGTTCAACCGTAGTACATCTGAAAAATGAAGTGTTAAATACCTTGAGAAGACCT  
CAACGTACAAGTTGGCATCATGTAGACTTTTTACTTCACAATTTATGGAAGTCTTCTGGA

PstI  
SphI Sse8387I BstBI

541  
TCATGGAAGCATGCCTGCAGGCGATTAGCTAAGAAAAAAAATAAATGTACTTTTCGAA  
AGTACCTTCGTACGGACGTCCGCTAATCGATTCTTTTTTTTTTATTACATGAAAAGCTT

3 / 27

601  
ACTTAATTTTGGAGTTAGATTTTAGGGTGTTCATCGTAGTGTATTTTCTACTATTGCA  
TGAATTAAACCTCAATCTAAATCCCACAAAGGTAGCATCACATAAAAGATGATAACGT

DraI

661  
GTTTAAACCGCTAATAGTCAGATATAAAATTTTATCTATAGATCATTTATAAATCATTTT  
CAAATTTGGCGATTATCAGTCTATATTTTAAATAGATATCTAGTAAATATTTAGTAAAA

MunI

BclI

721  
TAGTTGCTTCGTTTCTACCACTTATCAACCATAGCTCAACTGATCAATTGACAA  
ATCAACGAAGCAAGTAAAAGATGGTGAATAGTTGGTATCGAGTTGACTAGTTAACTGTT

781  
TAAAGTTACTAAACGACATCGCTCATCACACACCCAACGCTCACCGATGGGTGCCTCTC  
ATTTTCAATGATTTGCTGTAGCGAGTAGTGTGTGGGTTGCGAGTGGCTACCCACGGAGAG

BssSI

BsaBI

841  
GACCACGAGTTTAGCACTTGTGCAACATATATGCGTGCGATGAACATCTACTGATGCGCC  
CTGGTGCTCAAATCGTGAACACGTTGTATATACGCACGCTACTTGTAGATGACTACGCGG

Ppu10I

BspHI

AlwNI

Esp3I

SphI

NsiI

901  
ATGCGAATTTTAGCGTTCGTTTCATGACGCTTCCAACGGCAGAGGCTGAGCAGCAGCAT  
TACGCTTAAATCGCAAGCAAGTACTGCGAAGGTTGCCGTGTCTCCGACTCGTCGTCGTA

Ppu10I

NsiI

SphI

961  
GCATGCATGGCTCTTGTGAAAACAAAAAGGTTACTGGTAAATGACATGCTGCTGTAGCT  
CGTACGTACCGAGAACACTTTTGTTTTTTCCAATGACCATTTACTGTACGACGACATCGA

NdeI

Ppu10I

BsmI

NsiI

1021  
AGTTAGCAGAAATGCAAGGCCCATGCATATGCAATGCTATGCAACAAGTATAGTACCAGCA  
TCAATCGTCTTACGTTCCGGGTACGTATACGTTACGATACGTTGTTTCATATCATGGTCGT

BssSI

1081  
TGTATGGTAGCCAGCTAACTAATCTATCAGCAGAGGCAGCAAGCTCGTGCATGGTGTGAT  
ACATAACCATCGGTGCGATTGATTAGATAGTCGTCTCCGTCGTTGAGCAGCATACCACTA

XcmI

BpmI

NdeI

1141  
GCACTTCTCTCCAGTAATCTAGTGGTAATTTTACCCAAAGCGTTGCTCATATGGACAGT  
CGTGAAGAGAGGTCATTAGATCACCATTAAAGTGGGTTTCGCAACGAGTATACCTGTCA

FIG. 3CONT'D

SUBSTITUTE SHEET (RULE 26)



4/27

SspI

1201  
AATTAGTAATATTACCAAGGTTACAATCCCGTTACCTGACCAAATACTACTCACGAATG  
TTAATCATTATAATGGTTCCAAGTGTTAGGGCAATGGACTGGTTTATGATGAGTGCTTAC

1261  
GTATCTCTGGTTTTTCGTTAAAACCGTTGGTAAACCAGCAAAAATAGACAAAATTTGTCAA  
CATAGAGACCAAAAGCAATTTTGGCAACCATTTGGTCGTTTTTATCTGTTTTAAACAGTT

DraI

1321  
AATTTTAAATTTTAGTTTTTTTTTAACTTAGCCGGGAAACCTTGAAGTTTGTGCTGTGC  
TTAAAATTTAAATCAAAAAAAAAAATTGAATCGGCCCTTTGGAACCTCAAACACGACAGC

BsgI

1381  
AGCTGTCCTGGGAAGGACGGTTTTTGGTTGGGATTGTGAACCTTGGTTACTGCACTTCATT  
TCGACAGGACCCTTCCTGCCAAAACCAACCCTAACACTTGGGACCAATGACGTGAAGTAA

1441  
TTTGAACAGATATTAGTGCAACAGACAAATGCCAACGCATTTTTTTCTGTTACCGGGCAA  
AAACTTGTCTATAATCACGTTGTCTGTTTACGGTTGCGTAAAAAAGACAAATGGCCGTT

HindIII

Eco57I

BspMI

Esp3I

1501  
GCTGAAGCTTTTACGATCCCCATACCGCCGTTGCTGCAAACCTGCCAAGAAAGAGCAGCA  
CGACTTCGAAAATGCTAGGGGTATGGCGGCAACGACGTTTGGACGGTTCTTTCTCGTCGT

1561  
GAAACAGGTGTCATTTTGTGGTGGAAAGCCAAGTAAAGTAAACAGAAGATGGAAGATAGT  
CTTTGTCCACAGTAAACACCACCTTTCGGTTCATTTCAATTGTCTTCTACCTTCTATCA

BsgI

1621  
GAGGACCAGGGAGTGAGGCAGGGGACACATGGCCCACGCCTCCCTGCACATTTTTCGTGTA  
CTCCTGGTCCCTCACTCCGTCCCCTGTGTACCGGGTGCAGAGGGACGTGTAAAGCACAT

Ppu10I

NsiI

Esp3I

1681  
TAAATACAGGTGGATGCATCGCTCTCCAGCATCCATCGGTTCTCTGCTCTGTTTCATCCA  
ATTTATGTCCACCTACGTAGCGAGAGGGTCGTAGGTAGCCAAGAGACGAGACAAGTAGGT

EarI

Eco57I

EarI

1741  
TAGAGTTTCCTCCTCTCTCCTTCAGTGCAAGGTAGAGAAGAGCATGTGTGTGTGTGTGT  
ATCTCAAAGGAGGAGAAGAGGAAGTCACGTTCCATCTCTTCTCGTACACACACACACACA

BsgI

1801  
GTGAACTGTGAAGTGCAGAGTGCTTCTGTAGTTCTGTGTTATGTCCATAGTGATCTTGTT  
CACTTGACACTTCACGTCTCACGAAGACATCAAGACACAATAACAGGTATCACTAGAACAA

FIG. 3CONT'D

SUBSTITUTE SHEET (RULE 26)

5 / 27

Ppu10I  
NsiI

1861  
AGGATTGTTGCTATGGATGCATGATGTTATGGTTAATCTCTGAATTACAGTAGGGACTTC  
TCCTAACACGATACCTACGTACTACAATACCAATTAGAGACTTAATGTCATCCCTGAAG

BglII

1921  
TCTGAGATCTCTGGATTAGTGGGGGGTGCTAAATTTTTTCTGGTTGCATCAGCTTGGGT  
AGACTCTAGAGACCTAATCACCCCCACGATTTAAAAAAGACCAACGTAGTCGAACCCA

1981  
TTCTGGGATTGGTGTGGGTTCTTGCTCTGAATTTTGGTTCAGAATGTCGATTTGTTTGT  
AAGACCCTAACCAACCCAAGAACGAGACTTAAAACCAAGTCTTACAGCTAAACAAAACA

Eco57I

BspMI  
PstI

2041  
GTTTGCCCTCTGAAGTTGAGAGTAGCTATGATCCATCCAGCACAGAACTGCAGGTCCCTG  
CAAACGGGAGACTTCAACTCTCATCGATACTAGGTAGGTCGTGCTTTGACGTCCAGGGAC

NgoMI  
NaeI

2101  
CCTGCCGGCAGCATATACAGGACATGCCATTTTGCAAGCTCTGGGCTTATGGTTTCTCTT  
GGACGGCCGTCGTATATGTCCTGTACGGTAAAACGTTTCGAGACCCGAATACCAAAGAGAA

2161  
TTGGAGTTCTTCTTCTTGCAATGATCTGTGTTCTCTAACAAAGAAGCAAGATTTAGCAACT  
AACCTCAAGAAGAAGAAGCTACTAGACACAAGAGATTGTTTCTTCGTTCTAAATCGTTGA

2221  
TTATTCAGAGACAAGAAAAGGATCTGGCAACCTTTTGTTTCTGTTTTATCCTACTCGTAA  
AATAAGTCTCTGTTCTTTTCCTAGACCGTTGGAAAACAAAGACAAAATAGGATGAGCATT

DraI

2281  
AGATTGTTATTTAAGCAAAAATTTCCCAAAAGTTTTAAATATAATTTCCATGATGTGCCA  
TCTAACAAATAAATTCGTTTTTAAAGGGTTTTCAAATTTATATTAAAGGTACTACACGGT

2341  
CTCTCATGTCCTTGAACCTGGCACTCATTATGGGCTCCTCAGAAGTGCTGTAGCTAATGT  
GAGAGTACAGGAACCTTGACCGTGAGTAATACCCGAGGAGTCTTCACGACATCGATTACA

BsaBI

2401  
CACTAATCTTTTGTATCTTTGTTTCGTAGTCTTGTATTTTATGATGCTTATCCCTTTGTGC  
GTGATTAGAAAACATAGAAACAAGCATCAGAACATAAAATACTACGAATAGGGAAACACG

2461  
TTTCCATGTTTGATGTCCAAATGTCATGGCAATGTTTTTGACTTCTAGTAGGGGTTTTAG  
AAAGGTACAAACTACAGGTTTACAGTACCGTTACAAAACCTGAAGATCATCCCCAAAATC

FIG.3CONT'D

SUBSTITUTE SHEET (RULE 26)

6/27

2521  
 TACCTTTTTGTTAGATAAGTACATCCAAATTCTGTTTATTTATTCAAAAATCATTCTGTT  
 ATGGAAAAACAATCTATTCATGTAGGTTTAAGACAAATAAATAAGTTTTTAGTAAGACAA


PflMI

2581  
 TATTCAGTGAACATTTGTCCATTCAATGGAATCGTAAACTGTCTGTGTTTTTCAGGCT  
 ATAAGTGACTTTTGTAACAGGTAAGTTACCTTAGCATTGACAGACACAAAAAGTCCGA

BamHI

2641 2668  
 TGAGGATCCAACTAGAAGATAGCAATGG  
 ACTCCTAGGTTGATCTTCTATCGTTACC


FIG. 3CONT'D



Agarose gel showing the result of the semi-nested PCR with the primer pair AP2 and RSus3. Lane 1 and 12 molecular weight marker II; lane 2-6 EcoRV, DraI, PvuII, ScaI and SspI with buffer F; lane 7-11 same with buffer H.


FIG. 4

7/27





The promoter region from pScaK3 and pSspK3 were amplified from the primers M13 forward and RSusNco. The amplified products contain *XhoI* and *NcoI* sites for directional cloning into the unique *Sall* and *NcoI* in pGUSNOST as *XhoI/NcoI* fragments.



**FIG. 5**



9/27



10 / 27



11 / 27




FIG. 11



12 / 27




FIG. 12

pTBR-ScaK3:




FIG. 13





FIG. 14



Agarose gel showing the result of a digest of tandem repeat clones. Lane 1: HindIII digest of pTandem leg/pro, which gives a specific fragment of 740 bp. Lane 2: NheI digest of pTandem legumin, which gives a specific fragment of 570 bp. Lane 3: DNA marker VI. Lane 4: HindIII digest of pTandem prolamin, which gives a specific fragment of 160 bp.

FIG. 15

16 / 27




FIG. 16a




FIG. 16b

17 / 27




FIG. 16c




FIG. 16d

18 / 27




FIG. 16e



FIG. 16f

19 / 27

## Transient GUS expression in GUAR endosperms




FIG. 17

## Transient expression in guar tissue




FIG. 18






FIG. 19




FIG. 20

22 / 27




FIG. 21

23 / 27




FIG. 22

24 / 27




FIG. 23






FIG. 24







**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROMOTER

(Attorney Docket No. 078883-0139)

the specification of which (check one)

       is attached hereto.

  X   was filed on June 17, 1999 as United States Application Number or PCT International Application Number PCT/GB/00264 and was amended on        (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
9914210.1	Great Britain	06/17/1999	YES	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the registered attorneys and agents at Customer Number 22428



22428

PATENT TRADEMARK OFFICE

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Michele M. Simkin  
FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

10	Name of first inventor	<u>Iain Alasdair DONALDSON</u>
	Residence	<u>Frederiksberg, Denmark DKX</u>
	Citizenship	<u>Denmark</u>
	Post Office Address	<u>Dalgas Have 27</u> <u>1 TV</u> <u>Frederiksberg</u> <u>2000 Denmark</u>
	Inventor's signature	<u>Iain Alasdair Donaldson</u>
	Date	<u>22/5/02</u>
	<hr/>	
<del>Name of second inventor</del>	<del>Thomas Bruun RASMUSSEN</del>	
<del>Residence</del>	<del>Nakskov, Denmark</del>	
<del>Citizenship</del>	<del>Denmark</del>	
<del>Post Office Address</del>	<del>Gormsvej 10</del> <del>Nakskov</del> <del>4900 Denmark</del>	
<del>Inventor's signature</del>	<del></del>	
<del>Date</del>	<del></del>	

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROMOTER

(Attorney Docket No. 078883-0139)

the specification of which (check one)

       is attached hereto.

  X   was filed on June 17, 1999 as United States Application Number or PCT International Application Number PCT/GB/00264 and was amended on        (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
9914210.1	Great Britain	06/17/1999	YES	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the registered attorneys and agents at Customer Number 22428



22428

PATENT TRADEMARK OFFICE

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Michele M. Simkin  
FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

~~Name of first inventor      Iain Alasdair DONALDSON  
Residence      Frederiksberg, Denmark  
Citizenship      Denmark  
Post Office Address      Dalgas Have 27  
                                 1 TV  
                                 Frederiksberg  
                                 2000 Denmark  
Inventor's signature  
Date~~

2-20  
Name of second inventor      Thomas Bruun RASMUSSEN  
Residence      Nakskov, Denmark      DKX  
Citizenship      Denmark  
Post Office Address      Gormsvej 10  
                                 Nakskov  
                                 4900 Denmark  
Inventor's signature      *Thomas Bruun Rasmussen*  
Date      22. april 2002

10/009570  
12 DEC 2001  
Rec'd PCT/PTO  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 078883/0139

In re patent application of  
DONALDSON, IAIN ALASDAIR et al.  
Serial No. Unassigned  
Filed: Concurrently Herewith  
For: PROMOTER

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

10/009570


13 Rec'd PCT/PTO 12 DEC 2001

Serial No. Unassigned

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Nov. 23, 2001  
Date

  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021



## SEQUENCE LISTING

<110> DONALDSON, IAIN ALASDAIR  
RASMUSSEN, THOMAS BRUUN

<120> PROMOTER

<130> 078883/0139

<140>

<141>

<150> PCT/GB00/02641

<151> 2000-06-15

<150> GB 9914210.1

<151> 1999-06-17

<160> 43

<170> PatentIn Ver. 2.1

<210> 1

<211> 1772

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
promoter sequence

<400> 1

acttttagata	ataaagtaag	tcacaagaaa	aataaataat	aattccaaat	ttttttaata	60
agacgagtgg	tcaaacagta	caagtaaaaa	ctcaaaattc	cttatattat	gggacttata	120
ttatgggacg	gaggaagtag	aagattgtag	ccaagaaaaa	aacaaaaaca	aacacaccgc	180
cacctggcag	gcatgcatct	taggtcggca	cattgagagg	tcggcagtag	acgagttacc	240
ctacacaact	gcttcttcag	tgagctagct	gcatgttctg	ttctgcattt	acattgcagg	300
cagcagctag	caacagtttg	caggaacaat	cgataatcca	ttgtgtcagg	gaggaacatg	360
gagaaaaacc	ggggctggag	acgaacggga	gcagctgtac	cgtacgtttc	tgaaggctga	420
acctatctgc	gaaatccgca	gattggtttg	ttcaattcca	acttgcagtc	cttcagattg	480
gttgcatgtt	caaccgtagt	acatctgaaa	aatgaagtgt	taaatacctt	gagaagacct	540
tcatggaagc	atgctgcag	gcgattagct	aagaaaaaaa	aaataaatgt	acttttcgaa	600
acttaatttt	ggagttagat	tttaggggtg	ttccatcgta	gtgtattttc	tactattgca	660
gtttaaacgg	ctaatagtca	gatataaaat	tttatctata	gatcatttat	aaatcatttt	720
tagttgcttc	gttcattttt	ctaccactta	tcaaccatag	ctcaactgat	caattgacaa	780
taaaagttac	taaacgacat	cgctcatcac	acacccaacg	ctcaccgatg	gggtgcctctc	840
gaccacgagt	ttagcacttg	tgcaacatat	atgcgtgcga	tgaacatcta	ctgatgcgcc	900
atgcgaatth	tagcgttcgt	tcatgacgct	tccaacggca	cagaggctga	gcagcagcat	960
gcatgcatgg	ctcttgtaga	aacaaaaaag	gttactggta	aatgacatgc	tgctgtagct	1020
agtttagcga	atgcaaggcc	catgcatatg	caatgctatg	caacaagtat	agtaccagca	1080
tgtaggttag	ccagctaact	aatctatcag	cagaggcgag	aagctcgtgc	atggtgtgat	1140
gcacttctct	ccagtaatct	agtggtaatt	ttcacccaaa	gcgttgctca	tatggacagt	1200
aattagtaat	attaccaagg	ttcacaatcc	cgttacctga	ccaaatacta	ctcacgaatg	1260
gtatctctgg	ttttcgttaa	aaccgttggt	aaaccagcaa	aaatagacaa	aattttgtcaa	1320
aatttttaaat	tttagttttt	tttttaactt	agccgggaaa	ccttgaagtt	tgtgctgtcg	1380
agctgtcctg	ggaaggacgg	ttttggttgg	gattgtgaac	cctgggttact	gcacttcatt	1440
tttgaacaga	tattagtcca	acagacaaat	gccaacgcag	ttttttctgt	ttaccggcaa	1500
gctgaagctt	ttacgatccc	cataccggcg	ttgctgcaaa	cctgccaaga	aagagcagca	1560

```

gaaacaggtg tcattttgtg gtggaaagcc aagtaaagta aacagaagat ggaagatagt 1620
gaggaccagg gagtgaggca ggggacacat ggcccacgcc tccctgcaca ttttcgtgta 1680
taaatacagg tggatgcac gctctcccag catccatcgg ttctctgctc tgttcaccca 1740
tagagtttcc tcctcttctc cttcagtgcag ag 1772

```

<210> 2

<211> 865

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
intron nucleotide sequence

<400> 2

```

gtagagaaga gcatgtgtgt gtgtgtgtgt gaactgtgaa gtgcagagtg cttctgtagt 60
tctgtgttat gtccatagtgt atcttgtagt gattgttgct atggatgcat gatgttatgg 120
ttaatctctg aattacagta gggacttctc tgagatctct ggattagtgg ggggtgctaa 180
atctttttct ggttgcatca gcttgggttt ctgggattgg tgtgggttct tgctctgaat 240
tttggttcag aatgtcgatt tgttttgtgt ttgccctctg aagttgagag tagctatgat 300
ccatccagca cagaactgca ggtccctgcc tggcggcagc atatacagga catgccattt 360
tgcaagctct gggcttatgg tttctctttt ggagttcttc ttcttgcatg atctgtgttc 420
tctaacaaag aagcaagatt tagcaacttt attcagagac aagaaaagga tctggcaacc 480
ttttgtttct gttttatcct actcgtaaaag attgttattt aagcaaaaat ttcccaaaag 540
ttttaaatat aatttccatg atgtgccact ctcatgtcct tgaacctggc actcattatg 600
ggctcctcag aagtgtgta gctaattgtca ctaacttttt gtatctttgt tctagtctct 660
gtatcttatg atgcttatcc ctttgtgctt tccatgtttg atgtccaaat gtcattggca 720
tggttttgac ttctagtagg gggttttagta cttttttgtt agataagtac atccaaattc 780
tggtttattt tcaaaaatc attctgttta ttcactgaaa acatttgtcc attcaatgga 840
atcgtaaaact gtctgtgttt ttcag 865

```

<210> 3

<211> 1803

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
nucleotide sequence

<400> 3

```

acttttagata ataaagtaag tcacaagaaa aataaataat aattccaaat ttttttaata 60
agacgagtgg tcaaacagta caagtaaaaa ctcaaaattc cttatattat gggacttata 120
ttatgggacg gaggaagtag aagattgtag ccaagaaaaa aacaaaaaca aacacaccgc 180
cacctggcag gcatgcatct taggtcggca cattgagagg tcggcagtag acgagttacc 240
ctacacaact gcttcttcag tgagctagct gcatgttctg ttctgcattt acattgcagg 300
cagcagctag caacagtttg caggaacaat cgataatcca ttgtgtcagg gaggaacatg 360
gagaaaaacc ggggctggag acgaacggga gcagctgtac cgtacgtttc tgaaggctga 420
acccatctgc gaaatccgca gattggtttg ttcaattcca acttgcagtc cttcagattg 480
gttgcatgtt caaccgtagt acatctgaaa aatgaagtgt taaatacctt gagaagacct 540
tcatggaagc atgcctgcag gcgattagct aagaaaaaaa aaataaatgt acttttcgaa 600
acttaatttt ggagtttagt tttagggtgt ttccatcgta gtgtattttc tactattgca 660
gtttaaaccg ctaatagtca gatataaaa tttactata gatcatttat aaatcatttt 720
tagttgcttc gttcattttt ctaccactta ttaaccatag ctcaactgat caattgacaa 780
taaaagttac taaacgacat cgctcatcac acaccaacg ctacccgatg ggtgcctctc 840
gaccacgagt ttagcacttg tgcaacatat atgcgtgcga tgaacatcta ctgatgcgcc 900

```

```

atgCGaattt tagcgttcgt tcatgacgct tccaacggca cagaggctga gcagcagcat 960
gcatgcatgg ctcttgtgaa aacaaaaaag gttactggta aatgacatgc tgctgtagct 1020
agttagcaga atgcaaggcc catgcatatg caatgctatg caacaagtat agtaccagca 1080
tgtatggtag ccagctaact aatctatcag cagaggcagc aagctcgtgc atgggtgat 1140
gcacttctct ccagtaatct agtggttaatt ttcacccaaa gcgttgctca tatggacagt 1200
aattagtaat attaccaagg ttcacaatcc cgttacctga ccaaatacta ctcacgaatg 1260
gtatctctgg ttttcgttaa aaccggttgg aaaccagcaa aaatagacaa aatttgtcaa 1320
aattttaaat tttagttttt tttttaactt agccgggaaa ccttgaagtt tgtgctgtcg 1380
agctgtcctg ggaaggacgg ttttggttgg gattgtgaac cctggttact gcacttcatt 1440
tttgaacaga tattagtgc aacagacaaat gccaacgcat ttttttctgt ttaccggcaa 1500
gctgaagctt ttacgatccc cataccgccc ttgctgcaaa cctgccaaaga aagagcagca 1560
gaaacagggtg tcattttgtg gtggaaagcc aagtaaagta aacagaagat ggaagatagt 1620
gaggaccagg gagtgaggca ggggacacat ggcccacgcc tccctgcaca ttttcgtgta 1680
taaatacagg tggatgcac gctctcccag catccatcgg ttctctgctc tgttcatcca 1740
tagagtttcc tcctcttctc cttcagtgc aggcttgagg atccaactag aagatagcaa 1800
tgg                                                    1803

```

<210> 4  
 <211> 86  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic exon  
 nucleotide sequence

```

<400> 4
caggTggatg catcgctctc ccagcatcca tcggttctct gctctgttca tccatagagt 60
ttctctctct tctccttcag tgcaag                                     86

```

<210> 5  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic exon  
 nucleotide sequence

```

<400> 5
gcttgaggat ccaactagaa gatagcaatg g
                                                    31

```

<210> 6  
 <211> 1686  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 promoter sequence

```

<400> 6
actttagata ataaagtaag tcacaagaaa aataaataat aattccaaat ttttttaata 60
agacgagtgg tcaaacagta caagtaaaaa ctcaaaattc cttatattat gggacttata 120
ttatgggacg gaggaagtag aagattgtag ccaagaaaaa aacaaaaaca aacacaccgc 180

```

```

cacctggcag gcatgcatct taggtcggca cattgagagg tcggcagtag acgagttacc 240
ctacacaact gcttcttcag tgagctagct gcatgttctg ttctgcattt acattgcagg 300
cagcagctag caacagtttg caggaacaat cgataatcca ttgtgtcagg gaggaacatg 360
gagaaaaacc ggggctggag acgaacggga gcagctgtac cgtacgtttc tgaaggctga 420
acctatctgc gaaatccgca gattggtttg ttcaattcca acttgcagtc cttcagattg 480
gttgcattgt caaccgtagt acatctgaaa aatgaagtgt taaatacctt gagaagacct 540
tcatggaagc atgcctgcag gcgattagct aagaaaaaaa aaataaatgt acttttcgaa 600
acttaatttt ggagtttagat tttaggggtg ttccatcgta gtgtattttc tactattgca 660
gtttaaaccg ctaatagtca gatataaaat tttatctata gatcatttat aaatcatttt 720
tagttgcttc gttcattttt ctaccactta tcaaccatag ctcaactgat caattgacaa 780
taaaagttac taaacgacat cgctcatcac acacccaacg ctcaccgatg ggtgcctctc 840
gaccacgagt ttagcacttg tgcaacatat atgcgtgcga tgaacatcta ctgatgcgcc 900
atgcgaattt tagcgttcgt tcatgacgct tccaacggca cagaggctga gcagcagcat 960
gcatgcatgg ctcttgtgaa aacaaaaaag gttactggta aatgacatgc tgctgtagct 1020
agtttagcaga atgcaaggcc catgcatatg caatgctatg caacaagtat agtaccagca 1080
tgtatggtag ccagctaact aatctatcag cagaggcagc aagctcgtgc atgggtgtgat 1140
gcacttctct ccagtaatct agtggttaatt ttcacccaaa gcgttgctca tatggacagt 1200
aattagtaat attaccaagg ttcacaatcc cgttacctga ccaaatacta ctcacgaatg 1260
gtatctctgg ttttcgttaa aaccgttggt aaaccagcaa aaatagacaa aattttgtcaa 1320
aattttaaat tttagttttt tttttaactt agccgggaaa ccttgaagtt tgtgctgtcg 1380
agctgtcctg ggaaggacgg ttttggttgg gattgtgaac cctggttact gcacttcatt 1440
tttgaacaga tattagtga acagacaaat gccaacgcac ttttttctgt ttaccggcaa 1500
gctgaagctt ttacgatccc cataccgccg ttgctgcaaa cctgccaaaga aagagcagca 1560
gaaacagggtg tcattttgtg gtggaaagcc aagtaaagta aacagaagat ggaagatagt 1620
gaggaccagg gagtgaggca ggggacacat ggcccacgcc tccctgcaca ttttcgtgta 1680
taaata

```

<210> 7

<211> 2668

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic promoter sequence of the present invention

<400> 7

```

acttttagata ataaagtaag tcacaagaaa aataaataat aattccaaat ttttttaata 60
agacgagtgg tcaaacagta caagtaaaaa ctcaaaattc cttatattat gggacttata 120
ttatgggacg gaggaagtag aagattgtag ccaagaaaaa aacaaaaaca aacacaccgc 180
cacctggcag gcatgcatct taggtcggca cattgagagg tcggcagtag acgagttacc 240
ctacacaact gcttcttcag tgagctagct gcatgttctg ttctgcattt acattgcagg 300
cagcagctag caacagtttg caggaacaat cgataatcca ttgtgtcagg gaggaacatg 360
gagaaaaacc ggggctggag acgaacggga gcagctgtac cgtacgtttc tgaaggctga 420
acctatctgc gaaatccgca gattggtttg ttcaattcca acttgcagtc cttcagattg 480
gttgcattgt caaccgtagt acatctgaaa aatgaagtgt taaatacctt gagaagacct 540
tcatggaagc atgcctgcag gcgattagct aagaaaaaaa aaataaatgt acttttcgaa 600
acttaatttt ggagtttagat tttaggggtg ttccatcgta gtgtattttc tactattgca 660
gtttaaaccg ctaatagtca gatataaaat tttatctata gatcatttat aaatcatttt 720
tagttgcttc gttcattttt ctaccactta tcaaccatag ctcaactgat caattgacaa 780
taaaagttac taaacgacat cgctcatcac acacccaacg ctcaccgatg ggtgcctctc 840
gaccacgagt ttagcacttg tgcaacatat atgcgtgcga tgaacatcta ctgatgcgcc 900
atgcgaattt tagcgttcgt tcatgacgct tccaacggca cagaggctga gcagcagcat 960
gcatgcatgg ctcttgtgaa aacaaaaaag gttactggta aatgacatgc tgctgtagct 1020
agtttagcaga atgcaaggcc catgcatatg caatgctatg caacaagtat agtaccagca 1080
tgtatggtag ccagctaact aatctatcag cagaggcagc aagctcgtgc atgggtgtgat 1140
gcacttctct ccagtaatct agtggttaatt ttcacccaaa gcgttgctca tatggacagt 1200

```

```

aattagtaat attaccaagg ttcacaatcc cgttacctga ccaaatacta ctcacgaatg 1260
gtatctctgg ttttcgttaa aaccggttgg aaaccagcaa aaatagacaa aatttgtcaa 1320
aattttaaat tttagttttt tttttaactt agccgggaaa ccttgaagtt tgtgctgtcg 1380
agctgtcctg ggaaggacgg ttttggttgg gattgtgaac cctggttact gcacttcatt 1440
tttgaacaga tattagtgcg acagacaaat gccaacgcat ttttttctgt ttaccggcaa 1500
gctgaagctt ttacgatccc cataccgctg ttgctgcaaa cctgccaaaga aagagcagca 1560
gaaacagggtg tcatTTTTgtg gtggaaaagcc aagtaaagta aacagaagat ggaagatagt 1620
gaggaccagg gagtgaggca ggggacacat ggcccacgcc tccttgcaca ttttcgtgta 1680
taaatacagg tggatgcacg gctctcccag catccatcgg ttctctgctc tgttcatcca 1740
tagagtttcc tcctcttctc cttcagtgca aggtagagaa gagcatgtgt gtgtgtgtgt 1800
gtgaactgtg aagtgcagag tgcttctgta gttctgtgtt atgtccatag tgatcttgtt 1860
aggattgttg ctatggatgc atgatgttat gggttaatctc tgaattacag tagggacttc 1920
tctgagatct ctggattagt ggggggtgct aaattttttt ctggttgcac cagcttgggt 1980
ttctgggatt ggtgtgggtt cttgctctga attttggttc agaatgtcga tttgttttgt 2040
gtttgccctc tgaagttgag agtagctatg atccatccag cacagaactg caggtccttg 2100
cctgcgggca gcatatacag gacatgccat tttgcaagct ctgggcttat ggtttctctt 2160
ttggagttct tcctcttgca tgatctgtgt tctctaacaa agaagcaaga tttagcaact 2220
ttattcagag acaagaaaag gatctggcaa ccttttggtt ctgttttata ctactcgtaa 2280
agattgttat ttaagcaaaa atttcccaaa agttttaaat ataatttcca tgatgtgcca 2340
ctctcatgtc cttgaacctg gcactcatta tgggctcctc agaagtgtcg tagctaattg 2400
cactaatctt ttgtatcttt gttcgtatgc ttgtatttta tgatgcttat ccctttgtgc 2460
tttccatgtt tgatgtccaa atgtcatggc aatgtttttg acttctagta ggggttttag 2520
tacctttttg ttagataagt acatccaaat tctgtttatt tattcaaaaa tcattctgtt 2580
tattcactga aaacatttgt ccattcaatg gaatcgtaaa ctgtctgtgt ttttcagggt 2640
tgaggatcca actagaagat agcaatgg 2668

```

```

<210> 8
<211> 27
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: Primer

```

```

<400> 8
ggatcctaata acgactcact atagggc 27

```

```

<210> 9
<211> 17
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: Primer

```

```

<400> 9
aatagggctc gagcggc 17

```

```

<210> 10
<211> 22
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: Primer

```

<400> 10  
gctttccacc acaaaatgac ac 22

<210> 11  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 11  
cgaattctag taacatagat gacacc 26

<210> 12  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 12  
ggaattcccc gatcgttcaa acatttgg 28

<210> 13  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 13  
ggaagcttgc gaaaatgtgc aggg 24

<210> 14  
<211> 56  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 14  
cccatggcta tcttctagtt ggatcctcaa gccttgcaact gaaggggaag aggagg 56

<210> 15  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 15  
 cattttgctg ccggtc 16  
  
 <210> 16  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 16  
 caggaaacag ctatgac 17  
  
 <210> 17  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 17  
 ccgctagcac agaggctgag cag 23  
  
 <210> 18  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 18  
 tgctagctgg taaatgacat gctgctg 27  
  
 <210> 19  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Primer  
  
 <400> 19  
 cgctagcaga ggcagcaagc tc 22  
  
 <210> 20  
 <211> 22

<212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 20

gggctagcga aaatgtgcag gg

22

<210> 21

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 oligonucleotide

<400> 21

ctaatacgac tcactatagg gctcgagcgg ccgcccgggc aggt

44

<210> 22

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 oligonucleotide

<400> 22

acctgccc

8

<210> 23

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 23

ctggcgaaag ggggatgtgc tg

22

<210> 24

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 24

acgacggaat ggataatagc agata

25



<210> 25  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 25  
 gtttccccca tggctatctt c 21

<210> 26  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 26  
 cctccctgaa gcttttcgtg t 21

<210> 27  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 27  
 attaggcacc ccaggcttta cactttatgc ttccggctcg tatg 44

<210> 28  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 28  
 gtttccccca ttgctatctt c 21

<210> 29  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 29  
agtgccaggt tcaaggaca

19

<210> 30  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 30  
accaatccca gaaacccaag c

21

<210> 31  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 31  
gtgtcccctg cctcactcc

19

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 32  
ccggctaagt taaaaaaaaa

20

<210> 33  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 33  
ctgtgccgtt ggaagcgtca t

21

<210> 34  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 34

cgcatatggg ttcagccttc a

21

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 35

ggtcggcaca ttgagaggtc

20

<210> 36

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 36

cacacccaac gctcaccgat g

21

<210> 37

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 37

aggacggttt tggttgggat t

21

<210> 38

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 38

tcctcctctt ccccttcag tg

22

<210> 39

<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 39  
atctggcaac cttttgtttc t 21

<210> 40  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 40  
caggaaacag ctatgac 17

<210> 41  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 41  
cgacgttgta aaacgacggc cagt 24

<210> 42  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer


<400> 42  
acgacggaat ggataatagc agata 25

<210> 43  
<211> 11  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 43  
gtcgaccatg g 11

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

*Scanned copy is best available. Some Figures are dark.*